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ABSTRACT 
Oxidative stress has been associated with many disease conditions in adults and 
neonates based on clinical and post mortem studies.  Trauma is the commonest cause of 
oxidative stress. However a gap in knowledge of the natural history of oxidative stress in 
humans was identified as most studies have been post mortem or in animals.  
The aim of this research is to understand treat and oxidative stress in trauma and 
surgical patients. The study involved three components including: the development and 
evaluation of the novel oxistress assay; study of clinical trauma and oxidative stress; and 
clinical trial of alanyl-glutamine supplementation following major surgery. The novel 
oxistress assay was used on urine samples in the normal population to determine 
reference values and subsequently on hospital patients to determine sensitivity and 
specificity. The study of clinical trauma and oxidative stress evaluated plasma 
antioxidants (FRAP assay), red cell glutathione (Asensis method), plasma and urine 
protein carbonyl (Levines method) and total oxidants in plasma and urine (oxistress 
assay) over 7 day period following trauma. The clinical trial was a double blind study of 
69 major surgery patients evaluating biochemical and clinical parameters over 7 day 
period in comparison with pre-operative status. 
The novel oxistress assay proves to be a sensitive and accurate bedside diagnostic 
tool for oxidative stress. It can also be used in the laboratory setting. Oxidative stress is 
associated with increased trauma severity resulting in antioxidant depletion, strong 
oxidant production and protein degradation. The prescence of pre-morbid medical factors 
also increased oxidative stress in trauma patients. Oral alanyl-glutamine supplementation 
(0.3 g/kg) increased plasma glutamine and antioxidant levels while decreasing urine 
oxidant levels. It significatly reduced hospital stay in non-cancer and higher disease 
complexity patients. The intervention also reduced the resource intensity weighting 
(RIW) score.  
Oxidative stress is a clinical problem in surgery and trauma patients that can now 
be easily diagnosed at the bedside using the novel oxistress assay.  Treament with alanyl-
glutamine is effective in reducing oxidative stress and improving clinical outcome. It is 
highly recommended probably at a higher dose in order to achieve optimal results. 
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1. INTRODUCTION 
Oxidative stress is defined as a state in which the level of toxic reactive oxygen 
intermediates (ROI) overcomes the endogenous antioxidant defenses of the host. Toxic 
reactive oxygen intermediates (ROI) are produced by phagocytic cells following injury 
and inflammation of tissues as a mechanism to kill invading microorganism [1].  When 
inflammation becomes systemic as in inflammatory response syndrome there is loss of 
control of ROI production leading to non discriminant injury of tissues and organs in the 
host [1]. Oxidative stress has been shown to cause secondary damage through delayed 
cellular death and inflammation [2-4].  Therefore, minimizing oxidative stress may 
prevent cellular death, decrease inflammation, and prevent some morbidity and mortality 
[5]. 
Oxidative stress has been associated with many diseases such as diabetes, 
hypertension, heart failure, Parkinsons disease [6], renal disease, epilepsy [7], 
Alzheimer's [8] and other neurodegenerative diseases [9] by clinical and post mortem 
studies. It is also implicated in acute medical and critical care evident by increased 
oxidant activity in the lungs of patients with acute respiratory distress syndrome [10] 
resulting in the development of multiple organ failure and death [11]. Oxidative stress is 
associated with many neonatal diseases such as retinopathy of prematurity, 
bronchopulmonary dysplasia, necrotizing enterocolitis and periventricular leucomalacia 
[12]. All newborns, particularly preterm newborns are highly susceptible to oxidative 
tissue damage which may be caused by strong oxidants [13, 14]. 
Trauma is the commonest cause of oxidative stress [15, 16].  Sheridan and 
associates showed that antioxidant therapy in burn patients reduced the length of time on 
mechanical ventilation and levels of malondialdehyde as compared to controls [17].  The 
consumption of endogenous antioxidants by free radicals resulting in oxidative stress 
may promote the development of multiple system organ failure (MSOF) after 
polytraumatic injury [18]. 
Modulation of oxidative stress involves various measures to decrease the level of 
ROI or increase the level of antioxidants, which has been done mostly in animal models. 
A clear understanding of the natural history in the human population is required in order 
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to effectively modulate oxidative stress. Trauma patients present the best study group not 
only because trauma is the commonest cause of oxidative stress but also because of the 
advantage of an identifiable onset of injury. The aim of this research is to understand the 
natural history and treat oxidative stress in trauma and surgical patients. This is based on 
the hypothesis that modulation of oxidative stress will improve patient outcome after 
trauma or surgery.   
The study is divided into three components. The first component is the 
identification of clinically applicable methods for studying oxidative stress and 
subsequently understanding the natural history of oxidative stress after trauma. The 
second component is modulation of oxidative stress in surgical patients by the 
introduction of glutamine as a source of antioxidant during the postoperative course of 
the patient. The third component involves the development of new methods for 
measuring oxidative damage that should enable elucidation of the precise role of reactive 
oxygen species in a clinical setting.  
3 
2. LITERATURE REVIEW 
2.1. Concept and Components of Oxidative Homeostasis. 
Figure 2.1: Concept of Oxidative Stress. 
 
 
 
Oxidative homeostasis is the way the body maintains the balance between free 
radical (oxidants) production and antioxidant reserve. ROI are produced as a result of 
normal physiological processes such as oxygenation (2%-3% of metabolized oxygen is 
also converted to superoxide anion free radicals, electron transfer and lipid metabolism. 
ROI are quickly reduced by antioxidants. Antioxidants are defined functionally as 
compounds that provide protection against the harmful effects of free radicals and other 
reactive oxidants. They may be found either in the circulation such as in plasma or red 
blood cells, or in organs such as the kidney and the liver. Oxidative stress is a 
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derangement of the normal physiological balance defined as a state in which the level of 
ROI overcomes the endogenous antioxidant defenses of the host [19].  
Reactive oxygen species (ROS) is a collective term for radical or non-radical 
forms of partially reduced oxygen which include: superoxide, hydrogen peroxide, 
hydroxyl radical and hypochlorous acid [20-22], [23], [24]. ROS has been used 
interchangeably with ROI by different authors and the two terminologies are 
synonymous. 
During illness, phagocytic cells, as a mechanism to kill invading microorganisms, 
produce ROI. ROI cause direct injury to cellular proteins and nucleic acids by oxidative 
damage, and also cause lipid peroxidation, leading to cell membrane destruction. They 
also act indirectly as secondary messengers in the intracellular signaling pathways of 
inflammatory cells. The most significant of these is through the nuclear factor κB, which 
is a central transcription factor involved in the regulation of numerous pro-inflammatory 
genes [5, 25, 26]. When inflammation becomes systemic i.e. the inflammatory response 
syndrome, loss of control of ROI production may lead to nondiscriminant bystander 
injury in the host [1].  
 
2.2. Pathophysiology and Intrinsic Response to Oxidative Stress. 
2.2.1. Pathophysiology of Oxidative Stress. 
Oxidative stress is the enhancement of the bodys production of free radicals and 
other strong oxidants either by increased production of the radical or depletion of body 
stores of antioxidants. Free radicals can attack any biochemical component of the cell but 
lipids, proteins and nucleic acids are the most important targets. Free radicals generally 
react with the first structure they encounter- most frequently the ipid components of cell 
or organelle membranes [27].   
 Superoxide anions are produced by a number of cellular reactions, the most 
important of which is normal mitochondrial respiration, where a significant 1-3% of 
oxygen is partially reduced to the superoxide anion [28-30]. This proportion is increased 
during hypoxia and reperfusion following an ischemic insult [30]. Superoxide anion can 
also initiate the cascade of arachidonic acid metabolism, resulting in the formation of 
more superoxide and in the liberation of Fe2+ from ferritin stores [31]. The enzyme 
5 
superoxide dismutase (SOD) converts superoxide to hydrogen peroxide and molecular 
oxygen; however, superoxide can also spontaneously dismutate to form hydrogen 
peroxide and singlet oxygen, a strong oxidizing agent [20].  Hydrogen peroxide is a mild 
oxidant that readily crosses cell membranes. Hydrogen peroxide can dismutate to 
hydroxyl radical in the presence of transition metal ions such as Fe2+ [32]. The hydroxyl 
radical is the most powerful oxidant formed in the biological system with a diffusion ratio 
of 0.3 nm before it abstracts an electron from another molecule. A single hydroxyl radical 
and molecular oxygen can react with a poly-unsaturated fatty acid not only altering its 
structural and functional integrity but also generating multiple fatty acid peroxyl radical 
which spontaneously reacts with other lipids, proteins, or nucleic acids thereby 
propagating a cascade of electron transfer and the consequent oxidation of these 
substances. The cell injury produced by lipid peroxidation of cell membranes can range 
from increased permeability to cell lysis. Proteins, both structural and enzymatic are also 
vulnerable to free radical mediated denaturation [33]. Toxic oxygen metabolites can also 
directly attack nucleic acids causing base hydroxylation, crosslinking or scission of DNA 
strands that can result in cell death and mutation [34]. The hydroxyl radical can therefore 
wreak havoc in cells by causing DNA strand breakage, oxidizing proteins, as well as by 
causing lipid peroxidation [35-37]. 
 Lipid peroxidation is one of the major ways that ROS cause cell damage since 
peroxidation results in changes in fluidity, membrane permeability and may alter 
functions of proteins embedded in the membrane. The hydroxyl radical extracts a 
hydrogen atom from a methylene carbon of a polyunsaturated fatty acid forming a 
carbon-centered lipid radical. The lipid radical can interact with molecular oxygen to give 
rise to a peroxyl radical. The peroxyl radical is converted to a lipid hydroperoxide by 
extracting a hydrogen atom from a methylene carbon to form a new lipid radical, thus, 
initiating a propagating chain of lipid peroxidation. The lipid hydroperoxides formed are 
not innocuous entities since in the presence of iron complexes they decompose, forming 
alkoxyl and peroxyl radicals thus resulting in new chains of lipid peroxidation being 
initiated [38]. It is clear that iron in the presence of peroxides is a danger to the cell [38]. 
This peroxidation chain is generally ended when the lipid radicals interact with vitamin E 
forming a lipid alcohol and a tocopherol radical [37]. 
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2.2.2. Intrinsic Response to Oxidative Stress 
 Sources of strong oxidants are hydrogen peroxide and organic peroxides. These 
peroxides are scavenged by glutathione peroxidase using reduced-glutathione (GSH) as 
the electron donor [39]. In addition, vitamins E (tocopherol) and C (ascorbic acid) play 
central roles in inactivating free radicals, in particular lipid radicals [40, 41]. Tocopherol 
inactivates the lipid peroxyl radical forming a tocopherol radical and lipid peroxide. The 
tocopherol radical is inactivated by ascorbate resulting in the regeneration of tocopherol 
and the formation of ascorbate radical. The ascorbate radical dismutates forming 
ascorbate and dehydroascorbate, and the dehydroascorbate is subsequently reduced by 
GSH to form ascorbate and oxidized glutathione [42, 43]. 
 It is clear that GSH plays a central role in the cell's defense mechanisms against 
oxidative stress. It is required by glutathione peroxidase to eliminate peroxides 
(compounds that can form powerful oxidants in the presence of transition elements). 
GSH is also required for the ultimate regeneration of vitamin E, a compound that plays a 
critical role in scavenging lipid radicals. 
 
2.2.3. Trauma and Oxidative Stress 
Injury is the commonest etiology of oxidative stress. This injury could be post-
ischemic, reperfusion, heat, physical trauma, cold, excessive exercise, or exposure to 
toxin, radiation or infection. Trauma causes oxidative stress through three major 
pathways including necrosis, bacteria invasion and hypoxia. Each of the pathways results 
in activation of complement, polymorphonuclear cells and macrophages causing 
increased release of reactive oxygen intermediates (ROI). The release of ROI leads to 
further activation of neutrophils and macrophages. In addition hypoxia and shock 
increase the release of endothelin-1 and scavenging of nitric oxide (.NO) producing 
vasoconstriction, further hypoxia, ischemia, and subsequent release of tumour necrosis 
factor (TNF). These changes result in cell death or organ dysfunction [18, 44, 45]. Injury 
can give rise to systemic decreases in anti-oxidant capabilities beyond the tissues affected 
by the trauma. For example severe skin burn has been demonstrated to decrease brain 
GSH by 50-70% [46].  
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Figure 2.2: Mechanism of Oxidative Stress in Trauma 
 
 
Figure 2.2: Graph outlining how trauma causes oxidative stress.  PMN = polymorphonuclear cells; IL = 
interleukin; ROS = reactive oxygen species; SIRS= systemic inflammatory response syndrome; MODS = 
multiple organ dysfunction syndrome 
 
Burns increase xanthine oxidase activity in the affected tissue and cause neutrophil 
activation. Animal studies have demonstrated decreased burn edema and lessening of 
distant organ dysfunction with the use of antioxidants, suggesting a cause and effect 
relationship [47]. There are clinical and experimental findings supporting the depletion of 
hepatic stores of glutathione by systemic stress, such as that produced by major surgery, 
starvation, sepsis, organ transplantion, and neurologic death [48, 49]. Sepsis, in addition 
to depleting gluthatione also depletes the endothelial derived relaxing factor (EDRF). 
EDRFs are a group of substances such as .NO (nitrous oxide), prostaglandins, and 
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endothelium-derived hyperpolarizing factor (EDHF) produced by the endothelium to 
regulate the relaxation of the underlying smooth muscle layer and maintain vascular tone 
[50]. NO is a prominent EDRF as well as a potent antioxidant which terminates oxidant 
stress. It produces this effect by (i) suppressing iron-induced generation of hydroxyl 
radicals (.OH) via the Fenton reaction (ii) interrupting the chain reaction of lipid 
peroxidation, (iii) augmenting the antioxidative potency of reduced glutathione (GSH) 
and (iv) inhibiting cysteine proteases [51].  Sepsis causes endothelial damage from 
persistent and repetitive inflammation scavenging and inhibiting production of .NO [51-
53]. Oxygen free radicals contribute significantly to reperfusion injury as well as to 
preservation injury. Severe oxidative stress by reducing hepatic GSH can lead to 
hepatocyte necrosis [54].  
 
2.2.4. Neutrophils and Oxidative Stress  
Neutrophils are formed in the bone marrow. The turnover of these cells is very 
high, approximately 1011 cells/day or 100 g/day [55]. Neutrophils contain four well-
defined types of intracellular granules: azurophilic, specific, gelatinase (tertiary) and 
secretory vesicles. The azurophilic granules contain most antibacterial compounds such 
as myeloperoxidase, elastase, and neutral proteases. Fusion of these granules with 
phagocytic vesicles is important in bacteria killing. Elastase alters bacteria locomotion by 
hydrolysis of certain extracellular matrix components, neutral proteases damage the 
extracellular matrix and myeloperoxidase an oxidant combines with H2O2 and an 
oxidizable halide to form strong antimicrobial compound [55-57]. Specific granules are 
more readily released from the cell suggesting important function in the extracellular 
milieu. Some products of specific granules can activate compliment cascade [58]. 
Specific granules contain collagenase, which may be important in hydrolyzing 
extracellular matrix, as well as apolactoferrin which binds iron and may exert an 
antibacterial effect by depriving the bacteria of iron [59-61]. Tertiary and secretory 
vesicles contain membrane proteins that can be rapidly upregulated to the cell surface and 
may play a role in the alteration of functional utility of surface proteins following 
stimulation [62-64].  
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   Neutrophils also contain many lysosomes with a powerful hydrolytic and 
proteolytic potential. Normally, lysosomal enzymes along with oxidizing agents 
produced when phagocytosis is triggered, serve two main purposes: intracellular protein 
catabolism including the degradation of intra and extracellular endogenous substances 
and the degradation of phagocytized viruses and bacteria [65, 66]. Most lysosomal 
enzymes fulfil their physiological function in the cell with only small leaks but under 
certain circumstances major escapes occur [67].  
Leakages could result from incomplete phagocytosis of large structures, or 
disintegration of phagocytes by toxins causing irreparable damage to the cell structure 
and function [57, 68-70]. Neutrophil rupture and the resulting leakages have been 
associated with severe inflammation and multiple injury [65]. A positive correlation 
exists between myeloperoxidase, elastase levels and the Acute Physiology and Chronic 
Health Evaluation 3 (APACHE3) score [71]. 
Neutrophils possess antioxidant mechanisms that protect against host injury by 
the potent products of phagocytosis. These include superoxide dismutase, glutathione 
peroxidase, catalase, vitamin E and ascorbic acid.  They play a significant role in limiting 
tissue destruction caused by proteases however neutrophil oxidants are known to be the 
single most important direct mediators of immune injury [57].   
The relevance of the absolute neutrophil count in trauma has been highly debated 
with two major theories.  Some argue that the increased count is due to a balance between 
production and demargination rather than the trauma, while others argue margination and 
breakdown due to the trauma are responsible [72, 73]. There is however increasing 
evidence of a link between absolute neutrophil count and postoperative surgical stress or 
infection [74-78]. Inhibition of apoptosis (programmed cell death) and subsequent 
prolongation of inflammation have been suggested as the basis of the increase in 
neutrophil count [73, 79-82].  Mitogen -activated protein kinase (MAPK) and nuclear 
factor kappa B (NKκB) activation have been identified as proximal events signalling the 
inhibition of apoptosis [83, 84].  
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2.2.5. Sources of Antioxidants in the Body 
The main feature of living organisms is their capability to protect themselves 
against uncontrolled oxidation. All organisms are subject to the permanent influence of 
oxygen and other oxidatively active causes such as Ultraviolet (UV) sun radiation, 
atmospheric noxae (e.g. cigarette smoke, pollutants e.g ozone, ionizing radiation and 
xenobiotics i.e drugs such as paracetamol, bleomycin, anthracycline etc) [85-88]. 
Ultraviolet radiation is known to decrease the levels of antioxidants, inactivate the 
antioxidant enzymes and increase lipid peroxidation in the skin [85, 89, 90]. Atmospheric 
noxae deplete antioxidants and increase free radical formation especiall in the respiratory 
system [88]. Antioxidants play a critical role in health maintenance and the inhibition of 
oxidative damage. Therefore antioxidant activity could be defined as protection against 
oxidative damage and this is measured in terms of the antioxidative reserve or capacity in 
a biological substrate. 
Antioxidants in plasma can be classified into two groups namely the water-
soluble and lipid soluble. The water-soluble antioxidants include ascorbic acid or vitamin 
C, uric acid, protein thiols, and bilirubin. Plasma also contains very low levels of 
glutathione, which is a major intracellular antioxidant. The lipid-soluble antioxidants 
comprise of α and γ tocopherol, ubiquinol, lycopene, β carotene and some other 
caroteniods and oxycaroteniods [91]. 
The mechanisms of antioxidant protection can be classified into four categories: 
compartmentation, detoxification, repair and utilization. Compartmentation is both the 
spatial separation of potentially harmful but essential substrates (e.g. storage of iron in 
ferritin) and cell and tissue distribution of antioxidative compounds and serves the 
prevention of uncontrolled oxidation [87]. The most significant mechanism from the 
therapeutic point of view is detoxification because it results in the breakdown of free 
radicals to non-toxic substances (oxygen, water), thus protecting from many diseases. 
Detoxification of oxidative molecules i.e. radicals and peroxides, is ensured by enzymatic 
and non-enzymatic substances. The detoxification enzymes are present intra- and extra-
cellularly and protect cells from the destructive side effects of free radical chain reaction 
[87]. Antioxidants repair by reverting the original changes due to free radicals when they 
are still reversible [40, 87, 92]. Utilization is considered as a secondary antioxidant 
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protection mechanism whereby further degradation of denatured and peroxidized 
potentially toxic proteins and lipids occurs [87]. 
Total antioxidant capacity is therefore the total ability of the body to protect itself 
from destructive side effects of physiological metabolism. The human plasma is often 
used for studying free radical induced damage because it contains critical targets of 
oxidative damage such as lipoproteins and many important antioxidants in the same 
physiological environment.  
 
2.3. Measuring Oxidative Homeostasis Components Applicable to the Study 
2.3.1. Measuring Total Antioxidant Capacity in Plasma  
The concept of total antioxidant capacity of biological fluids is important because 
it determines the capacity of biological fluids to withstand oxidative stress. Most of the 
methods used for the measurement of antioxidant activity are inhibition methods except 
for the ferric reducing/ antioxidant power (FRAP) and total serum reductive capacity, 
which measure the reductive capacity of antioxidants. The inhibition methods involve 
two phases, the first in which there is free radical generation with an endpoint indicating 
the presence of the free radical. In the second phase the antioxidant activity of the added 
sample inhibits this endpoint by scavenging the free radical. The methods vary greatly 
with respect to the free radical that is generated, the reproducibility of the generation 
process and the end point used. The reductive methods do not generate free radical but 
measure serum abililty to act against an oxidizing agent which was Fe3+ for the FRAP 
assay and phospholipase A2 (PLA2) for TORC. This literature review will focus on three 
inhibition methods and two reduction methods. The unit of antioxidant capacity is the 
trolox which is defined as the millimolar concentration of a substance that has the same 
antioxidant capacity as a millimolar of Trolox i.e.Trolox equivalent activity (TEAC) [93]. 
 
2.3.1.1. Total Radical Trapping Potential (TRAP) Method: 
One of the most frequently employed procedures to evaluate the antioxidant status 
is the total radical trapping potential (TRAP) method developed by Wayner [94]. TRAP 
is defined as the number of molecules of peroxyl radicals trapped per litre of fluid. Total 
antioxidant activity (TAR) describes the ability of an antioxidant to instantaneously 
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reduce chemiluminescence in the TRAP assay. It is based on the measurement of 
induction times in the oxidation of a lipid dispersion exposed to a free radical source with 
constant and known rate of free radical production under aerobic conditions [94]; [95]. 
This method was based on the discovery that the thermal decomposition of the water-
soluble azo compound 2,2-azobis (2- amidopropane) hydrochloride (ABAP) yields 
peroxyl radicals at a known and constant rate. Each molecule of Trolox (Trolox, 
Hoffman-LaRoche, Basel, Switzerland) α-tocopherol and or phenolic antioxidant traps 
two peroxyl radicals giving the Trolox a stoichiometric factor of 2.0, in the TRAP assay. 
A serum sample is mixed with linoleic acid to prevent the termination reaction of two 
peroxyl radicals occurring, and an aliquot (25-50 µL) is added to the air-saturated buffer 
in the chamber of an oxygen electrode (Clark-Collip rate amperometric electrode). The 
reaction is initiated by the addition of ABAP and it is monitored until oxygen uptake is 
maximal. After 50% of the oxygen has been taken up, Trolox is added to calibrate the 
system and the oxygen uptake is further monitored. The total assay time for a single 
sample varies according to its antioxidant capacity, but that for serum takes 
approximately 90 min, the reference interval is 571-1284 µM of TEAC [94].  
A major problem with the original TRAP assay method lies in the oxygen 
electrode end point. An oxygen electrode will not maintain its stability over the period of 
time required (up to 2 hr) per sample. Such instability is more pronounced in plasma 
samples than with pure solutions. Hence a high degree of imprecision is inherent [95]. 
Other problems with the assay are that it is too lengthy to carry out precision monitoring 
or to permit analysis of large numbers of samples [95, 96]. 
There have been a few modifications to the original TRAP technique: the first 
involves the use of chemiluminescence, which lends itself to automation and is more 
precise. The process involves peroxyl radical enhanced chemilinescent reaction. The 
addition of an antioxidant extinguishes the chemiluminescence. The duration of the 
chemiluminescence is directly proportional to the radical trapping ability of the 
antioxidant sample. A further modification is the introduction of an assay for the lipid 
phase using 2,2'-azobis (2,4-dimethylvaleronitrile) (AMVN) TRAPLDL as the source of 
peroxyl radicals [95, 97].  
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TRAP measures the levels of the following antioxidants: Uric acid (urate), 
Protein-sulphydryl groups (-SH), α-Tocopherol, Ubiquinol-10 [98, 99]. The 
chemiluminescence enhanced TRAP method has been proven to be reliable in evaluating 
the total activity of chain-breaking antioxidants in biological fluids. The 
chemiluminescence method is also less laborious because up to 24 samples can be 
processed in 8 hr using an LKP Wallac luminometer [98].  
 
2.3.1.1.1. Pitfalls of the TRAP Method 
 There are numerous potential problems with the TRAP method: 
i. Uric acid gives the strongest contribution in the TRAP assay because of its high 
plasma concentration (120-350 µM in healthy adults). In patients with hyperuricemia 
(e.g. goiterous state and non-insulin dependent diabetes mellitus) changes in the 
levels of other antioxidants may not be reflected in the TRAP value due to the high 
concentration of uric acid. 
ii. Plasma TRAP may not be the tool of choice for measuring oxidative stress 
because free radical production would probably have to be very extensive to disturb 
the systemic steady-state level of antioxidants. Antioxidant systems are also highly 
compartmentalized in their actions such as on the cell membrane (e.g. glutathione, 
superoxide dismutase, catalase) or in extracellular fluids (e.g. ascorbic acid, uric acid, 
albumin). Since the TRAP method like others does not measure all of these 
antioxidants it will not measure the total antioxidant capacity in systemic oxidative 
stress [98].  
iii. The rate of lipid peroxidation as induced by azo inhibitors has been shown to be 
dependent on the pH of the buffer used [99-101]. It is therefore important to tightly 
control the pH of the TRAP buffer in order to control the amount of peroxyl radicals 
produced [98]. 
 
2.3.1.1.2. Clinical Utility of the TRAP method  
 The TRAP method has been used extensively in previous clinical studies. 
i. TRAP, TRAPLDL and their main components have been used to study the effects 
of acute infection, diabetes, immobilization, Alzheimer's disease, coronary heart 
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disease, and cancer [98]. It was observed that plasma antioxidant defenses seemed to 
respond to the basic metabolic rate and the challenges caused by physiological or 
pathological stress. 
ii. During acute infection and immobilization, levels of ascorbic acid and ∝-
tocopherol remained unchanged whereas the amount of TRAPUNID in TRAP declined 
sharply [102, 103]. The plasma of NIDDM (non-insulin dependent diabetes mellitus) 
patients with CHD (coronary heart disease) had a significantly higher value of 
unidentified antioxidative potential than that of patients without CHD [104]. This 
relation was strongly dependent upon smoking, but plasma TRAP was not changed in 
diabetes and but reduced in patients with Alzheimer's disease [104, 105]. 
iii. In lung cancer patients with a poor response to treatment, TRAP was reduced 
[106, 107]  
iv. The enhanced chemiluminescence assay demonstrated reduced serum antioxidant 
capacity in centenarians. The importance of this intriguing observation with regards 
to the aging process is yet to be determined [108, 109].  
The chemiluminescence-enhanced TRAP has revealed important information in 
evaluating the antioxidant status of human plasma [98]. The total antioxidative potential 
cannot be evaluated reliably by measuring only TRAP because of its dependence on uric 
acid. TRAP combined with its main components is likely to give more valid information 
in determining the total antioxidant status [98]. 
2.3.1.2. The 2-2-Azinobis(3 Ethylbenzothiazoline-Sulfonic Acid (ABTS) 
Method  
The 2-2-azinobis(3 ethylbenzothiazoline-sulfonic acid (ABTS) method is a 
spectrophotometric method for measuring antioxidant capacity which is based on the 
inhibition of the absorbance of the radical cation of ABTS by antioxidants [95]. 
Antioxidant compounds suppress the absorbance of the ABTS radical cation to an extent 
and on a time scale dependent on the antioxidant capacity of the substance under 
investigation [93, 110]. The ABTS radical cation can be generated by the interaction of 
ABTS (150 µM) with the ferrymyoglobulin radical species, which is a product of 
activation of metmyoglobin (2.5 µM) by H202 (75 µM).  
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The ABTS detects antioxidants such as bilirubin, urate, ascorbate, α-tocopherol, 
albumin and glutathione [95, 96, 111]. The different analytical strategies for assay design 
are: decolorization assay, inhibition assay (fixed time point), inhibition assay  (reaction 
rate), and lag phase measurement [95]. 
 
2.3.1.2.1. Advantages of the ABTS Method 
A number of advantages of the ABTS method have become evident: 
i. It can be done either as an automated or as a manual assay [93, 96]. 
ii. Analytical parameters of the assay i.e. intra assay and inter assay Coefficients of 
Variation (CV) are quite good. The CV interval ranges from 0.54%-1.59% in the intra 
assay and 3.6%-6.1% in the inter assay [95].  
 
2.3.1.2.2. Disadvantages and Pitfalls of the ABTS Method 
 Unfortunately a number of disadvantages of this method also exist: 
i. It has a lag phase [112]. 
ii. It requires fixed times in reading the reaction. 
iii. It is evident from the performance of the kit that even slight changes in reaction 
conditions have marked effects on the apparent contributions of individual 
antioxidants, notably albumin, thus any inference regarding contributions to total 
antioxidant activity in vivo must be done with even greater caution [96]. 
iv. The ABTS method is strongly influenced by temperature [113]. It is necessary to 
define a precise analytical protocol that merits valid comparison of results between 
laboratories [96]. 
v. The three key antioxidants of plasma (albumin, urate and ascorbate) inhibit the 
production of ABTS by differing mechanisms because the kinetics of chromophore 
generation may vary markedly. It is an essential requirement of any technique that 
proposes to measure total antioxidant capacity that all contributing antioxidants 
behave in an analogous manner. This requirement is clearly not met as previously 
discussed thus the result for the assay can only be regarded as semiquantitative. 
16 
vi. ABTS is also affected by increased levels of urate production and the levels fall 
after dialysis [114]. This will therefore lead to false- positive results in hyperuricemia 
and false-negative results in hypouricemia. 
vii. It is dependent on the solubility of the substrates. 
 
2.3.1.2.3. Clinical Utility of ABTS Method 
i. There is evidence using the ABTS method that preterms have significantly lower 
plasma antioxidant activity than term babies. The study showed that preterm babies 
required five days to stabilize their antioxidant levels to adult levels [93]. 
ii. There is also evidence that mothers of preterm babies less than 32 weeks have 
reduced antioxidant capacity when compared with mothers of term babies [115].  
iii. There is some evidence of significant decreased total antioxidant capacity in HIV 
patients [116, 117]. 
iv.  There is some evidence that total antioxidant capacity is reduced in critically ill 
patients compared to controls, and it is also reduced in hemodialysis patients [118].  
 
2.3.1.3. Oxygen-Radical Absorbance Capacity Assay (ORAC) 
A relatively simple but sensitive and reliable method of quantifying the oxygen-
radical absorbing capacity (ORAC) of antioxidants in serum using only a few microliters 
is described. In this assay system, beta-phycoerythrin (beta-PE) is used as an indicator 
protein, 2,2'-azobis(2-amidinopropane) dihydrochloride (AAPH) as a peroxyl radical 
generator, and 6-hydroxy-2, 5, 7, 8-tetramethylchroman-2-carboxylic acid (Trolox, a 
water-soluble vitamin E analogue) as a control standard. Results are expressed as ORAC 
units, where 1 ORAC unit equals the net protection produced by 1 microM Trolox. The 
uniqueness of this assay is that total antioxidant capacity of a sample is estimated by 
taking the oxidation reaction to completion. All of the non-protein antioxidants alpha-
tocopherol, vitamin C, beta-carotene, uric acid, and bilirubin and most of the albumin in 
the sample are oxidized by the peroxyl radical. Results are quantified by measuring the 
protection produced by antioxidants. This solves many problems associated with kinetics 
or lag-time measurements. There is linear correlation between the ORAC value and 
concentration of serum Trolox, vitamin C, uric acid, and bovine albumin. The coefficient 
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of variation within a run is found to be about 2% and from run to run about 5%. Trolox, 
alpha-tocopherol, vitamin C, beta-carotene, uric acid, and bilirubin completely protect 
beta-PE from oxidation, while bovine albumin protects beta-PE only partially. On a 
molar basis, the relative peroxyl radical absorbance capacity of Trolox, alpha-tocopherol 
acid succinate, uric acid, bilirubin, and vitamin C is at a ratio (1: 1: 0.92: 0.84: 0.52.). 
Bovine albumin per unit weight has a lower peroxyl absorbing capacity than these 
antioxidants [119, 120]. The ORAC assay requires more than 60 min to quantify results 
[121]. 
 
2.3.1.3.1. Clinical Utility of Oxygen-Radical Absorbance Capacity Assay 
The study comparing nephrotic syndrome patients with controls demonstrates 
decreased free-radical trapping capacity of plasma that is inversely correlated with 
hypoalbuminaemia in the patients.  This decreased total plasma antioxidant potential in 
combination with hyperlipidaemia may contribute to the increased risk of cardiovascular 
disease seen in nephrotic syndrome [122].  
In diabetes the ORAC has been used to provide evidence of oxidative stress in 
patients showing a decrease in the antioxidant capacity as compared with the controls 
[123]. Other studies by Pieri and Testa [124] showed an involvement of oxidative stress 
in the glycation of haemoglobin especially in old diabetic patients, and provide support 
for the potential use of an antioxidant therapy in these patients, irrespective of their 
glycaemic control. Wang [125] and Cao [121] demonstrated using ORAC method that 
increased consumption of fruit and vegetables can increase the plasma antioxidant 
capacity in humans. 
 
2.3.1.4. The Ferric Reducing / Antioxidant Power (FRAP) Method 
The Ferric Reducing/Antioxidant Power (FRAP) assay is a direct test of total 
antioxidant power [112, 126]. The FRAP assay an assay that measures the ferric 
reducing ability of the sample [121]. It uses antioxidants as reductants in a redox-linked 
colorimetric method, employing an easily reduced oxidant present in the stoichiometric 
process. The FRAP assay measures the total reducing power of the antioxidant based on 
the fact that electron-donating antioxidants can be described as reductants. These 
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reductants inactivate the oxidants in a redox reaction: one of the species is reduced while 
the other is oxidized, and it is this total reducing power that is referred to as total 
antioxidant power [127]. 
At low pH, reduction of a ferric tripyridyltriazine (FeIII - TPTZ) complex to a 
ferrous form results in the production of an intense blue color, and thus can be monitored 
by measuring the change in absorbtion at 593 nm. The reaction is nonspecific, in that any 
half-reaction that has a lower redox potential, under reaction conditions, than that of 
ferric/ferrous half -reaction will drive the ferric (Fe III) to ferrous (FeII) reaction. The 
change in absorbance therefore is directly related to the combined or total reducing of 
the electron -donating antioxidants present in the reaction mixture [112]. 
The ferric reducing/ antioxidant power and ascorbic concentration (FRASC) is a 
modification of the FRAP that quantifies three indices of antioxidant status: the total 
reducing (antioxidant) power, the absolute concentration of ascorbic acid, and the relative 
contribution of ascorbic acid to the total antioxidant power of the sample virtually 
simultaneously [112, 126]. This makes the FRASC more clinically relevant, however, 
this study employed the FRAP method because it was not deemed necessary to quantify 
ascorbic acid levelsa in plasma. 
 
2.3.1.4.1. Advantages of the FRAP Method 
The FRAP method as a measure of total antioxidants has certain advantages: 
i. It is a direct test of total antioxidant power unlike the previous methods which 
were all indirect tests [97, 99, 112, 119, 120, 128, 129]. 
ii. It does not use lag phase type of measurement [127]. 
iii. In FRAP assay, sample pre-treatment is not required, stoichiometric factors are 
constant, linearity is maintained over a wide range, reproducibility is excellent, and 
sensitivity is high [127]. 
iv. FRAP can be performed automated, semi-automated, and manually [127]. 
v. It does not require specialized equipment, skills, or critical control of timing and 
reaction conditions [127]. 
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vi. Uric acid accounts for most of the antioxidant capacity measured by all methods 
and this could affect the accuracy of the obtained results. The FRAP and its 
modification, FRASC have corrected for the high (60%) uric acid contribution. 
vii. The ferric reducing/ antioxidant power and ascorbic acid concentration (FRASC) 
supply three indices of antioxidant status: the total reducing  (antioxidant) power, the 
absolute concentration of ascorbic acid, and the relative contribution of ascorbic acid 
to the total antioxidant power of the sample virtually simultaneously [126, 127]. 
viii. It can be used for a wide range of biological fluids [127]. 
ix. Analytic performance of FRAP was quite satisfactory with the coeficient of 
variation of less than 1% within runs and less than 3%between runs. The FRASC was 
very good and the results were consistent [127]. 
 
2.3.1.4.2. Disadvantages of the FRAP Method 
   The use of ferric ion (Fe2+) as final product in the FRAP assay may cause 
problems when an analyzed antioxidant such as ascorbic acid, not only reduces Fe3+ to 
Fe2+ but can react with Fe2+ to generate additional free radical [121]. FRAP does not also 
measure the SH-group-containing antioxidants such as plasma proteins, which could 
potentially limit its clinical utility [121].  
 
2.3.1.5. The Total Reductive Capacity (TORC) Assay 
This is a simple fast substrate based assay developed by Mayer et al (2001) to 
measure the antioxidants in serum [130]. The assay uses a thiol-labelled arachidonic acid 
as substrate for the reductive action of tripeptides such as glutathione. The thiol-labelled 
arachidonic acid is suspended in a buffer containing hydroxyethylpiperazine-N'-2-
ethanesulfonic acid (HEPES), glycerol and Triton-X-100. The substrate (100 µl) and 
equal volume of the standard or serum are added to a microtitre plate and incubated at 
room temperature for 15 minutes. The standard is bee venom phospholipase A2 (PLA2). 
When coupled with monochrombimone serum free thiols (glutathione etc) produce 
fluorescence measured using a regular fluorometer and compared with a standard curve. 
The assay has >7% interassay variation and a 97% retrieval rate. The normal levels in 
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healthy population range from 100-120 ng/ml.  This method was found to of predictive 
value in evaluating patient outcome post-trauma.  
 
2.3.2. Glutathione System 
Glutathione (L-γ-glutamyl-cysteinyl-glycine; GSH) is an α-amino acid as well as 
tripeptide, it is formed from glutamine, cysteine and glycine [131].  This compound is 
widespread in animal tissue, plants and microorganisms; it is therefore the most prevalent 
cellular thiol and most abundant low molecular weight peptide. There is a wide variation 
in the concentration of glutathione in cells and organs. Red blood cells have ∼1 mM 
[132]; lens has 10 mM [133]; liver has 5-7 mM [134]; kidney, heart and lung have 2-3 
mM [134]; the brain and the spinal cord have concentration as low as 1-2 µMol/g [135] 
(≈1-2 mM), plasma 23 µM [136]. 
Glutathione has a number of functions including metabolism, catalysis, transport 
and protection of cells against oxidation [132, 137-139]. Glutathione reduces disulfide 
linkages of proteins and other molecules in the synthesis of the deoxyribonucleotide 
precursors of DNA.  It also plays a role in the inactivation of a number of drugs and in 
the metabolic processing of certain endogenous compounds such as estrogens, 
prostaglandins, and leukotrienes [137-139]. Glutathione acts as a coenzyme for several 
enzymes (catalysis). Glutathione is involved in transmembrane transport of amino acids 
particularly cysteine (and glutamine) which is regarded as the limiting amino acid for 
glutathione metabolism and for protein synthesis [137, 140]. Glutathione protects cells 
against the effects of free radicals and ROS (e.g peroxides) formed during metabolism 
[18, 137, 139, 141]. 
In this study changes in red cell glutathione was measured based on the 
hypothesis that trauma results in depletion of the red cell glutathione defense system. In 
addition, the red cell requires significant extracellular oxidative stress to produce 
depletion in its glutathione level thus making red cell glutathione a reasonable index of 
oxidative stress. The red cell also transports glutathione from organs such as liver and 
kidney to areas of need [142]. 
The red cell has concentration of glutathione ranging from 0.6 mM to about 2 mM 
[131, 143]. This concentration is about 100 times the concentration found in plasma. The 
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red cell only requires about 30%- 40% of the activity of the glutathione reductase to 
maintain normal levels of glutathione. Trauma causes the release of free radicals in the 
body leading to consumption of antioxidants in extracellular fluid and subsequent 
depletion of red cell glutathione [42, 132, 144]. This results in increased production of 
oxidized glutathione, which is reconverted to reduced-glutathione in the presence of 
NADPH and glutathione reductase.  
When there is severe oxidative stress the rate of depletion of reduced glutathione 
is faster than the production resulting in an efflux of oxidized glutathione from the cell 
into the plasma [145, 146]. This is measurable as a reduction in the total red cell 
glutathione and has been associated with multiple organ failure and death [145].  
 
2.3.2.1. Enzymatic Methods of Measuring Reduced Gluthathione 
There are several ways of measuring glutathione in the red cell. Some involve 
calculating the difference in the ratio of the reduced-and-oxidized glutathione to reduced 
glutathione using the Ellman's reagent (DTNB) from fresh blood and this could be read 
using a spectrometer at a wave length of 320 nm [147, 148]. Reed [149] measured GSH, 
GSSG and other thiols by making derivatives of free thiols with iodoacetic acid followed 
by conversion of free amino groups to 2,4-dinitro phenyl derivatives and HPLC 
separation and measurement.  
The Asensis modification of Brigeliuss method used in the study is a 
colorimetric method based on the conjugation of chlorobenzidine with glutathione and is 
catalyzed by glutathione-S-transferase. The adduct formed, S-(2,4-
dinitrophenyl)glutathione exhibits its maximum absorbance at 340 nm. The specimen is 
pre-treated with Trichloacetic acid (TCA) and the supernatant is stable for 1 wk when 
stored at -200C [150, 151]. The Asensis modification of Brigeliuss method provides an 
end point reading that can measure as low as 0.2 nm in the cuvette which corresponds to 
0.3 µM GSH [152].  
Brown and Armstrong [153] modified of the Beutler [154] method of measuring 
reduced glutathione. This involves the addition of meta-phosphoric acid / EDTA and 
sodium chloride as a stabilizing solution to fresh blood samples. The mixture is 
centrifuged and the supernatant can be stored at -800C. It is stable at this temperature for 
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one year and the glutathione content is measured using HPLC. This method was used by 
Richie et al [132] in a large-scale study with an absolute limit of 5 pmol and CV interval 
of 2.3%. Other methods using the HPLC include the N-(1-Pyrenyl) maleimide (NPM ) 
assay which is a rapid simple method for analyzing both oxidized and reduced 
glutathione as well as other thiols including cysteine, γ-glutamyl-cysteine, homocysteine, 
cysteinylglycine and N-acetylcysteine. The assay provides a sensitive and accurate means 
of correlating thiol status with alteration in metabolism, signal transduction and gene 
expression. 
 
2.3.3. Methods of Measuring Protein Carbonyl in Biological Samples 
All proteins are subject to modification by Hydroxyl radicals (.OH) or Hydroxyl 
and Oxygen radicals (.OH+O-2). The modifications includes alteration in molecular 
weight and net electrical charges [155] of which protein carbonyl is a product. Carbonyl 
formation is believed to be a result of Fe (II) binding to a metal binding site on the 
protein. The formed protein.Fe (II) complex reacts with H2O2 to generate an activated 
oxygen species in-situ an activated oxygen species which in turn reacts with the side 
chain of amino acid residues at metal binding sites resulting in its conversion to carbonyl 
derivatives [156, 157]. The carbonyl formation can either be primary or secondary.  
Primary formation results from protein exposure to reactive oxygen compounds leading 
to the modification and interconversion of amino acid side chains [155, 156, 158, 159]. 
Two mechanisms have been associated with secondary formation. The first is the 
oxidation of other modified proteins [160], while the other is amino acid reaction with 
lipid peroxidation products or reducing sugars [161-163].  Both primary and secondary 
reactions result in the α-amino acid yielding a Schiff base possessing carbonyl function. 
Schiff bases are produced by the condensation of an amine with the carbonyl group of an 
aldehyde or ketone in a reversible covalent reaction [164]. Carbonyl formation is not just 
a marker of oxidative damage but also part of the pathophysiology [161, 165]. A typical 
value of carbonyl content in a healthy animal is 2 nmol/mg protein [166]. 
 Protein carbonyls can be measured in any organ or tissue with protein. The tissues 
most commonly analyzed are the brain, liver, kidneys, muscles and plasma. All of these 
have been used for most clinical studies. Jones et al., (1956) were the first to identify 
23 
specific protein carbonyl using infrared and ultraviolet wavelengths. Their work 
enhanced easy identification of protein carbonyls. There are several highly sensitive 
methods for analyzing carbonyl groups. Some of these including colorimetric, ELISA, 
Western blot with its modification (Oxyblot), histochemical and urine methods will be 
discussed in the subsequent paragraphs. 
 
2.3.3.1. Colorimetric Method  
This was originally developed by Levine and Garland [167] and has undergone 
some modifications as documented by Evans et al [168]. It involves the formation of the 
protein-bound hydrazone from 2,4 dinitrophenylhydrazine which is read 
spectrometrically. The supernatant of the specimen or plasma is mixed with 
dinitrophenylhydrazine in hydrochloric acid at a ratio of 1:4 volume parts but the control 
excludes dinitrophenylhydrazine. Both sample and control are put on a rotator at room 
temperature for 20 minutes and the protein is then precipitated with trichloroacetic acid 
(TCA). The precipitate is washed thrice with ethyl acetate/ethanol mixture and 
redissolved in guanidine hydrochloride. The supernatant is read at 370 nm for evaluation 
of the carbonyl content. The concentration of carbonyl is determined by multiplying the 
absorbance by 45.45 nmol/ml using a microtitre plate reader with a path length check. 
The path length check makes the result of the absorption equivalent to a 1cm path. The 
protein content can either be evaluated using the bicinchoninic acid (BCA) method: 20 µl 
of plasma and albumin standard are added to 200 µl of the BCA solution which is read at 
562 nm [169]; or reading the blank supernatant at wavelengths 200 nm and 280 nm and 
using the difference to estimate the quantity of protein [170].  Plasma samples are 
compared with albumin standard at the same wavelength and the final result is carbonyl 
concentration divided by the amount of protein in mg/ml (the unit is nanomoles carbonyl/ 
mg of protein). Maximal plasma levels are about 12.5 nmol carbonyl /mg of protein with 
albumin constituting 6.7 nmol/mg of protein [171].  
 
2.3.3.2. Western Blot 
Oxidative changes in plasma can be measured by the western blot assay because it 
can identify individual oxidized protein in whole tissue. Protein oxidation results in the 
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formation of carbonyl groups (aldehydes and ketones) on some amino acids and these can 
be derivatized with 2,4 dinitrophenyl-hydrazine (DNPH). The derivatized protein are 
separated by SDS- PAGE and then analyzed for carbonyl contents by immunoassay with 
anti-DNP antibodies [157]. This process has been modified in the Oxyblot assay 
(Intergen) and provides reagent for a simple and sensitive immunodetection of carbonyl 
groups. The kit uses a membrane filter and provides primary and secondary antibodies as 
well as goat and anti rabbit IgG. These are treated with a chemiluminescent reagent. The 
protein is transferred to the membrane filter, which is treated with antibodies and the 
chemiluminescent reagent.  The luminol is converted to a light emitting form at 
wavelength 428 nm by the antigen-primary antibody-secondary-peroxidase complex in 
an H2O2 catalyzed oxidation reaction. The light is detected by short exposure to blue-light 
sensitive films. With the kit as little as 5 femtomoles of carbonyl can be detected. It is 
interesting to note that fibrinogen is about the most sensitive plasma protein to oxidative 
damage. It is 20 times more reactive than other proteins to oxidative damage (fibrionogen 
≈ 9.7molcarbonyl/mol of protein: albumin ≈ 0.5 mol carbonyl/mol of protein) [171]. 
Fibrinogen damage from free radicals may be responsible for bleeding disorders 
associated with multiple organ failure [172, 173]. 
 
2.3.3.3. Enzyme-Linked Immunosorbent Assay (Elisa Assay) 
The ELISA technique is a method of measuring protein carbonyl involving 
several reactions based on the recognition of protein bound DNP with an anti-DNP 
antibody. The protein from any sample is nonspecifically adsorbed to the ELISA plate. A 
DNP probe is inserted into the ELISA plate followed by the addition of a commercial 
biotinylated anti-DNP antibody and streptavidin-linked horseradish peroxidase. 200 µl of 
a solution containing o-phenylenediamine (0.6 mg/ml), H2O2 (1:2500) in 50 mM 
NA2HPO4 and 24 mM citric acid is added producing in a colour change. This is stopped 
at 25 minutes by the addition of 100 µl of 2.5M sulfuric acid. The absorbances are read 
with a 490 nm filter using a microplate reader.  This technique enables quantifying of the 
carbonyl produced and also has comparable sensitivity to the Western blot [174]. 
However there is anecdotal evidence that it is more sensitive and more quantitative than 
than a Wester blot. This technique was used by Buss et al [174] for concentrations 
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ranging from 0-2.5 nmol/mg of protein without the requirement of large sample 
quantities in a study. They concluded that the ELISA method was more sensitive and 
discriminatory than the colorimetric method [174].  
 
2.3.3.4. Urine Assays: Protein Carbonyl 
There are several methods of measuring the carbonyl in urine all of which use 
dinitrophenyl hydrazine (DNPH). The clinical method involves mixing equal quantities 
of filtered urine and DNPH. The production of a yellowish-white to yellowish precipitate 
is indicative of high keto acid in the urine. Acetone a source of interference could be 
excluded by boiling the urine to 100 degrees before doing the test [175].  This assay is 
also used in the diagnosis of maple syrup urine disease confirmed by Nuclear Magnetic 
Resonance Spectroscopy (NMR) [176].  The HPLC method involves acid hydrolysis of 
urine sample and a derivatization step of 2,5-hexanedione with 2,4 DNPH at 700C for 20 
minutes. A mixture of phosphate buffer (pH 3.3) and acetonitrile (50:50) is used as eluent 
and UV detection is at 334 nm. A linear response is obtained in the range of 0.19-20 mg/l 
of carbonyl [177]. Kim and Gallaher [178] evaluated the role of urine analysis as a mode 
of measuring oxidative stress using the HPLC method on urine samples to review 14 non-
polar and 11 polar aldehydes in determining carbonyl content. They concluded that 
urinalysis was not a reliable method for assessing oxidative stress.  
Gas chromatography/ mass spectrometry have also been used to measure urine 
carbonyl but the results were inconclusive [179]. We decided to review urine carbonyl 
levels in trauma as a visual marker of plasma carbonyl and subsequently quantified the 
precipitate in a neonatal study. 
 
2.3.4. Lipid Peroxide Measurements in Biological Samples 
Lipid peroxides are formed as a consequence of free radical attack on 
polyunsaturated fatty acids. The polyunsaturated fatty acids break down in the presence 
of iron or other metals forming aldehydes e.g. malondialdehyde (MDA) via the formation 
of cyclic peroxides and endoperoxides (precursors of prostaglandin). There are many 
ways of measuring lipid peroxides. The most common involves thiobarbituric acid (TBA) 
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reaction either directly in plasma or following the hydrolysis at acid pH producing MDA 
from the breakdown of lipid peroxides. It was applied first by Kohn and Liversedge in 
1944 who observed that brain incubated aerobically produced a color change with 2-
thiobarbituric acid. The color change is said to result from the formation of a complex 
between TBA and unsaturated fatty acid.  
The normal range of lipid peroxides in the plasma from 4 studies is 0.41- 1.29 
µmol/l in men and 0.33- 1.22 µM in women [180]. It could be measured using HPLC 
[181, 182] while flourimetric methods [183] are also available as a kit [184].  Other 
methods of measuring lipid peroxide involve the measurement of cholesterol oxidation 
products. The major product of cholesterol oxidation is cholesterol-3-5-diene-7-one while 
other products include cholesterol α- and β- epoxide, 7- ketocholesterol and 25-hydroxy 
cholesterol. The method for identifying these products was developed by Addis et al 
[185] and Subbiah et al [186], and subsequently modified by [187].  A commercial kit 
has been introduced which measures plasma lipid peroxides by utilizing hemoglobin 
catalysis of the reaction between hydroperoxides and 10-N-methylcarbamoyl-3-7- 
dimethylamino-10 H-phenothiazine to produce methylene blue [180]. 
 
2.3.4.1. D-Roms Test 
This method developed by Cesarone, Belcaro et al. (1999) measures free radical-
derived products in plasma based on the ability of transition metals to catalyze the 
breakdown of peroxides to free radicals which are trapped by an alchilamine [188]. Iron 
ions bound to serum proteins catalyze in vitro the breakdown of hydroperoxides to 
alkoxyl and peroxyl radicals. Iron ions bound to serum proteins catalyze in vitro the 
breakdown of hydroperoxides to alkoxyl and peroxyl radicals. The alchilamine reacts, 
forming a colored radical detectable at 505 nm through a kinetic reaction. The 
measurement of free radicals requires the addition of 10 µl of heamolysis-free serum to 1 
ml buffer (R2) at pH 4.8. The mixture is added to the chromogen R1 (alchylamine) and 
incubated for 1 minute at 370C. A color change is read initially and subsequently after 
one minute and the difference is multiplied by a K factor (9000) to give the concentration 
of free radicals in the plasma [188]. This method was effective in assessing the 
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bioavailabity of antioxidants in food supplements [189] and the effect of antihypertensive 
drug on oxidative stress [190]. 
 
2.3.5. Urine Measurement of Oxidative Stress 
There has been an increasing need to develop biomarkers of oxidative stress 
applicable to humans. Some markers found in urine, breath and blood could be used as 
indices of oxidative stress. Urine analysis provides a non-invasive evaluation of 
metabolites like F2-isoprostane, urinary aldehydes, hydrogen peroxide and total oxidants 
including, lipid peroxides and other hydroxyl products of oxidative damage. It can 
therefore be a useful tool for measuring oxidative damage in the clinical setting. 
F2- Isoprostane is formed as a result of direct attack of reactive oxygen species on 
arachidonic acid resulting in the formation of 64 different isoprostanes of which 8-
isoprostaglandin F2α  (8-iso-PGF2α) is the most stable product. F2-isoprostane and has 
been shown to be a reliable indicator of lipid peroxidation that may be related to in vivo 
free radical generation, oxidative damage, and antioxidant deficiency [191] but it has a 
short half-life of 20 min in blood. The urine method has the advantage of circumventing 
this short half life even though it has the potential of contribution from the kidney [192]. 
The urine assay of 8-iso-PGF2α has been used to monitor treatment of patients on 
antioxidant therapy [193] and as a mode of assessing oxidative stress in asthmatic 
patients [194]. To measure 8-iso-PGF2α mass spectrometry and ELISA methods have 
been employed [195], but the latter method has shown some inconsistencies when 
compared with the former or gas chromatographic methods [196]. 
 
2.3.5.1. Peroxide Measurement Using the Oxoglutarate Decarboxylation Assay 
Long et al. (1999) reported urine peroxide levels ranging from 22- 173 µM 
(CI=38.5-46.3 µM) in healthy controls using the oxoglutarate decarboxylase assay 
method. Both male and female subjects were studied and the average concentration of 
H2O2 was approximately 100 +/- 60 µM [197]. Peroxide excretion was found to be 
unexpectedly high and might thus be useful for clinical diagnosis and therapy in diseases 
purported to be related to oxidative stress [197, 198].  
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This is a new radio-isotopic method for determination of peroxide in 
subnanomolar concentrations based on the reactivity of peroxide with alpha-ketoglutaric 
acid containing [I-14C]-alpha-ketoglutaric acid, and measurement of the resulting 1-
14CO2 by radioactivity[199]. The measurement of standard peroxide, alone or mixed 
with some biologically derived samples, using this technique was found to be 97 +/- 
2.7% [199]. The use of radioactivity enabled demonstration of H2O2 in human urine. 
Urine samples were incubated with alpha ketoglutarate pulsed with iwts 1-14C-analogue, 
and CO2 formed by decarboxylation was determined by radioactivity measurements. 
Blanks were prepared by pre-incubation of the samples with catalase.  
 
2.3.5.2. 8-Oxoguanine Assay 
Free radicals may react with DNA causing reversible and irreversible damage, 
leading to mutation, carcinogenesis or cell death [200, 201]. Free radical damage to DNA 
leads to the formation of  8-oxoguanine, a sensitive and specific indicator of oxidative 
DNA damage. A highly sensitive and selective method for determining 8-oxoguanine in 
plasma and urine was developed by high-performance liquid chromatography with 
electrochemical detection. The compound was separated by gradient elution on a C-18 
reversed-phase column with a mobile phase of acetonitrile and 0.1 M sodium acetate at 
pH5.2. The internal standard was 8-hydroxy-2'-deoxyguanosine and 8-oxoguanine was 
detected electrochemically by setting the potential to +300 mV vs. Pd reference (Potential 
difference reference). The sensitivity of the assay was 22 ng/ml with a signal- to-noise 
ratio of 7:1. The within-day relative standard deviations for 8-oxoguanine quality control 
samples with concentrations of 3340, 1340 and 84 ng/ml were 3.6, 4.3 and 5.7% for 
plasma, and 4.1, 4.6 and 6.2% for urine respectively. The day-to-day relative standard 
deviations for the same samples were 3.8, 6.8 and 7.1% for plasma, and 3.9, 7.0 and 7.9% 
for urine respectively [197].  
 
2.3.5.3. The Novel Oxistress Assay  
 The novel oxistress assay was developed based on the principle that glucose has a 
very rapid reaction to the presence of hydroxyl ion. The assay measures the quantity of 
hydrogen peroxide equivalents in urine and plasma that creates a color change in the 
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presence of thiobarbituric acid. This is then quantified using a spectrophotometer at a 
wavelength of 532 nm. The details of the assay and the results are further discussed in 
Chapters 4 and 5. 
 
2.3.6.  Myeloperoxidase (MPO): 
 Myeloperoxidase is a product of a single gene on chromosome 17 whose 
primary translational product is an 80kD protein that undergoes two cleavages to form 
the mature MPO. The mature MPO is 150 kD, consisting of a pair of heavy-light 
protomers whose heavy subunits are linked by disulfide bonds. They are made up of both 
carbohydrate (4% mannose rich) and two hemes per molecule that are covalently linked 
to the heavy subunits [202, 203]. Myeloperoxidase is in high concentration in azurophilic 
granules and is released into the phagosomes during the granule-phagosome fusion 
Myeloperoxidase, H2O2 generated during phagocytosis, and a halide constitute a potent 
antimicrobial system which are effective against bacteria, fungi, viruses, mycoplasma and 
cancer [204-206]. MPO is also released to the outside of the cell by leakage prior to the 
closure of phagosome, and finally by secretion as when neutrophil binds to a complement 
and or antibody coated nonphagotosable surface or by neutrophil lysis [207]. 
 Patients with hereditary MPO deficiency have their fungicidal capacity greatly 
depressed and the bacterial killing is characterized by a lag period following which the 
bacteria is killed [207]. Hydrogen peroxide is a weak antimicrobial however the MPO 
and the halide augment its antimicrobial effect [205, 208]. There is an association 
between severity of illness and myeloperoxidase levels as in Chronic Myeloid Leukeamia 
(CML) [56] and sepsis [209, 210].   
  
2.3.7.  Plasma Elastase and Elastase Inhibitor: 
 Neutrophil elastase (NE) is a 30 kd neutral proteinase consisting of 218 amino 
acids present in the azurophilic granules of polymorphonuclear cells [211]. Elastase is 
produced in the azurophilic granules of polymorphonuclear leucocytes and is active at a 
neutral pH. It is thought to be an important mediator of connective tissue destruction 
[212, 213]. It can degrade almost all components of the extracellular matrix. It also 
cleaves plasma proteins and attacks intact cells [214]. There is considerable variation in 
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elastase activity between individuals which may be genetically determined [215, 216]. 
The suggested physiologic action of elastase is in the destruction and the digestion of 
ingested microorganism [214]. In support of this premise the plasma and interstitial fluids 
contain a series of powerful antiproteinases that can effectively regulate extracellular 
neutrophil elastase and prevent the enzyme from attacking extracellular substrates [214]. 
The presence of active proteinases suggested that the antiproteinase shield had been 
subverted and the exudate fluid had lost the ability to inhibit exogenous protienases, 
which is evidence that activated neutrophil can circumvent the entire antiproteinase 
shield and attack host tissue [57].  
 The activity of the elastase is increased by the lipopolysaccharrides, the activity 
of other free proteases and the oxidant load [217, 218]. Increased elastase levels have 
been associated with septicemia head injury, pancreatic shock and acute inflammation 
[65, 219]. This is a result of acute response of neutrophils to injury and increased 
endothelial permeability resulting in the release of elatsase from the primary granules and 
a leak to the surrounding tissue. In patients with multiple injury and blood transfusion, 
the elastase levels rise from 5 to 10 fold within 8 to 14 hr after injury depending on 
severity [65]. Low serum elastase activity and high elastase inhibitor levels are associated 
with increased carotid plaque occurrence [220]. Elastase is also seen as an independent 
marker of the severity of chronic inflammatory bowel disease [211]. 
 
2.3.8. Summary:  Methods Used for the Study: 
 In order to understand the natural history of oxidative stress in trauma patients 
clinically applicable methods are required to diagnose the condition. The methods need to 
be easy, simple, sensitive, accurate, and provide results that have potential benefit to the 
clinical settings. In the preceeding sections various methods of evaluating oxidative stress 
have been discussed but only four of these were employed for this study based on the 
above criteria. 
 The FRAP method was used to estimate total antioxidant capacity in plasma 
because it is simple, cheap and the results were consistent irrespective of the dilution 
factor. None of the available techniques that claim to measure total body antioxidant 
capacity (FRAP, TRAP, ABTS, ORAC and TORC) do so individually but the FRAP 
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method has the advantage of a shorter reactive time. However, the FRAP does not 
measure serum protein (including lipoic acid and amino acids like glutathione) but it was 
the best option in the group. 
  The Asensi modification of Brigelius method was chosen for red cell glutathione 
measurement because it is easy, does not require incubation and can be measured using a 
spectrometer unlike the other methods that require the HPLC machine.  
 Protein carbonyl was evaluated with the colorimetric method because it is an easy 
method. It does not require antibodies unlike the Western blot and ELISA, and can be 
measured using a spectrometer. 
 The novel oxistress assay (Chapters 4& 5) measures antioxidant status, which is a 
summation of the reaction between antioxidants and free radicals produced. This assay 
therefore allows an evaluation of the circulating free radicals thereby providing a total 
picture of the oxidative status of the patient. It is therefore an assay that be singularly 
used to diagnose oxidative stress in a clinical setting. In addition it is fast (5 min), 
inexpensive and produces a visible colur change at 370C. 
 Neutrophil activity was evaluated with the Myeloperoxidase assay, which though 
not fast provides accurate and reliable results[221, 222]. Neutrophil count was done by 
the hospital laboratory. 
 
2.4. Modulation of Oxidative Stress 
Glutamine is classified as an intervention aimed at reducing oxidative stress 
irrespective of the aetiology. The two-fold mechanism via glutamate include increasing 
glutathione by alleviating the GSH inhibition of GCS and regulating uptake of cystine 
[223]. Trauma is the commonest cause of oxidative stress [15, 16].  Sheridan and 
associates showed that antioxidant therapy in burn patients reduced the length of time on 
mechanical ventilation and the level of malondialdihyde as compared to controls [17].  
The consumption of endogenous antioxidants by free radicals resulting in oxidative stress 
may promote the development of multi system organ failure (MSOF) after polytraumatic 
injury [18].  Our unpublished preliminary results reflect a correlation between the 
severity of trauma and oxidative stress. 
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2.4.1. Elective Surgery and Oxidative Stress  
Lou et al., (1996) reported 40% depletion in skeletal muscle glutathione and 20% 
depletion in plasma glutathione in elective abdominal surgery compared with pre-
operative levels [224].  In another study Morris et. al.(2000) observed a depletion in the 
total antioxidant levels in plasma 6 hr postop compared with pre-operative levels and a 
return to the basal levels after 12 hr [225].  It is important to note that most of their 
patients had mastectomy and lumpectomy because these are regarded as mild to moderate 
surgery. Maximum decrease in glutathione levels occurs at 24 hr after surgery [226]. 
 
2.4.2. Glutathione Cycle 
Glutathione is an α-amino acid as well as tripeptide; it is formed from glutamine, 
cysteine and glycine (L-γ-glutamyl-cysteinylglycine; GSH) [131]. Glutamate and 
cysteine are direct precursors of glutathione production. Animal studies have shown that 
glutathione depleted rats benefited from glutamine supplements [227], [228]. Glutamate 
has two-fold way of increasing glutathione by alleviating the GSH inhibition of GCS, and 
by regulating uptake of cystine (Figure 2.3) [223]. 
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Figure 2.3: Glutathione Cycle 
 
 
Figure 2.3: Flow chart showing the role of glutamine and other substrates in glutathione synthesis 
 
2.4.3. Glutamine as an Intervention in Oxidative Stress 
Glutamine is the most abundant non-essential amino acid in plasma (Darmaun, 
Matthews et al. 1986) that can be reclassified as a conditionally essential amino acid 
because of the bodys inability to synthesize glutamine in sufficient quantities under 
certain circumstances such as major surgery, shock, traumatic injury and severe sepsis 
[229], [230]. 
Although glutamine constitutes >50% of the unbound amino acid pool in human 
skeletal muscle, rapid reduction in blood and tissue glutamine have been noted following 
catabolic events such as major surgery [231], trauma [232] and sepsis [233]. A summary 
of the functions of glutamine is presented in Table 2.1. 
Glutamine exhibits extremely rapid cellular turnover rates and is a source of 
oxidative energy. It also serves as a metabolic precursor in the biosynthesis of 
nucleotides, glucose, amino sugar, as well as in glutathione homeostasis and protein 
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synthesis. It is a key link between carbon metabolism of carbohydrates and proteins in 
mammalian cells playing an important role in the growth of fibroblasts, lymphocytes and 
enterocytes [234]; [235]. Glutamine synthesis occurs in skeletal muscle and liver when 
the plasma level is insufficient to satisfy the bodys requirement. Decreased glutamine 
availability for macrophages and lymphocytes correlated with low plasma glutamine and 
citrulline levels [236]. Glutamine acts as the preferred respiratory fuel for lymphocytes, 
hepatocytes and intestinal mucosal cells and is metabolized in the gut to citrulline, 
ammonium and other amino acids [237]. Reduced arginine levels observed after trauma, 
can be restored to physiological levels using glutamine supplementation whereas, the 
physiological levels of glutamine (650 µM) are only partly restored [238]. Hepatic and 
renal nitrogen metabolism are linked by an interorgan glutamine flux, which couples both 
renal ammoniagenesis and hepatic ureogenesis to systemic acid-base regulation [239].  
Glutamine via glutamate is converted to α-ketoglutarate, an integral component of 
the citric acid cycle. Glutamate is a component of the antioxidant glutathione and of the 
polyglutamated folic acid. The cyclization of glutamate produces proline, an amino acid 
important for synthesis of collagen and connective tissue. 
Glutamine and cysteine are direct precursors in the production of glutathione. 
Animal studies have shown that glutathione depleted rats benefited from glutamine 
supplements [227], [228]. Glutamate has a two-fold way of increasing glutathione by 
alleviating the GSH inhibition of GCS, and by regulating uptake of cystine [223]. 
 
2.4.3.1.1. Glutamine Metabolism  
In a cellular milieu, glutamine is transferred from extracellular medium to the 
cytoplasm and may be transported to the mitochondria via a transport system specific for 
L-glutamine and asparagine. This system is inhibited by thiol reagents and by -
glutamate- -hydroxamate a glutamine analog [240]; [241] and [242]. The two most 
important enzymes in glutamine metabolism are glutamine synthetase and glutaminase. 
Glutamine synthetase has high concentrations in muscle, liver and lungs. It catalyzes the 
reaction in which glutamine is formed from glutamate adding an amide group. 
Glutaminase is most abundant in tissues that consume glutamine and it converts 
glutamine to glutamate and ammonia [243]. 
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Table 2.1: Key Functions of Glutamine 
Glutamine function Mechanism 
Nitrogen shuttle: urea and ammonia clearance. 
! Takes up excess ammonia and forms urea [244].  
! Nitrogen from ammonia is transferred to alanine 
via transamination with glutamate formed by 
reductive amination of alpha-ketoglutarate[245]. 
Function in metabolism 
Direct source of cell energy 
Decreases protein breakdown  
Rate-limiting factor or muscle growth 
Anabolism: anticatabolism 
Stimulates release of human growth hormone 
Direct fuel for fibroblast and macrophages Effect on wound healing 
Indirectly by preserving lean body mass 
Preserves gut integrity Primary fuel for gut enterocytes via glutamate via 
glutathione antioxidant action. 
Immune function Improves neutrophil bacterial killing and is a 
lymphocyte fuel 
Antioxidant Substrate for the key cellular and plasma glutathione 
via glutamate. 
 
Table 2.1: Adapted from Robert H. Demling, M.D., Patrick Seigne, M.D., World J. Surg. 24, 673-680, 
2000. 
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2.4.3.1.2. Clinical Evidence for the use of Glutamine 
There have been several studies showing the beneficial effect of glutamine on 
complications and clinical outcome. Some of such studies were done on trauma, burns, 
abdominal surgery and sepsis patients. Demling et al., (1998) demonstrated that 
glutamine therapy reduced hospital stay and improved patient outcome [246] In a 
randomized trial of sixty patients grouped to either a standard enteral feeding or one 
containing 14.2 g glutamine/l within 48 hr of admission, Houdijk et al., (1998) observed a 
significant reduction in the infection rate in the supplement group - 17% vs. 45% 
(p<0.02) [247]. A randomised prospective study using glutamine dipeptide as total 
parenteral nutrition concluded that the supplemented group had shorter hospital stay, 
improved immune status and nitrogen after abdominal surgery [248]. In another double 
blind randomised controlled trial in 168 patients glutamine therapy was significantly 
associated with a reduction in hospital stay among surgical patients [249] [250]. 
 
2.4.3.1.3. Glutamine Administration in the Elective Surgery Patient 
 A mild catabolic response has been well documented in patients following 
elective surgery. By standardizing the operation and anesthesia provided and by 
excluding patients with associated disease (such as diabetes mellitus or those requiring 
steroids), the effects of manipulations such as glutamine administration on postoperative 
catabolic response have been investigated.  
No outcome studies are available in which to evaluate the effect of postoperative 
enteral nutrition with and without glutamine [251]. However, Dechelotte et al. (1998)
studied protein turnover in 16 patients receiving tube feeding after esophagectomy with 
enteral glutamine supplementation. The endogenous de novo synthesis of glutamine was 
reduced by 32% (p < 0.03) and phenylalanine oxidation was reduced by 26% (p > 0.05). 
Protein turnover was similar in both groups.  Aosasa et al. (1999)  gave oral glutamine to 
patients receiving preoperative parenteral nutrition and compared their findings with 
nonsupplemented individuals. After surgery, they harvested blood mononuclear cells and 
stimulated production of tumor necrosis factor and interleukin-10. In patients receiving 
standard parenteral nutrition, there was an increase in cytokine production; this was 
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greatly attenuated in the glutamine group, supporting the concept that glutamine may 
modulate the proinflammatory cytokine response.  
 Fish et al. (1997) compared the effects glutamine-enriched parenteral nutrition 
with enteral feedings of similar composition administered to patients after gastric or 
pancreatic resections. Nitrogen balance and plasma protein concentrations were 
comparable between the two groups. Plasma concentrations of glutamine did not differ 
significantly between the two groups although these data tended to suggest that glutamine 
levels, which fell postoperatively, recovered more slowly in the enterally fed group. It 
should be noted, however, that nutrient delivery was increased only gradually to 100% of 
recommendations in the postoperative period in both groups. This gradual increase in the 
intravenous solution is inconsistent with clinical practice, and administering the usual 
quantity of total parenteral nutrition on the first postoperative day may have resulted in 
higher glutamine concentrations by day 5 post-surgery when measurements were made.  
 
2.4.3.1.4. Glutamine and the Immune System 
A recent in vitro study by Furukawa, Saito et al., (2000) evaluating the effect of 
glutamine supplements on phagocytosis and reactive oxygen intermediates (ROI) 
production by neutrophils and monocytes in postoperative patients concluded that 
glutamine enhances both phagocytosis and ROI production by neutrophils [252]. They 
observed a dose dependent response most effective at concentrations >2000 µM. This is 
in keeping with the findings of Wilmore, et al., (1998) who conclusion that immune 
function will be jeopardized at plasma glutamine levels <400 µM in post-op surgical 
patients [253]. 
 
2.4.3.1.5. Recommend Doses and Equivalent Supplements of Glutamine 
The estimated recommended typical post-operative dose is about 0.1-0.3 g/kg/d (≈ 
20 g/day), however in severely stressed patients such as burns, up to 40 g/day may be 
required to correct the deficit [254, 255]. This is equivalent to 3.8 g of total nitrogen 
[250]. 
 
38 
2.4.3.1.6. Glutamine and Liver Disease  
Much debate over the use of glutamine in the setting of liver disease has 
prevented general clinical use [256].  However, recent animal studies have shown that 
glutamine is protective against oxidative stress and has no effect on the liver oxidative 
metabolism [257].  
 
2.4.4. Enteral Feeding Versus Nil by Mouth 
The practice of nil by mouth (no oral feeds) post-gastrointestinal surgery during 
which an intestinal anastomosis has been formed is common. The rationale of nil by 
mouth is to prevent postoperative nausea, vomiting and protect the anastomosis. However 
clinical and animals studies suggests that initiating feeding early is advantageous [258]. 
Catchpole (1989) showed that postoperative dysmotility affects stomach and colon while 
the small bowel function returns to normal within 4-8 hr [259].  Feeding within 24 hr 
after laparotomy is tolerated and feed is absorbed [260] [261]. A large meta-analysis 
reviewing 11 controlled trials by Lewis et al [258], concluded that there was no 
advantage in keeping patients nil by mouth after gastrointestinal surgery. There was a 
reduction in the septic complication and length of stay in patients receiving enteral feeds. 
The incidence of anastomostic dehiscence, wound infection, pneumonia, intra abdominal 
abscess and mortality were reduced although not statistically significant (p>0.10). The 
increase on the vomiting with early feeds (within 24 hr) had borderline significance 
(p=0.046). 
 
2.4.5. Clear Fluid Versus Regular Diet Post-Operatively 
A large scale prospective study of 241 patients by Jeffery et al. (1996) comparing 
increased dietary intolerance in post-op patients receiving clear fluids vs. regular diet as 
the first oral intake concluded that there was no difference in both groups (p< 0.5) [262].  
Gonzalez Ojeda A et al, also showed regular diet reduced length of hospital stay by 2.6 
+/- 2.0 days compared with 3.4 +/- 2.6 days in controls (p <0.005) in post-op patients. 
The cost of hospital stay after commencing oral intake was 2726 +/- 2107 pesos in the 
treatment group compared with 3547 +/- 2690 in controls (p < 0.005). The caloric and 
protein intake were 1307 +/- 523 Kcals and 55.9 +/- 23.2 grams of proteins in the 
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treatment group; and 651 +/- 204 Kcals and 0 grams of proteins in controls (p < 0.00001) 
[263]. 
 The results suggest that the routine use of clear fluids as initial postoperative diet 
may be unnecessary and nutritionally sub-optimal compared to regular diet [262-265].  It 
is therefore safe to give enteral glutamine as the first oral intake after surgery.  We intend 
to give oral glutamine as an elemental supplement because it is easily absorbed without a 
need for digestion.  
 
2.4.6. Enteral Versus Parenteral Nutrition 
Parenteral nutrition is designed to provide nutrition to patients who cannot be 
nourished adequately by enteral nutrition for critical periods. Enteral nutrition could 
either be tube feeding or standard care. Tube feeding is defined as either surgical or non-
surgical placement of a small flexible tube into the gastrointestinal tract to provide 
required nutrients. Standard care is defined as the gradual reintroduction of oral diets 
where tolerated interruption was caused by a disease or a surgical procedure that resulted 
in several days of inadequate nutrient intake and the use of intravenous dextrose or fluids 
for hydration [266]. 
There is overwhelming evidence that the enteral route for nutrient delivery is by 
far superior to the parenteral route [267-269]. The results from a prospective trial by 
Kalfarentzos et al (1997) on enteral nutrition in acute pancreatitis showed that enteral 
feeding was well tolerated without adverse effect on the course of the disease [270]. The 
study concluded that enteral nutrition should be used preferentially in patients with severe 
acute pancreatitis [270]. 
 
2.4.6.1. Advantages of Enteral Nutrition 
There are many purported advantages of the enteral route of nutrition. 
i. Enteral nutrients more effectively preserve gut barrier function and lead to 
modification of the intestinal hormonal environment by as yet undefined mechanism. 
ii. Gut absorption of peptides and amino acids from protein hydrolysis leads to much 
higher nitrogen retention than does the delivery of parenteral amino acids [271]. 
iii. The average cost of TPN is as much as five times that of total enteral nutrition. 
40 
iv. All forms of enteral nutrition have a lower infection rate in all classes of patients 
when compared to parenteral nutriton [266, 272]. Well nourished patients had a lower 
complication rate on enteral nutrition, however, there was no difference in the 
complication rate or mortality in the high risk malnourished surgical patient [266, 
272, 273]. 
v. Easy access and catheter infection associated with total parenteral nutrition is 
avoided. 
vi. Early enteral feeding in particular has been shown to enhance enteral nutrition 
[274]. 
 
2.4.6.2. Complications of Enteral Nutrition 
Enteral feeds have diverse side effects such as metabolic disturbance, fluid and 
electrolyte imbalance and gastrointestinal side effects such as cramps, diarrhoea, nausea, 
vomiting, flatulence and heartburn [275]. Several studies have shown that complications 
were worse in malnourished and high-risk patients [266, 273]. Diarrhoea is the 
commonest side effect of enteral nutrition [276] which could be as high as 40 % in 
patients who are critically ill to as low as 3% in patients admitted for general treatment 
[277, 278].  
 
2.4.6.3. Complications of Tube Feeding 
Tube feeding has been shown to be generally safe and effective however there 
have been several associated complications such as nutrients pneumonitis, pneumothorax 
and pulmonary haemorrhage [279, 280]. The results of a prospective study comparing the 
blind to the fluoroscopic guided technique for placement of naso-enteric (Jejunal) tubes 
revealed most complications occurred in the blind group including aspiration pneumonia, 
repeat insertions [281]. There is however less complication with jejunal tubes than gastric 
tubes. 
 
2.4.6.4. Elemental Diet  
Elemental chemically defined formulations are designed for use in patients with limited 
digestive capacity [282] Elemental diets are traditionally used for nutritional support in 
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patients with diseases that affect absorption and digestion.  An elemental diet has been 
recommended for initial enteral feeding during parenteral nutrition [283].  It is 
particularly useful in the transition period while the patient completely recovers bowel 
function as in cases of peritoneal sepsis, prolonged ileus and major surgery [284-286]. 
 
2.5. Evaluating Outcomes 
Outcomes may be defined as changes either favorable or adverse that can be 
attributed to prior or concurrent care [287]. Outcome studies are necessary to provide 
objective evaluation of what might be labeled as habitual practices in the delivery of 
health care. These studies also validate the effectiveness of interventions and add to the 
body of evidence-based practices [288]. Outcome parameters not only include death, 
disability, dissatisfaction, disease and discomfort, but they also relate to health status, 
functional status and quality of life of patients [289]. 
 Outcomes could be classified as patient focused, provider focused or organization 
focused. The patient focused outcomes can be defined as measures of the physical, 
physiologic, psychosocial and functional consequence of an individuals experiences with 
health and illness [290]. Our study will focus on physiologic quantifiable outcome. 
Comparison of changes in the lean body mass of glutamine treated surgical patients with 
the non-glutamine treated surgical patients. A comparison of disease specific outcome of 
each group of surgical patients will be undertaken.  
Provider focused outcome involves the cost, length of stay, complications and 
readmissions, but it fails to address the patients health status. Our study will take this 
into consideration by the measuring the Resource Intensity Weighting score for each 
patient and the length of hospital stay.  
 
2.5.1. Laboratory Related Outcome  
The role of the laboratory test in assessing clinical outcome has been 
controversial. This is because outcomes are viewed either in terms of health or cost. 
Laboratory tests are more useful for prognostic accuracy, which is the ability of a test to 
predict mortality, morbidity and risk stratification. Outcome studies on the other hand 
address questions that relate the use of a test to patient outcome. An ideal outcome study 
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can answer the question whether use of the studied intervention produced the anticipated 
outcome. A randomized controlled trial is a powerful tool for such studies [291]. Our 
study is a randomized controlled trial aimed at evaluating the effect of glutamine on 
outcome in the surgical patient, and at the same time evaluating the outcome benefit of 
oxidative stress assays in patient care. The other challenge to the use of laboratory related 
outcome is the remoteness of the many potential outcomes to the testing. This is the case 
with the fecal occult blood test in which the response to the result varies between 
physicians and patients [292]. The recommended way to overcome this problem is for 
both patients and physicians to specify a course of action. In our study both the 
intervention and the laboratory test are not routine therefore no course of action is 
required in response to the biochemical result [291]. The dual-energy x-ray 
absorptiometry (DEXA) machine will be used to evaluate lean body mass changes after 
surgery as it has been successfully used in previous human studies evaluating chronic 
conditions or the effect of treatment [293-296].  
 
2.5.2. Resource Intensity Weights (RIWs) 
RIWs define the relation between the medical and financial dimensions of 
hospital cases for use in planning and management ([297]). Ontario and Alberta are the 
first provinces to use them to adjust hospital funding ([297]).  RIW ratios show the 
relative use of hospital resources for a typical case (successful course of treatment in an 
acute care hospital and discharge when the patient no longer requires the hospital's 
services) and atypical cases (death, transfer, sign-out and substantially longer than 
average stay) [297]. Different types of inpatients "consume" differing amounts of hospital 
resources, and it is important to be able to measure these differences in resource 
consumption. An equitable methodology for funding hospitals must take into account 
differences in case mix between facilities. An ability to examine these differences in case 
mix and resource utilization allows hospitals to focus efforts to improve efficiency. A 
standardized methodology for measuring resource consumption is critical to funding and 
resource allocation both at a global and organizational level.  
A study was conducted on inpatient cases at the Greater Victoria Hospital Society 
(GVHS), British Columbia, to identify the difference between the RIWs and GVHS cost 
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weights. A regression analysis was performed on the more than 30,000 inpatient cost 
profile records from the GVHS 1995-96 cost and patient activity data. The scope of the 
analysis was restricted to the 424 Case Mix Groups (CMGs) that had a minimum 
composition of five patient profiles. Comparisons of GVHS cost weights to CIHI- RIWs 
yielded mostly positive results, with the noted exception of about 20 CMGs, there was a 
high correlation between the CIHI-RIW and the GVHS actual cost weights [298]. The 
use of RIWs* for equity funding and utilization management assumes validity of the cost 
estimates, reliability of the patient categorization scheme, equivalence of the bases for 
cost comparison, and equity of the subsequent resource distribution. Chu (1994) 
examined these assumptions, and concluded that caution must be taken when using the 
current RIWs and Case Mix Groups (CMGs*) for resource allocation and performance 
evaluation purposes [299]. RIW has represented a milestone in the history of Canadian 
health care product costing and management. It would be prudent for health care 
professionals at the operational level to provide structured and continuing feedback that 
can contribute to the validation and refinement of these valuable management tools. A 
clinical application of the RIW score in a study by Brackstone et al., (2002) concluded 
that RIW underrepresented trauma case cost by a factor of 3.5, which could result in 
underfunding and potential fiscal difficulties for a leading trauma hospital [300, 301].  
 
2.5.3. Estimation of Physiologic And Surgical Stress (E-PASS) 
The E-PASS is a way of quantifying postoperative risk by quantification of the 
patients reserve and surgical stress. This estimation is based on the principle that surgical 
insults induce the production of proinflammatory responses [302], which are considered 
beneficial in augmenting immune functions and facilitating tissue repair [303].  When the 
surgical stress exceeds the patients reserve capacity, homeostasis cannot be maintained 
and various complications result. Surgical insults prime neutrophils, which in turn attack 
vital organs leading to dysfunction [302]. The E-PASS scoring system is generated based 
on quantifying the patients preoperative risk (PRS) and surgical stress. The preoperative 
risk is calculated from factors such as age, sex, performance index and the American 
society for anesthesiologist (ASA) classification. Based on the preoperative risk 
evaluation the referring physician will be able to estimate surgical stress in a patient. It is 
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estimated from the effect of blood loss/kg body weight, skin incision, operating time and 
the preoperative risk. The postoperative values i.e comprehensive risk score (CRS) for 
individual patients are estimated by calculating the patients real surgical stress (SSS- 
Table 2.2) with the comprehensive risk score (CRS). The formula for comprehensive risk 
score (CRS) = 0.328 +0.936 (PRS) + 0.976 (SSS) [304]. 
 
Table 2.2: Equation  
 
Source: Haga et al., 2001 
 
The result of the initial E-PASS study showed a correlation between the CRS, 
SSS and the postoperative inflammatory parameters [305].  The E-PASS could be useful 
in our study for evaluating the effect of glutamine as an indirect precursor of glutathione 
(via glutamate) on the inflammatory parameters such as antioxidant levels and free 
radical production after surgery leading to oxidative stress. Table 2.2 shows how to 
calculate for the various components of the E-PASS. In a multicenter trial the E-PASS 
has been shown to be useful not only for predicting risk but also for estimating surgical 
quality and medical expense [304]. Our study will also evaluate the effects of the 
introduction of glutamine on the overall medical expense of the surgery. 
 
2.5.4. Quality of Life  
 Quality of life in surgery could be broadly defined as the impact of the disease 
process on physical, psychologic and social aspects of a person's life and feeling of 
wellbeing. The objective dimension is the functional assessment of health status [306] 
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while the subjective assessment isbased on the patients perception. Quality of life 
instruments have a number of applications broadly categorized as: screening and 
monitoring for psychosocial problems, population surveys, medical audit, outcome 
measures (which are relevant to the glutamine study), clinical trials and cost utility 
analyses. These instruments could be discriminative, predictive or evaluative. 
Discriminative implies they can be used for separating groups of patients based on their 
quality of life e.g. patient satisfaction [307]. Predictive implies they can predict outcomes 
such as return to normal function [308],  and evaluative when they can be used to 
measure the magnitude of change in an individual or group of patients over time [309]. 
The essential characteristic of quality of life instruments include reliability, validity, 
sensitivity to change, appropriateness and practicality [309, 310]. Although quality of life 
data provides pertinent information on patient outcome, it will not be evaluated in our 
study, which focuses on the acute effect of antioxidant therapy after surgery. 
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3. RATIONALE AND OBJECTIVES 
3.1. HYPOTHESIS 
The study is based on the following hypothesis: 
1. Trauma results in oxidative stress 
2. Measuring oxidative stress in the clinical setting results in early diagnosis 
3. Antioxidant therapy can ameloorate oxidative stress in surgical patients (controlled 
trauma) 
 
3.2. RATIONALE 
3.2.1. Reasons for Studying Oxidative Stress? 
Based on increasing awareness of the importance of oxidative stress in diseases 
and the limited clinical knowledge of the pathophysiology, this research was conducted 
to understand and modulate oxidative stress in the clinical setting. This is based on an 
assumption that early prevention and treatment of oxidative stress will prevent the 
development of the associated morbidity and mortality.  
   Our study focuses on understanding the natural history of oxidative stress in 
humans using the trauma model as most of the previous studies on the subject were 
conducted on animal models. There have been many methods of monitoring the effect of 
oxidative stress however most of these are applicable to tissue culture, organ injuries and 
animal studies. Our study focuses on identifying clinically applicable modes of 
evaluating oxidative stress therefore making the concept more clinically relevant.  
 
3.2.2. Reasons for Studying Trauma 
Trauma is relevant since the onset time can be reliably determined in the normal 
population, and there is evidence that trauma is the commonest cause of oxidative stress 
[15].  The injury could be post-ischemic, reperfusion, heat, physical, cold, excessive 
exercise, or exposure to toxin, radiation or infection.  Injury can give rise to systemic 
decreases in anti-oxidant capabilities not just in tissues affected directly by the trauma 
e.g. severe skin burn has been demonstrated to decrease brain GSH by 50-70% [46].  
Burns increase xanthine oxidase activity in affected tissue and cause neutrophil 
activation. Animal studies have also demonstrated a decreased burn edema and a 
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lessening of distant organ dysfunction with the use of antioxidants, suggesting a cause 
and effect relationship [47]. 
 
3.2.3. Reasons for Measuring Oxidative Stress in the Clinical Setting: 
Oxidative stress is a preventable etiological factor in several diseases however it 
is neither treated nor prevented in the clinical setting because there are currently no tests 
to assess a patients oxidative status. Most of the therapeutic approaches are aimed at the 
complications rather than prevention of the oxidative stress induced damage. The 
presence of bedside evaluation of oxidative stress will therefore make early identification, 
prevention and institution of treatment possible [311, 312]. Can oxidative stress be 
measured in a clinical setting? Yes, based on the various methods explored in our study. 
 
3.2.4. Reason for Measuring Red Cell Glutathione  
The erythrocyte was an early model for studies of oxidative stress because of its 
relatively high oxygen tension, the presence of heamoglobin, and a plasma membrane 
rich in polyunsaturated lipids, and as a result, should be prone to oxidative stress. 
Erythrocytes have many scavenger systems, and can be used to examine the balance 
between pro-oxidants and antioxidants since they are representative cells where 
superoxide radicals are being continuously generated by auto-oxidation of hemoglobin 
[313]. 
The oxidative status of intact erythrocytes measures both the concentration and 
redox state of intracellular glutathione. The novel findings of a study of preeclamptic 
patients and normal pregnant women suggests that some patients may be unusually 
susceptible to erythrocyte glutathione oxidation, possibly leading to general cellular 
damage, in particular the HELLP Syndrome (Hemolysis Elevated Liver Enzymes Low 
Platelets) [314]. When there is severe oxidative stress the rate of depletion of reduced 
glutathione is faster than production resulting in an efflux of oxidized glutathione from 
the cell into the plasma [145, 146]. A depletion of reduced intracellular glutathione 
causes changes in the physicochemical state of the erythrocyte membrane and the 
accumulation of lipid peroxidation products [315]. The red cell has the capacity to 
replenish plasma antioxidants because it has 100 times the concentratin of plasma GSH 
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[42, 316]. The normal range of erythrocyte GSH in the population is 0.6-1.4 µmol/L 
[317, 318]. Erythrocyte GSH changes were measured in our study using Asensis 
modification [150] of Brigelius method [151]. Changes in GSH levels are indicative of 
the severity of oxidative stress and the antioxidant reserve in the red cell. 
 
3.2.5. Reasons for Measuring Plasma Antioxidants  
 An antioxidant significantly delays or inhibits the oxidation of an oxidizable 
substance when present in lower concentration than that substance [319].  The 
physiological role of antioxidants, is to prevent damage to cellular components arising as 
a consequence of chemical reaction involving free radicals [88]. Human plasma is often 
used in studying damage induced by free radicals because it contains critical targets of 
oxidative damage such as lipoproteins and many important antioxidants in the same 
physiological environment.  Measurement of antioxidant defenses has consistently 
demonstrated depressed plasma levels of vitamin E and C in patients with sepsis and 
adult respiratory distress syndrome (ARDS) [10, 113, 320].   Low plasma Vitamin C 
levels have been shown to be predictive of the development of multiple organ failure 
syndrome in populations at risk [11]. Plasma glutathione levels are depressed in patients 
with hepatic failure, polytrauma and critically ill patients [18, 321]. The plasma 
antioxidant capacity which is indicative of the ability of antioxidants in circulation to 
respond oxidant release was measured using the FRAP method [126]. 
 
3.2.6. Reasons for Measuring the Total Oxidant in the Body  
A free radical can be defined as any molecular species capable of independent 
existence that contains an unpaired electron in an atomic orbital [322]. Oxidant 
generation is part of normal human metabolism and host defense mechanism, however 
when produced in excess oxidants cause tissue injury. Tissue injury can itself cause more 
oxidant generation which may further worsen the injury as examplified in crush injury 
[323, 324] and ischemia/ reperfusion injuries [325, 326]. Many free radicals are highly 
reactive and can either donate an electron to or extract an electron from other molecules 
therefore behaving as oxidants or reductants. Many radicals have very short half-life (106 
seconds) however the most important free radicals in many diseases are oxygen 
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derivatives particularly superoxide anion and the hydroxyl radical.  The hydroxyl radical 
or a closely related species, is probably the final mediator of most free radical induced 
tissue damage [327]. 
 The choice of plasma and urine analysis is because an evaluation of biomarkers in 
the circulation fluid (plasma) and in the elimination fluid (urine) will provide a 
comprehensive picture of the oxidant status in the organism [328]. The total oxidant 
levels were measured using a novel oxistress assay developed in the early phase of the 
study. The assay focuses on measuring the concentration of hydroxyl radical and other 
free radical chain reactions stimulated by the OH- radical effect in biological fluids. This 
assay measured both the total oxidant level in plasma and the patients oxidative status in 
the urine. 
 
3.2.7. Reasons for Measuring Plasma Protein Carbonyl: 
 Another means of estimating the activity of antioxidant in vivo is to assess their 
effects on markers of oxidative damage to lipid, protein and DNA. Protein carbonyl 
formation is the effect of oxidative damage on protein [161, 165]. All proteins are subject 
to modification by .OH (Hydroxyl radicals) or .OH+ O2.-  (Hydroxyl and Oxygen radicals) 
which includes alteration in molecular weight and net electrical charges [158] resulting in 
protein carbonyl formation. Protein carbonyl formation could either be primary or 
secondary, occurring in the blood, liver, brain, spinal cord and other organs. Primary 
formation results from protein exposure to reactive oxygen compounds leading to the 
modification and inter-conversion of amino acid side chains [155, 156, 158, 159]. The 
presence of protein carbonyl has become a widely accepted measure of oxidative damage 
under conditions of oxidative stress, aging and disease [329]. Measuring protein 
carbonyls in our study may provide a clinical index of the severity of oxidative stress in 
trauma. Protein carbonyl levels were measured using our modification of the colorimetric 
method originally described by Levine [167]. 
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3.2.8. Reasons for Studying the Role of Neutrophils Activity in Oxidative 
Stress 
 Neutrophils are thought to play a key role in tissue injury [330] and are also 
known to play a unique role in the etiology of oxidative stress because they release a lot 
of active substances such as elastase, toxic oxygen radicals and vasoactive substances at 
the site of injury or inflammation [73, 331-333]. Activation of the neutrophil enhances 
its adhesiveness of neutrophil to endothelium, associated with the release of reactive 
oxygen intermediates (ROIs) and degranulation with release of proteases [334]. A study 
by Tanaka [332] suggests that neutrophil O2- production increases acutely in trauma. 
Tumor necrosis factor may mediate this .O2- and GE production by neutrophils through 
increased vascular permeability and induction of endothelial adhesion molecules thereby 
exposing surrounding tissue to free radicals [335, 336]. The level of granulocyte elastase 
at 3 months after Percutanueous Transluminal Coronary Angioplasty (PTCA) correlated 
significantly with the percent luminal stenosis at the angioplasty site (p < 0.05) and the 
authors suggests granulocyte activation may be involved in restenosis after PTCA [337].  
The enzyme elastase is released from stimulated neutrophils at the site of injury, infection 
or inflammation and can cause tissue damage and subsequent organ dysfunction. By 
measuring the complexes of elastase with its' inhibitor α1-proteinase (elastaseα1-
proteinase inhibitor complex) in plasma, the degree of neutrophil activition can be 
quantified [332, 338].  Plasma elastase concentration on admission had the highest 
sensitivity (84%) but the lowest specificity (39%) in predicting multiple organ 
dysfunction (MODS) after trauma [331]. Plasma elastase concentration above 500 ng/ml 
on day 3 post-trauma was predictive of subsequent severe MODS with 95% specificity 
and 69% sensitivity. The negative predictive value (the probability that the patient will 
not have the disease when restricted to all patients who test negative) was 93% [331]. The 
present evidence suggests therefore that elastase is an important marker of 
polymorphonuclear cell activity and possibly a predictor of ARDS and MODS [331].  
 In addition to releasing large amount of oxidants, activated neutrophils also 
release myeloperoxidase, the enzyme that generates the most potent neutrophil oxidant, 
hypochlorous acid [209].  MPO activity is correlated to the absolute number of 
neutrophils and therefore constitutes a specific and sensitive marker to quantify its 
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infilteration into the injured tissue [222, 339]. MPO activity assay has been been used to 
study Leukocyte infilteration and accumulation after traumatic brain injury in rat [221, 
339]. It has also been used to predict early risk of myocardial infarction, as well as the 
risk of major adverse cardiac events in the ensuing 30-day and 6-month periods. [340]. 
Given its proinflammatory properties, MPO may serve as both a marker and mediator of 
vascular inflammation and further points toward the significance of PMN activation in 
the pathophysiology of ACS (Acute Coronary Syndrome) [341]. Myeloperoxidase 
activity was significantly higher in the plasma of the sepsis patients who subsequently 
died. [209]. In order to determine the relationship of neutrophils to the development of 
oxidative stress after trauma we examined both neutrophil count and activity with the 
Myeloperoxidase assay. 
 
3.2.9. What is the Role Antioxidant Therapy after Surgical Trauma? 
 There is anecdotal evidence in clinical and animal studies [342] [343] [135] 
indicating that the introduction of antioxidant therapy reduces oxidative stress and its 
complications. In a study by Marzi et al (1993) recombinant human superoxide dismutase 
(rhSOD) therapy after polytrauma attenuated multiple organ failure [342].  This effect 
was most evident in cardiovascular and pulmonary function.  The authors speculate that 
earlier administration of rhSOD (such as at the onset of resuscitation) may provide even 
better results than they observed because therapy was commenced late in their study 
(about the end of the first day after trauma).  A recent study by Tardiff (1997) concluded 
that the antioxidant probucol was effective in reducing the rate of restenosis after balloon 
coronary angioplasty [343]. Sheridan and associates (2000) showed that antioxidant 
therapy in burn patients reduced the length of time on mechanical ventilation and the 
level of malondialdehyde as compared to controls [17]. The consumption of endogenous 
antioxidants by free radicals resulting in oxidative stress may promote the development 
of MOF after polytraumatic injury [18]. Our prospective study looking at the role 
antioxidant therapy on oxidative stress and patient outcome will give an opportunity to 
assess the benefit of antioxidant therapy in the surgical setting.  
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3.2.10. Reasons for Evaluating Outcome 
 Outcome studies are usually used to assess large cohorts of patients often using 
adminstrative databases [344].  Outcomes studies often use patient based or patient 
derived evaluation of care. Our outcome study is aimed at providing information on two 
related questions about the intervention. The first question is to determine if enteral 
glutamine will raise erythrocyte glutathione levels, maintaining plasma antioxidants and 
reduce free radical production. The second question is to assess the impact of these 
changes on clinical outcome using objective measures such as the RIW score or the E-
PASS method. In this era of evidence based medicine there is a need for more objective 
measures than mortality, morbidity and length of stay to assess the impact of the 
antioxidant therapy [299, 345, 346] (Avery-jones 1964). Our study is a randomized 
clinical trial, differences in the outcome will be used to make inferences about the 
treatment effectiveness [347].  
 
3.3. Objectives of the Study 
! To understand the natural history of oxidative stress in humans.  
! To identify clinically applicable modes of evaluating oxidative stress. 
! To examine the relationship of neutrophil count and activity to the development of 
oxidative stress in trauma and surgical patients. 
! To develop and carry out a randomized prospective study to define the role 
antioxidant therapy on oxidative stress and the outcome of surgical patient. This will 
provide an opportunity to assess the benefit of antioxidant therapy in the surgical 
setting.  
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4. METHODS  
4.1. Red Cell Glutathione Measurement 
Red cell glutathione was measured using Asensi's (1999) modification [150] of 
the method by Brigelius et al (1983) [151]. The measurement is based on the conjugation 
of chlorobenzene with GSH in a reaction catalyzed by glutathione transferase forming an 
adduct of s- 2,4 dinitrophenyl glutathione which is read at 340 nm wavelength. This 
method measures reduced-glutathione (GSH) levels in the red cell. It is an end point 
reading that can measure as low as 0.2 nm in the cuvette which corresponds to 0.3 µM 
GSH [152]. The following describes the procedure:  
 
1. Take the whole blood and centrifuge at 300 rpm for 5 minutes. 
2. Remove the plasma  it can be used for frap or oxidant studies. 
3. Add equal volumes of TCA (trichloroacetate) to the RBC.  
a. 0.5 ml of ice cold 30% trichloroacetic acid (TCA) to 0.5 ml of RBC. 
4. Centrifuge mixture at 15,000 g for 5 min. 
5. Take the supernatant  use immediately or this can be stored at -200C (stable for 1 
week). 
6. Measure GSH at 340 nm wavelength after 5 minutes. 
7. Phosphate buffer pH = 7.2. 
Control Test sample 
 
• 25 µL of supernatant 
• 10 µL of CDNB (2 mg/ml 
ethanol) 
• 825 µL of K2PO4 buffer * 
 
• 25 µL of supernatant 
• 10 µL of CDNB 
• 825 µL of K2PO4 buffer  
• 10 µL of 500 U/ ml of 
GST 
 
 
 
4.2. The Novel Oxistress Method  
 This is used for measuring oxidants in plasma and urine. The concept of oxidative 
stress has been a well-known clinical problem in many disease states such as adult 
respiratory distress syndrome, diabetes mellitus, neurodegenerative diseases and many 
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other diseases. However the ability to make such diagnosis has been limited to either post 
mortem studies or research laboratories because the available methods are cumbersome 
and technically involved. Therefore the concept of the Oxistress assay is aimed at making 
the measurement of oxidative stress rapid, easy, accurate and without the need for 
technical support. The assay development process and clinical application is fully 
discussed in chapter 5 and the following is a summary of the method for the final assay 
component. 
 
4.2.1. Principle of the Oxistress Assay 
The principle of the assay is based on the rapid reaction of deoxyglucose in the 
presence of hydroxyl ion or peroxyl radical to produce a color change in thiobarbituric 
acid. 
 
4.2.2. Components of the Oxistress Assay 
• Deoxyglucose reagent (100 mM)  
• Thiobarbituric acid (TBA) (50 mM)  
• Ferrous sulfate (1 mM) 
Hydrogen peroxide standard with concentrations of 50, 100, 250, 500, 1000, 2500, 5000, 
10,000 & 20,000 µM were used. The reagent is stable for over four weeks if divided into 
two components:  
♦ Reagent 1 (R1) is a mixture of Thiobarturic acid (TBA) (50 mM) & Ferrous 
sulfate (1 mM). 
♦ Reagent 2 (R2) is the Deoxyglucose reagent (100 mM). 
Equal volumes of R1 and R2 are mixed prior to use but if using freshly prepared all the 
components can be added at the same time.  
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Figure 4.1: Slide Showing Colour Reaction Of The Oxistress Solution With 
Different Concentrations Of Hydrogen Peroxide (Microtitre Plate Method) 
 
 
 
 
 
 
 
Figure 4.2: 1 Ml Cuvette Method Showing Colour Reaction Of The Oxistress 
Solution With Different Concentrations Of Hydrogen Peroxide 
 
 
4.2.3. Procedure for the Oxistress Assay 
4.2.3.1. 1 ml Curvette Method for Urine  
1. Add 200 µl of urine specimen to 800 µl of Oxistress reagent. 
2. Read color reaction after 5 minutes using a spectrophotometer at a wavelength of 532 
nm. 
3.  Calculate the value against a hydrogen peroxide standard.  
The evaluation of plasma is similar however the plasma is mixed at a one in ten ratio 
to the reagent (100 µl of plasma to 900 µl of Oxistress reagent). 
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4.2.3.2. Deoxyglucose Microtitre Method for Plasma 
1. Make blank and peroxide standard 
2. Add 100µl of blank and peroxide standard concentrations 10, 25, 50, 80, 100 µmol/l 
3. Add 10 µl of plasma sample to 90 µl of buffer solution 
4. Add 100 µl of deoxglucose reagent  
5. Read at 540 nm wavelength for fresh samples or incubate for 10 minutes at 370C for 
frozen samples before reading.  
 
4.2.3.3. Deoxyglucose Microtitre Method for Urine  
1. Make blank and peroxide standard 
2. Add blank and peroxide standard concentrations 10, 25, 50, 80, 100 µmol/l 
3. Add 20 µl of urine sample to 80 µl of buffer solution 
4. Add 100 µl of deoxglucose reagent  
5. Read at 540 nm wavelength for fresh samples or incubate for 10 minutes at 370C for 
frozen samples before reading. 
 
4.3. Protein Carbonyl Method  
This is done using a modification of the colorimetric method (Figure 4.3) 
originally developed by Levine [160, 167]: 
1. Add 100 µl of serum to 300 µl of 0.4 g/100 ml 2,4- Dinitrophenylhydrazine (DNPH) 
in 1.25 M hydrochloric acid and prepare blanks using hydrochloric acid only.  
2. Vortex and allow 20 min for the reaction to take place.  
3. Precipitate the proteins using 400 µl of trichloroacetic acid (TCA).  
4. Centrifuge the samples for 5 minutes at 11,000 g, discarded the supernatant wash the 
pellets with ethanol: ethyl acetate (1:1) three times to remove the excess 2,4-DNPH.   
5. Dissolve the pellets in 1ml of 6 M guanidine HCl in 20 mM potassium phosphate 
buffer (pH 2.3).  
6. Re-centrifuge samples for 5 min to remove insoluble materials and supernatant. 
7. Read with a spectrometer at 370 nm wavelength.  
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8. Calculate protein carbonyl levels using the molar absorbance coefficient of 22,000 
M1cm-1.  
9. Evaluated total protein concentrations were using the bicinchoninic acid (BCA) assay 
[348] compared with bovine serum albumen standards both before and after washing 
the blanks with ethanol: ethyl acetate. A difference was found in the protein 
concentration in samples before diluting with hydrochloric acid, and before and after 
the washing process. There was a reduction of 2.73 ± 0.35 mg protein/ml (23%) in the 
samples diluted with hydrochloric (p=0.02). There was also a difference of 3.59 ± 
0.52 mg protein/ml (39%) before and after washing (p< 0.001). This difference 
greatly influenced the calculated carbonyl content (Figure 4.4). 
 
 
Figure 4.3: Levines Method & Modification 
Figure 4.3: 0.4% DNPH (our modification) without vortexing measured higher carbonyl levels in the same 
sample implying better accuracy. 
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Figure 4.4: Effect of Various Methods Of Protein Analysis on Plasma Carbonyl 
Values 
Figure 4.4: Washing reduces plasma protein levels by up to 39% thus yielding higher protein carbonyl 
levels. 
 
 
4.4. Neutrophil Count and Activity in Oxidative Stress 
In order to determine the role of neutrophils in the development of oxidative 
stress in trauma and elective surgery patients we examined both neutrophil count and 
activity. 
 
4.5. Neutrophil Count 
 Neutrophil count was done as part of routine blood investigations at the Royal 
University Hospital. 
 
4.5.1. Neutrophil Activity 
 Neutrophil activity was measured with the Myeloperoxidase assay [221, 222] 
The procedure is as follows: 
1. Mix plasma with Solution A [0.5% hexadeccyltrimethylammonium bromide 
(HTAB) in 50 mM Potassium phosphate buffer (pH 6.0)]. 
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2. Centrifuge at 40C for 15 min. 
3. Mix 6.7 ml of the supernatant with 200 µl of Solution B [50 ml of 50 mM 
potassium phosphate buffer (pH 6.0) mixed with 8.35 mg of o-dianisidine 
dihydrochloride and 25 µl of hydrogen peroxide] in a microtitre plate. 
4. Read at 460 nM as a kinetic assay every 11 sec for 5 min. 
 
4.6. The Total Antioxidants in Plasma Using the FRAP Method 
 The FRAP assay measures the total reducing power of the antioxidant [112]. At 
low pH, ferric tripyridyltriazine (FeIII-TPTZ) complex is reduced to a ferrous form 
producing an intense blue color, which can be monitored by measuring the change in 
absorbtion at 593 nm. The working solution is made up of a mixture of 25 ml of acetate 
buffer to 2.5 ml of TPTZ solution and 2.5 ml of FeCL.6H20 (ratio 10:1:1), it should be 
kept at 370C and the sample must be fully thawed. A fresh working solution must be 
made every day because it is stable for only 24 hr.  
 
4.6.1. Procedure for the FRAP Method 
The FRAP method was modified in this study using the micotitre plate in the 
following steps: 
1. Add 5 µl of sample to the microtite plate 
2. 150 µl of reagent (working solution) 
3. Add 15 µl of distilled water  
4. Stir with the pipette tip 
5. Read at 593 or 600 nm wavelength. 
    
4.7. Prospective Study on Antioxidant Therapy  
4.7.1. Study Design:  
This is a prospective study of surgical patients at the Royal University Hospital. 
Ethics approval will be sought from the University and the Saskatoon Health Region. The 
study will be randomly divided into two arms (treatment and non- treatment). There will 
be about 60 patients in each of the arms and they will be recruited pre-operatively from 
general surgery, neurological surgery, plastic surgery and anterior spinal fixation patients. 
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Informed consent will be obtained but the patients will not however know their group 
allocation in the study. 
The magnitude of the surgery will be evaluated from the pre and post operative 
notes and from the neutrophil counts which have been shown to be an index of severity of 
trauma [349, 350], (Obayan, unpublished observation).  The degree of oxidative stress 
will be evaluated by measuring changes in red cell glutathione [150, 151] and strong 
oxidants in urine (Obayan, unpublished method).  The outcome of glutamine therapy will 
be evaluated both clinically and biochemically. Some of the clinical outcomes will 
include length of hospital stay, wound complication rate, the resource intensity weight 
information (RIW), Karnosky score [351] and Glasgow outcome score.  The biochemical 
index will evaluate the degree to which glutamine inhibits oxidative stress after elective 
surgical trauma. 
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Figure 4.5: Study Protocol For Evaluating The Effect Of Enteral Antioxidant 
Therapy On Biochemical And Clinical Outcomes 
 
 
 
 
                     1. Pre-admission 
Consent: 
           2. In hospital pre-op 
- Pre-incision baseline blood &urine 
 
- Block randomization: Post-operatively in recovery room. 
Treatment: 
 
i. N/G tube placed in OR. 
ii. 2nd blood &urine in RR 
iii. Initiate N/G feeding @ 8 hr post-
op volume 200ml (20g)/ 24hrs 
iv. 3rd blood & urine at 24 hr post-op
v. D/C N/G feeding at 24 hr post-op 
vi. Initiate standard feeding protocol 
vii. 4th blood & urine at 72 hr post-op 
viii. 5th blood & urine at 120 hr post-
op 
ix. 6th blood & urine at 168 hr post-
op 
Control: 
♦ N/G tube placed in OR. 
♦ 2nd blood &urine in RR 
♦  Initiate N/G suction as 
needed  
♦ 3rd blood & urine at 24 hr 
post-op 
♦ D/C N/G at 56 hr post-op 
♦ Initiate standard feeding 
protocol 
♦ 4th blood & urine at 72hr post-
op 
♦ 5th blood & urine at 120 hr 
post-op 
♦ 6th blood & urine at 16 8hr 
Measure RIW After Discharge 
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4.7.2. Exclusion Criteria 
1. Patients with urea nitrogen concentration ≥ 25 mmol/l. 
2. Patients with total bilirubin concentration ≥ 175 mmol/L (Ziegler et al 1992).   
 
4.7.3. Potential Benefit of the Study 
Antioxidant therapy in a clinical setting will not only improve biochemical 
outcome but may also improve patient outcome.                                                                                                 
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5. THE NOVEL OXISTRESS ASSAY 
 Oxidative stress has been implicated as a factor in many disease and injury states 
such as adult respiratory distress syndrome, diabetes mellitus, neuro-degenerative 
diseases. The extent to which oxidative stress could be predictive of clinical outcome has 
been largely unknown and a satisfactory method for rapidly evaluating total oxidative 
stress in a human subject has been unavailable. The ability to make such diagnosis has 
been limited to either post mortem studies or research laboratories because the available 
methods are cumbersome and technically involved. As well, these methods usually 
measure a single oxidized compound, or a narrow class of compounds, as indicators of 
oxidative activity making them unreliable in assessing overall oxidative stress (or status). 
Some of these methods have been discussed in Chapter 2.  
 A measure of oxidative stress in body fluids may be predictive of clinical 
outcome and the need of a rapid clinically applicable assay that has the ability to assess 
overall oxidative stress (or status) was identified at the preliminary stage of this study. 
One of the ways of assessing oxidative stress is by the measurement of peroxide levels in 
biological fluids [182, 183, 197]. Hydrogen peroxide (H2O2) has been widely used in the 
standardization of the various methods [182, 183, 188]. The Novel Oxistress Assay is an 
invention that aims at an easier and rapid clinically applicable method of measuring 
strong oxidants (H2O2 equivalents) in biological fluids such as plasma and urine. The 
ability to measure all strong oxidants should make this assay better than others.  
 
   
5.1. Principle of the Oxistress Assay 
The principle of the assay is based on the rapid reaction of glucose in the presence 
of hydroxyl ion or other peroxyl radicals to produce a colour change. The procedure 
requires the oxidation of 2-deoxysugars to dialdehydes by strong oxidants derived from 
peroxide; the dialdehydes subsequently form a coloured adduct with thiobarbituric acid 
(TBA).  Ferrous Sulphate in the reagent provides the ferrous ions that convert the 
peroxides to strong oxidants. 
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5.2. The Oxistress Assay Development Process 
 The process involved the evaluation of the reaction of hydrogen peroxide with 
certain chemicals at different concentrations and conditions to determine the optimal 
composition of the assay. The objective was to measure strong oxidants in biological 
samples known to have hydrogen peroxide concentrations less than 200 µl [197]. The 
assay was pink in colour and stable at room temperature with the following components: 
• EDTA (1.4 mM), a chelating agent  
• Deoxyglucose reagent (100 mM), a 2- deoxysugar  
• Thiobarturic acid (TBA) (50 mM)  
• Ferrous sulfate (1 mM) 
• Freshly prepared Hydrogen peroxide standard in concentrations of 50 µM, 
100 µM, 250 µM. 
 
5.2.1. Standard Curve and Calibration of Assay 
500 µl of various concentrations of H2O2 from 1 µM to 250 µM was added to 
500µl of the reagent to develop a standard curve for the experiment. A linear relationship 
was observed between H2O2 concentration and TBA Reaction product absorbance at 
wavelength 532 nM (Figure 5.1). The reaction occurred within five minutes producing 
visible colour change from pink to red at 100 µM  250 µM hydrogen peroxide levels. At 
higher peroxide levels (>1000 µM) orange colour change was observed (Figure 5.2).  
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Figure 5.1: Standard Curve of the Oxistress Assay 
 
 
Figure 5.1: Oxistress assay produces a linear curve with different concentrations of hydrogen peroxide 
standards 
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Figure 5.2: Oxistress Assay Colour Changes With Varied Hydrogen Peroxide 
Standards (8-16,000 µM) 
 
 
 
 
5.2.2. Clinical Evaluation of the Oxistress Assay  
The assay was also used for biological samples such as urine specimens from 
normal volunteers (general population) and hospital samples, as well as whole blood 
samples from the blood bank of the Royal University Hospital, Saskatoon. 100 µl of 
plasma (from blood bank blood) or urine samples was added to 900 µl of the reagent at 
370C and measured at wavelength of 532 nM.  The results were similar to those of other 
methods such as the Xylenol Orange method [197, 352].  
 
5.2.2.1. Measuring Strong Oxidants in Plasma with the Oxistress Assay 
Plasma from blood bank blood was used as a standard to determine the optimal 
concentration of the deoxyglucose component by evaluating various concentrations (10 
mM  100 mM) and plasma/ assay dilution ratios of 1/3 -1/20 (Figure 5.3).  A linear 
curve was observed at 100 mM deoxyglucose concentration while a flat curve was 
observed at 10 mM implying that the latter concentration is not suitable for plasma 
peroxide measurement. The use of 100 mM of deoxyglucose as the 2-deoxysugar in the 
reagent was based on this finding. 
 
Figure 5.2A: Oxistress Assay (Acid EDTA) with 
Varied Concentrations of Hydrogen Standards
Figure 5.2B: Oxistress Assay (Sodium EDTA) with 
Varied Concentrations of Hydrogen Standards
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Figure 5.3: Plasma Peroxides at 10 & 100 mM Deoxyglucose Concentrations  
 
 
 
 
Figure 5.3: 100 mM deoxyglucose produced a linear curve with various dilutions of blood bank blood 
while 10 mM produce a flat graph. 
 
 
5.2.2.2. Measuring Strong Oxidants in Urine with the Oxistress Assay 
The analysis of 60 urine samples of hospital patients Stat urinalysis from the 
Dept. of Chemical Pathology, Royal University Hospital, Saskatoon, in comparison with 
50 samples from the general population was undertaken.  Patient diagnosis was unknown 
prior to sample analysis and no medical history was obtained from the general 
population, hence the assumption of a healthy group. The following results illustrated in 
Figure 5.4 were obtained: 
1. The values for the hospital patients ranged from 0 µM to 1060 µM with a median 
(inter-quartile range) of 102 µM and mean 168 µM (95 %CI range 119-217 µM). 
2. The values for the general population ranged from 0 µM to 231 µM with a median 
(inter-quartile range) of 36 µM and a mean of 49 µM. 
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3. The Mann-Whitney test for non-parametric analysis showed an extremely significant 
difference between the median values of the two groups, two-tailed p=0.0001. 
4. The estimated reference value range for the normal population range is 34 µM 65 
µM. 
An analysis of patients with twice the estimated normal reference value of urine 
peroxide was also done (Figure 5.5). The diagnosis in most of these patients has been 
associated with oxidative stress making the Oxistress assay a clinically applicable 
diagnostic tool. 
 
69 
Figure 5.4: Urine Peroxide Levels In Hospital Patients Vs. General Population 
 
Figure 5.4: Patients had higher urine peroxide levels than the general population (p=0.0001) 
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Figure 5.5:  Peroxide Levels In Patients With Twice The Reference Values  
 
Figure 5.5: Diagnosis in patients with twice the reference values that has been associated with oxidative 
stress.   
 
5.2.3. Further Evaluation of the Oxistress Assay: See appendix 
The following were the aims and objectives of this phase of the evaluation: 
♦ To better evaluate the role of EDTA  
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♦ To better evaluate the role of deoxyglucose (or glucose) in the assay.  
♦ To evaluate the stability of the assay and the type of color change with storage and 
reactions with hydrogen peroxide standards over time. 
 
5.2.4. Discussion 
This assay was developed because of the need for a less cumbersome or simple 
reliable method that can measure a wide range of peroxide levels in biological fluids thus 
making bedside clinical diagnosis of oxidative stress a reality. The assay components 
were determined based on their individual properties and potential to produce a colour 
change in a reaction with hydrogen peroxide. The Oxistress assay (with the EDTA 
component) was used on hydrogen peroxide standards as well as biological samples from 
the general and hospital populations. The microtitre plate and 1 ml cuvette methods 
produced similar results and the dipstick method presently in the developmental phase is 
also expected to produce similar results as these two methods.  
Our study demonstrated that EDTA has an inhibitory effect on the color reaction 
produced by the assay at higher hydrogen peroxide concentrations (>800 µM). Kikugawa 
et al. (1992) also reported partial inhibitory effect of EDTA on the ability of 
thiobarbituric acid to form a color complex in rat brain samples [353]. The removal of 
EDTA from the assay resulted in a linear curve with hydrogen peroxide standards at all 
concentrations. This limitation with EDTA was not observed in the biological samples 
because with sample dilutions up to 1500 µM peroxide levels were measured. The 
observed limitation with EDTA however suggests it may not be an ideal component of a 
bedside or dipstick Oxistress assay measurement tool even though the dilution method 
makes it a very easy and reliable laboratory tool. 
 Deoxyglucose and glucose were separately evaluated to determine the ideal sugar 
for optimal assay function. Glucose required higher concentration of hydrogen peroxide 
to produce a visible color change and deoxyglucose produced a deeper color change 
making it the preferred assay sugar. The optimal deoxyglucose concentration was also 
determined to be 100 mM.   
Reference ranges were established with urine samples from the general and 
subsequently applied hospital population. The Oxistress Assay urine study has the largest 
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reported population (N=110) and a statistically significant difference was established 
between hospital patients and the general population. The Oxistress Assay was both 
sensitive and specific in disease states associated with oxidative stress. Previous studies 
had indicated very low levels of H2O2 (<100 µM) in human urine samples, however our 
study has established measurable high peroxide equivalents in both general and hospital 
populations. These findings agree with those of Long et al (1999) [197], who reported 
much higher levels than previously published (>100 µM)  using 3 different methods of 
measuring H2O2 in urine. The Oxistress Assay was also successfully used in human 
plasma samples. We measured a consistent concentration of H2O2 equivalent in plasma 
irrespective of the plasma/ assay dilution ratio.  
The novel Oxistress Assay has proven to be a reliable clinical diagnostic tool for 
Oxidative Stress. In its current form the assay can be used on plasma urine samples for 
rapid (5 min) patient evaluation. The Oxistress assay dipstick being developed will 
provide a bedside test making diagnosis easier. The EDTA-free assay is also very good 
laboratory tool for measuring high levels of hydrogen peroxide making it useful in both 
human and non-human samples. The novel Oxistress assay has received full patent rights 
from the United States Patent Office in June 2004. 
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6. STUDY OF CLINICAL TRAUMA AND OXIDATIVE STRESS  
6.1. Introduction 
This is a study of the natural history of Oxidative Stress in Trauma since the onset 
time can be reliably determined in the normal population, and there is evidence that 
trauma is the commonest cause of oxidative stress [15, 16]. Trauma patients also form a 
good cohort for understanding the natural history since most are not known to have prior 
oxidative stress. Animal studies suggest strong oxidants and neutrophils play important 
roles in the pathophysiology of oxidative stress after trauma, shock and burns.  The 
consumption of endogenic antioxidants by free radicals resulting in oxidative stress may 
promote the development of multiple organ organ failure (MOF) after polytraumatic 
injury [18] which would result in death.  Therefore the need to make an early diagnosis of 
oxidative stress based on a clear understanding of the pathophysiolgy cannot be 
overemphasized. 
A prospective observational study of the natural history was conducted on all 
multiply injured patients over 15 yr in age (N= 120) admitted to a regional trauma unit 
(Royal University Hospital, Saskatoon) between April and September 2000 were entered 
into the study.  Patients were subsequently divided into four groups, the first three based 
on the injury severity score (ISS) and the fourth based on pre-morbid medical factors. 
The ISS classifies patients into two broad groups i.e. major (or severe = ISS ≥ 16) and 
minor trauma (ISS ≤ 15). The minor group could be sub-classified into moderate (ISS 8-
15) and mild trauma (ISS ≤ 7) [354-356]. Further analysis was done based on the body 
region affected by trauma. 
The aim of the study was to understand the effect of trauma on oxidative stress by 
measuring the production of strong oxidants in plasma and urine, strong oxidant protein 
damage (protein carbonyl) and changes in antioxidant reserves in blood (red cell and 
plasma). The parameters studied over a 7 day period were red cell glutathione levels, total 
antioxidants in plasma, free radicals in plasma and urine, and neutrophil count & activity. 
The methods were discussed in Chapter 4 and the results are presented in this chapter. 
Glutathione (GSH) an antioxidant abundant in erythrocytes was measured using a 
modification of the Brigelius method in packed red cell samples taken at 0, 6, 12, 24, 72 
hr and on day 7. Changes in plasma antioxidant reserve were measured with the ferric 
74 
reducing ability (FRAP) assay, changes in strong oxidants with the novel Oxistress assay 
and changes in protein carbonyl with a modification of Levines method. This study 
formed the basis of patient selection for the evaluation of prophylactic antioxidant in 
therapy elective surgery patients. 
 
6.2. Red Cell Glutathione  
6.2.1. Red Cell Glutathione Measurement in Trauma Patients  
 Changes in red cell Glutathione levels for each trauma patient group is 
summarized in Table 6.1. The effect of trauma on the red cell glutathione defense system 
over a 7 day period for all trauma patients is also shown in Figure 6.1. In all trauma 
groups combined there is no significant change in the red cell glutathione within the first 
6 hr (p =0.09) however between 6-18 hr an increment of 20%-30% (p = 0.004) followed 
by a decline at 24-30 hr is observed. The maximum depletion in the red cell glutathione 
was at 24-30 hr (p =0.037). A gradual increase to the 12 hr levels occurs at 72 hr (p 
=0.16) and the upward trend continues until 168 hr (day 7).  
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Table 6.1: Changes In Red Cell Glutathione Levels In The Patient Groups 
Patient group GSH 
Levels 
(µM) 
0-6 hr 
(µM) 
6-12 hr 
(µM) 
12-18 hr 
(µM) 
18-24 
hr 
(µM) 
72 hr  
(µM) 
168 hr 
(µM) 
Mean 714 880 860 656 877 1018 All trauma  
(N=120) SEM 43.8 71.7 71.0 51.3 96.5 193.3 
Mean 819 1054 902.5 546 930 1165 Severe trauma 
(ISS score >16) 
(N =39) 
SEM 66.5 149.7 110.4 52.0 127.9 237.5 
Mean 635 797 789 698 760 757 Moderate trauma 
(ISS score 9-15) 
(N =39) 
SEM 67.1 55.4 112.4 83.9 103.4 177.1 
Mean 669 725 869 841 973 973 Mild trauma 
(ISS score 1-8) 
(N =22) 
SEM 99.0 104.9 149.2 160.2 322.7 170.0 
Mean 632 992 840 550 808 1217 Preexisting 
Medical Condition 
(N =10) 
SEM 49.3 198.5 133.4 109.9 130.4 427.3 
Mean 857 815 700 496 750 707 Head injury 
(N =11) SEM 91.0 15.0 85.4 89.4 145.9 154.3 
Mean 608 968 903 762 798 773 Body injury 
(N =30) SEM 97 122.7 129.6 130.9 83.3 31.8 
Mean 891 906 993 566 932 730 Combined head/ 
body injury 
(N=12) 
 
SEM 73.5 88.9 298.7 73.3 217.2 111.6 
Mean 790  740 970 808 1080 990 Spine trauma 
(N=9) SEM 10 140 319 308 480 0 
 
  The natural history of the effect of trauma on red cell glutathione in the different 
patient groups at different time points is summarized in Figure 6.3. Severe trauma 
patients had the greatest depletion at 24 hr (p = 0.0024), followed by patients with 
preexisting medical problems (p=0.0907) and moderately injured patients (p = 0.1759), 
while minimally injured patients had an increase in the red cell glutathione levels at 24 hr 
(p = 0.09). Patients with pre-existing medical problems had lower baseline red cell 
glutathione levels than the other three patient groups (p = 0.1). Unlike the other groups, 
similar red cell glutathione response was observed in patients with pre-existing medical 
problems irrespective of their trauma severity score. There was a rise in red cell 
glutathione levels between 6 and 12 hr followed by depletion similar to the severe trauma 
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patients at 24 hr (p = 0.09) and subsequently a gradual rise until day 7 when the levels 
were comparable with the severe trauma group.  
Patients with head injury had a continual decline in the red cell glutathione levels 
from admission till 24 hr (p = 0.041) followed by a sustained rise from 72 hr till day 7 (p 
=0.001), by which time they still failed to reach the initial level (Figure 6.4). Combined 
head and body injury patients had a rise in glutathione levels between 6 and 18 hr 
followed by a sharp decline at 24 hr (p = 0.0087) and although there was a significant rise 
at 72 hr the initial values were also not attained by this group. Patients with severe body 
injury demonstrated a pattern similar to the combined head and body injury except that 
the decline at 24 hr was not as sharp (p = 0.127) and achieved higher than initial red cell 
glutathione levels by the seventh day. Isolated spinal injury patients demonstrated and 
maintained a continual rise in red cell glutathione levels throughout the study period 
except for the slight decline at 24 hr (p = 0.8582) (Figure 6.4). The severity of trauma, a 
pre-existing medical problem and organ affected by the trauma appear to be factors most 
responsible for the observed decline in the red cell glutathione defense system at 24 -30 
hr. 
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Figure 6.1.  Red Blood Cell Glutathione (GSH) Levels In All Trauma Patients 
Figure 6.1: Red blood cell glutathione (GSH) levels (mean ± SEM) in all trauma patients (n=120) seen 
between 0168 hr. There is an increment of 20-30% (p = 0.004) between 6-18 hr and maximum depletion 
at 24-30 hr  (p =0.037) in the red cell glutathione. 
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Figure 6.2: Changes In Glutathione Levels At 6 And 24 Hr Versus Trauma Severity 
 
  
Figure 6.2: Scattergram showing the distribution of red cell GSH in relation to trauma severity. The higher 
the trauma score or severity the greater the depletion in red cell GSH (p = 0.0024) at 24 hr. 
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Figure 6.3: Red Cell GSH Changes Versus Trauma Severity/ Preexisting Medical 
Problem 
 
 
 
Figure 6.3: The relation ship between trauma severity (ISS score), pre-existing medical problems and 
changes in red cell glutathione (mean ± SEM) content is demonstrated above.  The SEM of some sample 
sets are so small they do not appear on the graph. All four groups except ISS score < 8 had maximal 
depletion at 24 hr. Severe trauma patients (ISS score >16) had the greatest depletion at 24 hr (p= 0.0024), 
moderately injured patients (ISS score 9-15) had less depletion (p = 0.042), while minimally injured 
patients (ISS score 1-8) had an increase in the red cell glutathione levels at 24 hr (p =0.09). Patients with 
pre-existing medical problems had depletion similar to severe trauma patients (p = 0.09) and lower baseline 
red cell glutathione levels than the other three patient groups (p = 0.1). (ISS 1-8 = mild trauma; ISS 9-15 = 
moderate trauma and ISS >15 = severe trauma). 
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Figure 6.4: Red Cell GSH Changes Versus Body Region Affected By Trauma.  
 
Figure 6.4: In comparison with admission baselines head jury caused the greatest depletion at 24 hr (p= 
0.041) followed by combined head and body injury (p= 0.0087), and severe body injury (p= 0.127) with the 
least depletion in spinal injury (p= 0.8582).  
 
 
6.2.2. Discussion: Trauma and Red Cell Glutathione 
Studies have shown a clear association between severe trauma and the release of 
reactive oxygen species [44] which results in the consumption of antioxidants and 
subsequently oxidative stress [357]. The red blood cell has been shown to have high 
concentrations of GSH [131] and about 95% of its GSH is in the reduced form [18]. The 
red cell also has the ability to regenerate about 35 µmol/l of ascorbic acid every 3 min 
from ascorbate radical [42]. Significant extra-cellular oxidative stress is required to 
deplete the GSH level in the red cell [316]. As reported in the previous section, an initial 
increase in the red cell GSH between the 6 and 18 hr (Figures 6.1 - 6.3) was observed. 
The mechanism of this increase could be red cell transportation of GSH produced in the 
liver [142, 358], however, other factors such as increased concentration of red cell 
glutamic acid, glycine and the maintenance of body temperature may  play a role in the 
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rapid production of GSH in the red cell during this period of oxidative stress [131, 143, 
359]. Maintaining the body temperature is very important for GSH metabolism because 
heat stress not only produces oxidants but it impairs the enzyme systems necessary for 
detoxification [143]. The possible role of fresh blood transfusion in increasing red cell 
GSH can also not be excluded. Another possibility is an increase in red cell release from 
the bone marrow and other stores in response to hypoxia and hemodynamic instability.  
The maximal depletion observed in red cell GSH at 24- 30 hr in all patients was 
more in those with elevated neutrophil activity [76, 360], shock or multi-organ damage 
[361]. The groups most affected were the severely injured, head injured and patients with 
pre-existing medical problems (Figures 6.1-6.4).  This observed depletion in red cell 
GSH may be due to peak strong oxidant release in plasma and subsequent consumption 
of plasma antioxidants. Other researchers have also reported decreased plasma GSH 
associated with severe multiple trauma thus validating our findings [18, 130]. 
Patients with pre-existing medical problems such as liver cirrhosis, diabetes and 
chronic obstructive lung disease form a special group in trauma because outcome is more 
dependent on these medical co-morbidities than the trauma severity based on injury 
scoring system [362]. This finding was demonstrated in an earlier study by Mackenzie, 
which recommends that all patients with pre-existing medical problems be treated in a 
trauma center irrespective of their trauma severity [363]. Our study results show that 
patients with pre-existing medical problems have lower baseline GSH than the other 
groups and were as depleted as the severely injured patients at 24 hr irrespective of their 
trauma severity (Figure 6.3). These findings agree with a study on insulin-dependent 
diabetic patients who had lower basal levels of antioxidants and demonstrated lower 
plasma and erythrocyte antioxidant capacity when confronted with oxidative stress [364].  
The researchers suggest their findings may be due to lower erythrocyte glutathione 
reductase (46%), glutathione peroxidase level (30%) and glutathione -s transferase (26%) 
activities when compared to the controls [364]. 
Animal studies have shown that the cytotoxic process triggered by head injury 
causes the release of reactive oxygen species leading to the development of secondary 
injury [365], and systemic depletion of low molecular weight antioxidants such as GSH 
[360, 366], maximal at 24 hr. These findings were supported by our study, which 
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revealed the maximum depletion of red cell GSH was at 24-30 hr after head injury. The 
return to baseline levels had not yet occurred by day 7 (Figure 6.4), a finding not 
previously reported in human studies. The depletion was worse in head and multiple 
system compared with severe single system injured patients (without head injury). Spinal 
cord trauma resulted in less red cell GSH depletion than in other organ systems at 24 hr 
when compared with the levels at 6 hr. This is not surprising because spinal injuries are 
usually minimal injuries, but there was an expectation of greater systemic impact on the 
red cell GSH because of the CNS involvement. 
 
6.3. The Role Of Neutrophils in Trauma:  
6.3.1. Neutrophil Count and Trauma: 
A direct relationship between quantitative neutrophil count and trauma severity 
within 6-12 hr of trauma was observed (Figure 6.5). The more severe the trauma the 
higher the neutrophil count between patient groups (p = 0.019). The effect of organ 
specific damage on neutrophil count in the first 6-12 hr revealed higher counts in head 
injury (similar to the animal head injury models) [360] than in isolated body injury 
patients although this difference was not statistically significant (p = 0.38) (Figure 6.6). 
Head injury patients also had higher neutrophil count (15 × 109/ l) than spine injury (8 × 
109/ l).  
Debate exists about the cause and the clinical value of changes in the absolute 
neutrophil count in trauma. Some suggest these changes are due to an imbalance between 
production and demargination while others feel margination and breakdown are 
responsible [72, 73]. Recent studies have linked changes in the absolute neutrophil count 
with post-operative surgical stress [74-78].  Most of these studies were related to surgical 
stress or infection and the earliest changes were observed after 24 hr [74].  
Our results however depicted an increase in the absolute neutrophil count, which 
correlated with trauma severity based on the injury severity score (p = 0.019) as early as 
6 hr (Figure 6.5). One possible reason for the increased neutrophil count is the inhibition 
of apoptosis (programmed cell death) and subsequent prolongation of inflammation [73, 
79-82]. Trauma not only reduces the rate of apoptosis but increases the functional 
longevity of neutrophils [73]. Recent studies have shown that mitogen activated protein 
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kinase (MAPK) and nuclear factor kappa B (NKκB) activation by oxidative stress appear 
to be responsible for the reduction in apoptosis [83, 84]. Neutrophil count appears to be 
associated with the degree of the trauma and may be predictive of the eventual outcome 
of the patient.  
Neutrophil accumulation contributes to host defense via their bactericidal and 
phagocytic properties. However this could potentially exacerbate injury by obstructing 
brain microvasculature and aggravating the ischemic process secondary to trauma. 
Animal studies have shown that traumatic brain injury results in neutrophil infiltration of 
the brain as well as systemic increase within the first few hours [360, 365-368] but 
previous human studies have not reported the significance of systemic neutrophil count in 
head injury.  Our results suggest that neutrophil count may be predictive of oxidative 
stress in head injury patients contrary to previous reports. Head injured patients in our 
study had higher absolute neutrophil count than spinally injured patients and this finding 
suggests a direct relationship between injury severity and post injury neutrophil count. 
This suggestion is supported Malone et al (2001) who concluded that neutrophil count on 
admission is an independent marker predicting outcome in trauma [369]. We observed an 
increase in the systemic neutrophil count in our head injury patients highest at 6 hr and 
similar to the animal head injury models. 
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Figure 6.5: Neutrophil Count (Mean ± SEM) At 6hr Relative to Trauma Severity. 
 
Figure 6.5: A significant variation in neutrophil count based on trauma severity (p= 0.019) is observed. 
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Figure 6.6: Neutrophil Count (Mean ± SEM) At 6 Hr In Head And Body Trauma 
 
Figure 6.6: Graph comparing neutrophil count in isolated head trauma with body trauma. Neutrophil count 
was higher in head trauma than in body trauma at 6 hr (p= 0.38). 
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Figure 6.7: Neutrophil Count (Mean ± SEM) At 6 Hr In Head And Spine Trauma 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.7: Graph comparing neutrophil count in head versus spine trauma. Neutrophil count in head 
trauma was approximately double that in spine trauma. 
 
Discussion: Neutrophil Activity and Trauma: 
Activated PMN cells have the capacity to generate and release substantial 
amounts of reactive oxygen species after trauma. A study by Tanaka suggests that 
neutrophil O2ú- production increases acutely in trauma [370]. They reported highest 
sensitivity (84%) but low specificity (39%) in predicting multiple organ dysfunction 
(MODS) after trauma with admission plasma elastase levels. However another study 
reported concentrations above 500 ng/ml on day 3 post-trauma was predictive of 
subsequent severe MODS with 95% specificity and 69% sensitivity [331]. In our study 
population we observed two neutrophil activity peaks irrespective of the injury score, the 
first between 7 hr and 10 hr and the second smaller peak between 13 hr and 16 hr (Figure 
6.8). We also observed a tendency towards increased neutrophil activity with increase 
trauma severity (Figure 6.9), however this trend was not statistically significant. 
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Our study also showed minimal changes in systemic neutrophil activity in 
previously healthy spinally injured patients however the presence of previous medical 
morbidity had priming effect on the neutrophils thus increasing their activity (Figure 
6.10). Head injury increased systemic neutrophil activity in all patients and this might be 
responsible for the severity of antioxidant depletion in head injured as compared to 
spinally injured patients.  The observed increased in activity may also be due to the 
synchronous effect of increased neutrophil count and up regulation of neutrophil activity, 
which is associated with trauma. 
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Figure 6.8: Plasma Neutrophil Activity Following Trauma 
 
Figure 6.8: Graph showing changes in Neutrophil activity over 7-day period. Two activity peaks were 
observed following trauma  1st between 7 and 10 hr and second smaller peak between 13 and 16 hr.  
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Figure 6.9: Neutrophil Activity Versus Trauma Severity 
 
Figure 6.9: Graph showing the relationship between trauma severity and neutrophil activity. There is 
increased neutrophil activity with trauma severity, however this is not significant (p=0.349) 
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Figure 6.10: Changes In Neutrophil Activity In Organ Specific Trauma 
Figure 6.10:  Graph comparing myeloperoxidase activity in healthy spine injury, spine/ medical injury and 
head injury. Neutrophil activity is highest in spinal/ medical injury patients. 
 
 
6.4. Strong Oxidants in Plasma and Urine (Oxistress Assay). 
Plasma or urine oxidant level is the quantity of strong oxidants generated after 
trauma. Similar pattern of urine and plasma oxidant levels were observed in all trauma 
patients (Tables 6.2; 6.3). Peaks were noticed at 6 hr and 24 hr and depletion at 12 hr and 
72 hr. It is important to note that the oxidant levels were higher (about five-fold) and the 
changes were more profound in plasma than in urine.  
 
6.4.1. Plasma Oxidants in Trauma 
Our results revealed fluctuating plasma oxidant levels post trauma - levels were 
highest within the first 6 hours with a 25% decrease between 6 and 12 hr (p= 0.0205). 
Subsequently a 30% increase between 12-18 hr (p= 0.0047) followed by a steady decline 
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over the next 48 hr (p= 0.0104) was observed. A 10% increase between 72 hr and day 7 
(p=0.2) likely due to complications in patients following trauma was noticed subsequent 
to the previously observed decline (Figure 6.11). There were significant plasma oxidant 
changes resulting from physical trauma (p =0.041) and a similar trend was observed in 
relation to trauma severity.  
 
Table 6.2: Changes in Plasma Oxidant after Trauma 
Time in hr 0-6 hr 6-12 hr 12-18 hr 24-30 hr 72 hr 168 hr 
Mean oxidants 
(peroxide 
equivalent)  
755.71 471.5 797.5 649.4 532.12 639.3 
SEM 55.55 79.58 46.01 60.47 75.23 90.27 
95% CI 619 -891 283 -659 688.7 -
906.3 
512.6 
786.2 
354.2 -
710 
407.2 - 
871 
 
Table 6.2: Mean plasma oxidant for all patients revealed fluctuating levels: high on admission (0-6 hr) and 
highest at 12- 18 hr. Decline between 6- 12 hr was significant (p= 0.02). This trend occurred irrespective of 
trauma severity. 
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Figure 6:11 Plasma Free Radicals Post Trauma (Oxistress Assay Method) 
 
Figure 6.11: Mean plasma oxidant for all patients revealed fluctuating levels: high on admission (0-6 hr) 
and highest at 12- 18 hr. Decline between 6- 12 hr was significant (p= 0.02). This trend occurred 
irrespective of trauma severity. 
 
6.4.2. Urine Oxidants in Trauma 
The prospective study revealed trauma results in more than two-fold the normal 
urine excretion of oxidants. Changes in urine were similar to plasma however the highest 
oxidant levels were observed between 24-30 hr as compared to the finding in plasma.  
There is a high urine oxidant level followed by a significant decline between 6 and 12 hr 
(p=0.02).  An increase between 12-18 hr post injury (p=0.1) and a further increase in the 
24-30 hr period (p=0.2) were observed. Trauma results in a significant increase in 
excretion of urine oxidants between 12 hr and 24 hr (p=0.012). This increase was 
followed by a significant decline at 72 hr (p= 0.01). 
 
 
0
250
500
750
1000
Pl
as
m
a 
O
xi
da
nt
s (
H
20
2
eq
ui
va
le
nt
 µ
M
/l)
Time in hr
168 hr
72+  hr
24 - 30 hr
12 - 18 hr
6 - 12 hr
0 - 6 hr
93 
Table 6.3: Changes in Urine Oxidant Levels After Trauma
Time in hr 0-6 hr 6-12 hr 12-18 hr 24-30 hr 72 hr 168 hr 
Mean oxidants 
(peroxide equivalent)  
157.2 127.4 153.88 164 129.5 142.5 
SEM 4.14 8.9 6.2 4.9 9.9 11.2 
95% CI 148-
166 
107-
147 
139 -168 152175 106 -
152 
115.8 
169 
Table 6.3: Mean urine oxidant levels for all patients after trauma were high on admission (0- 6 hr) but 
peaked at 24- 30 hr. This trend also occurred in all groups irrespective of trauma severity.  
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Figure 6.12: Urine Free Radicals Post Trauma (Oxistress Assay Method) 
 
Figure 6.12: Mean urine oxidant levels for all patients after trauma were high on admission (0- 6 hr) but 
peaked at 24- 30 hr. This trend also occurred in all groups irrespective of trauma severity. 
 
6.5. Plasma Antioxidant Reserve (FRAP Method) 
The highest concentration of plasma antioxidant reserve (total antioxidants in 
plasma) was 1000 µM ferrous sulphate equivalent in all patients and this was observed on 
admission irrespective of trauma score. There was however a 30% drop within 6 hr 
followed by a further 15% depletion in the first 24 hr of trauma. This depletion in plasma 
antioxidants was significant (p = 0.017). There was slight recovery from 72 hr but only 
15% increase from the lowest level (at 24 hr) was observed by day 7 (Figure 6.13). The 
admission levels were therefore not regained by day 7 in all patients. Trauma severity and 
pre-morbid medical conditions had similar trend as observed in all patients combined. 
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Figure 6.13: Plasma Antioxidant Changes Over Time FRAP Method 
   
Figure 6.13: Trauma results in significant depletion in antioxidant reserve in all patients (p = 0.017).  
Highest level was on admission and greatest depletion was at 24 hr. Baseline levels were never regained 
and similar trend was observed irrespective of trauma severity. 
 
6.6. Protein Carbonyl in Plasma and Urine 
6.6.1. Plasma Protein Carbonyl Analysis 
The average age of patients in the plasma protein carbonyl group was 40.7 ± 5.6 
yr (range 1781 yr, n=15). The average carbonyl content across all samples over the 
study period was 1.49 nmol/mg protein. There were two peaks, first on admission and 
slightly higher peak on day 7 (168 hr) and declines were observed within 6-12 hr and 24 
hr (Figure 6.14). 
The two main ISS groups (minor and major trauma) were equally matched in age 
and sex. There were five patients in Group 1 (minor trauma). The mean ISS-90 was 9.4 ± 
1.91 (Range 4-16, n = 5). The average carbonyl content on admission to hospital was 
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0.87 ± 0.2 nmol carbonyl/mg total protein (range 0.45-1.61 nmol/mg, n=5) and 0.93 
nmol/mg over the study period. The rise in carbonyl content varied in time between 
patients. Group 2 (major trauma) consisted of ten patients. The mean ISS-90 was 25.3 ± 
1.86 (range 17-34, n=10). The average carbonyl content on admission to hospital was 
1.95 ± 0.38 nmol carbonyl/ mg total protein (range 0.03- 3.87, n=10.) and 1.68 nmol/mg 
over the study period. The individual peak carbonyl levels occurred at the time of 
hospital admission and on day 7. Day 7 levels were higher than admission levels in the 2 
groups although more marked in severe trauma. The carbonyl content was significantly 
higher than in minor trauma throughout the study period (p<0.001). The same trend was 
noticed on admission and the difference between the two groups was also significant 
(p=0.025) (Figure 6.15).  
Grouping the patients into ISS-90 scores of 0-9, 10-19, 20-29, and >30 (Figure 
6.16) produced similar results as grouping into minor and major trauma (Figure 6.15) but 
the difference between these four sub-groups was not statistically significant (p=NS). 
Comparing plasma carbonyl with oxidant levels in the same patient revealed a linear 
relationship (p= 0.031) between the two groups (Figure 6.17). 
 
Figure 6.14: Plasma Carbonyl Content in All Trauma Patients 
 
Figure 6.14: Changes in plasma carbonyl in all trauma patients reveled 2 peaks on admission and 168 hr. 
Declines occurred at 6-12 hr and 24 hr. Average carbonyl content over the study period was 1.49 nmol/mg 
protein. 
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Figure 6.15: Plasma Carbonyl Content in Major and Minor Trauma Patients 
 
 
 
Figure 6.15: Carbonyl content in severe trauma was significantly higher in severe trauma than in minor  
trauma on admission (p= 0.025) and throughout the study period (p<0.001).  Day 7 levels were higher than 
admission levels in the 2 groups although more marked in severe trauma. 
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Figure 6.16: Plasma Carbonyl versus Trauma Severity 
 
 
Figure 6.16: Carbonyl content was directly related to trauma severity but the difference between these four 
sub-groups was not statistically significant (p=NS).  
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Figure 6.17: Plasma Carbonyl versus Oxidant Levels In Trauma Patients  
 
Figure 6.17: Linear relationship is observed between plasma oxidant and carbonyl formation (p=0.031).                               
`` 
 
 
6.6.2. Urine Carbonyl Analysis 
Mixing urine with 0.2% 2,4-DNPH or 0.2% 2,4-DNPH + equal volume of 30% 
TCA in 1 mM EDTA produced no precipitate in the Eppendorf tube irrespective of injury 
severity. There were large precipitates (0.01 ml in an Eppendorf tube) in all urine samples 
using the recommended 0.4% 2,4-DNPH irrespective of the trauma score. Using our 
modification of 0.4% 2,4-DNPH with equal volume of 30% TCA in 1 mM EDTA, it was 
easy to distinguish small from large precipitates with variation according to trauma score 
(Figure 6.18).  A positive correlation between the presence of precipitate and trauma 
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severity (p= 0.000) was also observed (Figure 6.19), however the presence of precipitate 
was not necessarily predictive of trauma severity (p= 0.36).  
 
 
Figure 6.18: Grades of Urine Precipitation 
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Figure 6.19: Appearance of Urine Precipitate with Trauma Severity Over Time 
 
 
Figure 6.19: Positive correlation between the presence of precipitate and trauma severity (p= 0.000) but 
precipitate not necessarily predictive of trauma severity (p= 0.36). 
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6.7. Discussion: The Effect of Trauma on Plasma Oxidative Homeostasis:  
Plasma is the unique site to study oxidative homeostasis in the body not only 
because it contains antioxidants [103] and the targets of oxidative stress but it is in 
constant interaction with the red cell which is source of antioxidant regeneration [42].  
The choice of trauma patients as the study population is also important in that polytrauma 
results in generation of reactive oxygen species and could play a role in the 
pathophysiology of systemic inflammatory response and depletion of antioxidants 
following trauma.   
 
6.7.1. Plasma Antioxidants: 
The highest levels of antioxidants in our patient population was on admission 
which is similar to the findings of Mayer et al [130] and Kretzschmar et al [18] in 
multiple trauma patients.  These levels are likely to be the patients baseline before the 
trauma because patients were recruited within 6 hr of trauma and were previously 
healthy. The full effect of strong oxidants production particularly from neutrophil 
activation takes about 6hr as observed in our study and others [221]. Previous studies 
have also reported no significant change in strong oxidant levels within 6 hr of trauma 
[371].  This however is the only study using the FRAP method to measure antioxidant 
capacity in trauma, other studies have used TORC [130] or plasma GSH levels [18]. The 
FRAP method has however been used in other clinical conditions such as eclampsia, 
diabetes and following bone marrow transplant [372-374]. It was used in this study 
because it is an easy, stable, reliable, sensitive, inexpensive, and fully automated method 
for measuring total antioxidant capacity [375]. While most studies [18, 376, 377] report a 
depletion in individual plasma antioxidants at 24 hr  we observed significant depletion in 
antioxidant capacity as early as 6 hr and the trend continued over the next 18 to 24 hr 
after trauma. Mayer et al [130] also observed early depletion in antioxidant capacity in 
multiple trauma patients but they monitored these changes for only 21 hr after which they 
reported a return to normal levels. We observed a slight recovery in the antioxidant 
capacity over the next 7 days but the initial admission levels were not attained. Maderazo 
(1990) also observed this failure to regain baseline levels by the 8th day when reviewing 
changes in serum ascorbic acid and alpha-tocopherol in trauma patients [377]. Some 
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studies have also reported many days of antioxidant decline [376] or a complete lack of 
recovery at 8 days  after trauma [18]. The pattern of change in antioxidant levels was 
similar in all patients irrespective of trauma severity or premorbid medical condition, a 
feature observed by other studies [18, 376]. 
 
6.7.2. Plasma Oxidants 
 Plasma oxidants levels present a cyclical graph pattern with two peaks in our 
study - the first on admission and the second was observed between the 12 and 18 hr.  A 
similar initial peak was noted by Arand et al [378] however in their study the 2nd peak 
was at 24 hr. The study period also differs, while ours was 7 days theirs was only 24 hr. 
These results differ from those of Kretzschmar et al [18] in which the plasma oxidants in 
the study population only began to increase after 7 days, and Winterboun et al [209] in 
which there were fluctuations and a peak value at 12 days. The reason for the difference 
might be because these studies measured plasma oxidant levels daily while our study had 
more frequent evaluation during the first 24 hr of the trauma. It is well known that trauma 
results in ischemia, hypoxia, necrosis and shock, thus the initial peak observed could be 
due to the production of reactive oxygen species from the ischemic bed during 
resuscitation [1, 18, 376] and neutrophil infiltration which is  a known source strong 
oxidant production after trauma [334, 369, 379]. The cyclic pattern observed in plasma 
may be a result of the neutralization of oxidants by  antioxidants in order to maintain 
oxidative homeostasis. This view is also shared by Lalonde et. al., (1997) who stated that 
maintaining circulating antioxidants may prevent distant organ lipid peroxidation and 
may be of clinical use in devising treatment strategies for smoke inhalation injury with 
the availability of antioxidants [380].  
 
6.7.3. Plasma Protein Carbonyl: 
The presence of carbonyl groups has been widely accepted as a measure of 
oxidative damage under conditions of oxidative stress [329]. The amino acids of 
normally oxidized and degraded proteins are reutilized for protein synthesis however 
during oxidative stress the proteolytic capacity of the cells is not sufficient to cope with 
the number of oxidized protein molecules being generated. Under such circumstances, 
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oxidized proteins cross link with one another or form extensive hydrophobic bonds which 
are detrimental to normal cell function and lead to further problems [381].  We observed 
that trauma causes extensive generation of oxidized protein as seen by protein carbonyl 
production about 10 times the normal levels. These levels were highest on admission and 
there was another peak at 168 hr. The second peak of carbonyl content is likely due to 
complications associated with the severity of the trauma resulting in further oxidative 
stress.  These findings are similar to those of Winterbourn et al (2000) [209] but differs in 
that we had another peak at 168 hr while their patient population showed continuous 
decline 24 hr after trauma in a 12 day study. Theirs was however a small study of 8 
severe trauma (ISS 25 50; mean ISS = 35) patients most of whom were recruited 2 days 
after admission so the oxidative changes occurring in the first 48 hr could not be 
accounted for. Our study has been able to demonstrate changes from the time of trauma 
making it more beneficial in understanding the effect of oxidative stress. 
This research also aimed to understand the relationship between strong oxidant 
production and protein damage. The observed linear correlation and symmetry between 
carbonyl and oxidant levels with peaks occurring at similar intervals (p=0.031) in this 
research suggests increased oxidant levels results in protein damage therefore oxidized 
proteins could be used as an early marker of disturbances in oxidative homeostasis.   
 
 
6.8. Discussion: Urine and Oxidative Homeostasis  
  There has however been no previous study on urine markers of oxidative stress 
after trauma. This may be because most available methods of urine analysis for oxidative 
stress require 24 hr urine samples that may be of little benefit in the management critical 
trauma patients. In addition the methods used are usually technically involved and 
cumbersome so timely results may not be available for clinical management. Urine an 
ultra-filtrate of plasma represents a non-invasive, and potentially accurate method of 
measuring oxidative stress [382-384].  Plasma and urine analysis may yield divergent 
results thus emphasizing the importance of measuring a biomarker both in the circulation 
fluid (plasma) and in the elimination fluid (urine) in order to have a general idea of what 
is occurring in the organism [328]. This research decided to explore the use of urine 
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markers in evaluating oxidative stress because of its focus on identifying clinically 
applicable and beneficial diagnostic methods. The Oxistress assay was used to measure 
urine oxidants thereby evaluating the patients oxidative status. Urine carbonyl analysis 
was used to evaluate excreted protein degradation products resulting from strong oxidant 
damage. Similar markers had been evaluated in plasma and comparisons enabled us to 
obtain a total picture of oxidative stress in the same trauma patient.   
 
6.8.1. Urine Oxidants  
The various mechanisms by which trauma causes increased production of strong 
oxidants including shock, hypoxia, ischemia, necrosis and bacteria translocation may be 
responsible for the two-fold increase in urine oxidant levels in our study population as 
compared with normal values. These levels were highest on admission irrespective of 
trauma severity. The changes in urine oxidant levels in our study population were similar 
to the trend in plasma however the peak was observed at 24 hr compared to 18 hr in 
plasma. The difference in peak oxidant levels between the plasma and urine markers of 
oxidative stress may be due to urine representing the summation of the reaction between 
the antioxidants and the oxidants in plasma while the difference in the timing of the peaks 
may be a time-phased relationship [385]. Buss et al (2001) observed similar results in a 
spinal ischemia model reporting that trauma results in increased measurable free radical 
(strong oxidant) production within 60 minutes in plasma and 90 minutes in urine [386]. 
There was significant decline in strong oxidant levels in both urine and plasma 72 hr after 
trauma that seems to be associated with a rebound in the red cell GSH seen at the same 
time in our study. This may be the result of the bodys attempt at restoring oxidative 
homeostasis through increased antioxidant production.  
  
6.8.2. Urine Carbonyl 
There are several methods of measuring protein carbonyl in urine all of which use 
DNPH. Most urine carbonyl analysis has been done in animals using the HPLC, mass 
spectrometry and gas chromatography methods [387, 388] and very few human studies 
have been reported [389]. There appears to be much controversy on the benefits of urine 
carbonyl analysis, some studies suggest it is a useful tool [383, 389] while others disagree 
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[390]. Our study adopted the clinical method involving mixing equal quantities of filtered 
urine with DNPH to produce carbonyl precipitates. We modified this method by the 
addition of equal volume of 30%TCA in1mM EDTA because TCA reduces solubility of 
protein and enhances precipitation [391].  We tried lower concentrations of DNPH and 
failed to get a reaction even when TCA was added. This confirms that the recommended 
0.4% 2,4-DNPH is the ideal concentration for the reaction.  
We observed large precipitates in all patients using 0.4% 2,4-DNPH alone which 
was non-diagnostic. The addition of TCA however improved the diagnostic accuracy of 
this test enabling us to distinguish between small and large precipitates. Grading the 
precipitate was based on both the composition of the precipitate and the clarity of the 
solution. We defined small precipitates as particles still in suspension that can be easily 
displaced, while large precipitates are particles that have formed a hard substrate at the 
bottom of the tube that cannot be displaced by tilting the tube (Figure 6.19). Large urine 
Carbonyl precipitates were associated with plasma carbonyl levels greater than 
1.5nmol/mg protein and this correlated with the level of plasma protein carbonyl in each 
trauma group.  Trauma in patients with previous medical morbidity appears to be an 
independent predictor of the presence of urine precipitate. There is a positive correlation 
between trauma severity, plasma carbonyl and the appearance of large carbonyl 
precipitates in urine. Based on the evidence-based medicine guidelines provided by 
Archibald et al., (2001) [392] urine carbonyl test appears to be a simple preliminary test 
that can be used in patients prone to oxidative stress and a positive result is indicative of 
high plasma carbonyl in patients.   
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7. THE PROSPECTIVE ENTERAL ANTIOXIDANT (ALANYL-GLUTAMINE) 
CLINICAL STUDY  
7.1. Introduction 
 The prospective enteral antioxidant study was designed as a follow up to the 
natural history of oxidative stress reported in Chapter 6 which identified head injured, 
combined head and body, and body injured patients as most susceptible to oxidative 
stress in comparison to those with minor and single system trauma. As well antioxidant 
depletion has been reported in major elective surgery patients. Lou et al., (1996) 
demonstrated a 40% depletion in skeletal glutathione as well as 20% depletion in plasma 
glutathione after selective abdominal surgery compared with pre-operative levels [226]. 
Following minor elective surgery (mastectomies and lumpectomies) a depletion in total 
plasma antioxidant 6 hr post-op compared with pre-operative levels and a return to basal 
levels after 12 hr similar to our findings in minor trauma has been reported by Morris et. 
al., (2000) [225].  
 The choice of major elective surgery patients for the enteral antioxidant study was 
based on the expectation of similar antioxidant response as observed in trauma patients. 
The justification for this clinical trial is based on anecdotal evidence in clinical and 
animal studies [17, 135, 342, 343] suggesting that the introduction of antioxidant therapy 
reduces oxidative stress and its complications. This is an interventional study with the 
aim of evaluating the effect of glutamine (a precursor to glutamate and a conditional 
essential amino acid that enhances glutathione synthesis) on antioxidant homeostasis and 
patient outcome.  Glutamine was chosen as the enteral supplement because it is a direct 
precursor of glutamate and an indirect precursor of glutathione (Smith, 1990) (Lacey and 
Wilmore 1990). Glutamate has a two-fold way of increasing glutathione by alleviating 
the GSH inhibition of GCS and by regulating uptake of cystine [223]. Glutathione is a 
major antioxidant made up of glutamate, cystine and glycine, previously discussed in 
Chapters 2 and 6.   
A double blind prospective randomized controlled trial as well as an outcome 
study in elective surgery patients was conducted at the Royal University Hospital 
between the October 2002 and April 2003.  Ethics approval was obtained from both the 
University and the Saskatoon Health Region. The methodology is described in Chapter 
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4.6  4.7. The study patients were recruited from the preoperative assessment clinic and 
divided into two groups (treatment and non treatment). The graphs and most of the tables 
are generated using the SPSS program. 
 
7.2. Demographics 
 The study consisted of eligible patients with craniotomy, significant head and 
neck, abdomen, thoracic and back surgery.  A total of 283 patients were approached for 
participation, 200 declined, 14 withdrew and 69 completed the study (Table 7.1). The 69 
study patients had a Male: Female ratio of 1.1:1 (Table 7.2). The study group is quite 
similar to the normal surgery patient population with 80% of the patients over 40 yr in 
age and 43.5% over 60 yr (Table 7.3; Figure 7.1). Cancer patients constituted 55.7 % of 
the study population (Table 7.5), most patients >60 yr had cancer while most < 40 yr had 
no cancer, and the 40-60 yr age group was mixed (Fig 7.2). There were comparable 
cancer and non - cancer patients in the treatment and non- treatment group irrespective of 
the age group (Figure 7.3). All craniotomy patients in the treatment group were over 40 
yr while most of those in the non- treatment group were between 40-60 yr. The thoracic 
patients were between 40-60 yr.  Laparotomy patients in the non-treatment group and 
66% of those in the treatment group were over 40 yr. Laparotomy made up 76% of study 
population followed by craniotomies (14.5%) [Table 7.4]. The non-treatment group 
included 57% of the laparatomies while 70% of the craniotomies and 100% of the 
thoracic patients were in the treatment group (Figure 7.5).  
 
Table 7.1: Patient Selection Process For The Alanyl  Glutamine Study  
Eligible Patients 
(All patients approached) 
283 
Declined Participation 
(Did not want Nasogastric 
tubes) 
200 
Patients enrolled (agreed to 
participate) 
83 
Withdrawal from the study 
(Could not tolerate tube/ 
inability to insert tube) 
14 
Final Study Patients  69 
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Table 7.2: Sex Distribution  
 Frequency Percent Valid 
Percent  
Cumulative 
Percent 
Valid  
           
           
Female 
Male 
Total 
33 
36 
69 
47.8 
52.2 
100.0 
47.8 
52.2 
100.0 
47.8 
100.0 
SPSS derived table. 
 
 
Table 7.3: Age Distribution of Study Patients  
 
SPSS derived table. 
 
 
 Frequency Percent  Valid 
Percent 
Cumulative 
Percent 
Valid Ages 20-
40 
41-60 
>61 
Total 
 
 
14 
25 
30 
69 
 
 
20.3 
36.2 
43.5 
100.0 
 
 
20.3 
36.2 
43.5 
100.0 
 
20.3 
56.5 
100.0 
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Figure 7:1: Age Distribution of Study Patients (Bar Chart) 
 
Figure 7.1: y-axis = no. of patients; x-axis = age group with 80% of patients over 40 yr in age and 43.5% 
over 60 yr. 
 
Table 7.4: Surgery Type:  
Table 7.4: SPSS derived table. H&N = head and neck dissection; LAP = laparotomy.  
SURGTYPE
1 1.4 1.4 1.4
3 4.3 4.3 5.8
10 14.5 14.5 20.3
1 1.4 1.4 21.7
53 76.8 76.8 98.6
1 1.4 1.4 100.0
69 100.0 100.0
Back
chest
crainy
H&N
LAP
plastic
Total
Valid
Frequency Percent Valid Percent
Cumulative
Percent
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Table 7.5: Cancer Versus Non Cancer Patient Distribution: 
 Frequency Percent Cumulative Percent 
Cancer 39 56.5 56.5 
No cancer 30 43.4 100.0 
Total 69 100.0  
Table 7.5: SPSS derived table. Cancer patients were slightly higher than non-cancer patients. 
 
Figure 7.2: Age Distribution - Cancer Versus Non Cancer: 
 
Figure 7.2: Graph showing the distribution between cancer and non-cancer patients in each age group. Most 
between 20-40 yr were non-cancer; 40-60 yr were almost equally distributed; ≥ 61 were mostly cancer 
patients; and dx= disease type 
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Figure 7.3: Treatment Specific Demographics - Cancer versus Non Cancer: 
 
Figure 7.3: dxtype = disease type; glnrx 1.00 = controls; glnrx 2 = treatment group. Fairly equal distribution 
of patients in both groups. 
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Figure 7.4: Treatment Specific Demographics  Age Distribution: 
Figure 7.4: Age groups 20-40 yr; 40-60 yr; and   ≥ 61 had fairly equal distribution of patients in glnrx 
group 1.00 (controls) and glnrx 2.00 (treatment group) 
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Figure 7.5: Surgery Site - Treatment versus Non Treatment 
  
Figure 7.5: glnrx 1.00 = controls and glnrx 2.00 = treatment group. 57% Laparatomies were in non-
treatment group; 70% of craniotomies and 100% of thoracotomies were in treatment group. 
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7.3. Results: The Biochemical Outcome of Glutamine Treatment  
7.3.1. Changes in Plasma Glutamine 
Surgery appears to reduce plasma glutamine levels in all patients combined with a 
progressive decline until 72 hr (Figure 7.6). The pre-operative plasma glutamine levels in 
the treatment group were much lower than in the non-treatment group (p= 0.002), 
however a reduction was observed in the non-treatment group in contrast to an increase 
observed in the treatment group [Figure 7.7]. With respect to pre-operative glutamine 
levels the treatment group had an increase of 10 µM while the controls had a 26 µM drop, 
with trend continuing till 72 hr.  However glutamine treatment did not yield a significant 
increase at post-op (p= 0.602; Figure 7.7-7.8; Table 7.6) but the observed increase at 72 
hr i.e. 48 hr after completion of treatment had a greater tendency towards significance (p 
= 0.196) [Figures 7.7; 7.9; Table 7.6]. Patients between 41 and 60 yr had lower plasma 
glutamine levels post-surgery but age does not appear to be an independent predictor 
(Figure 7.10).  
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Figure 7.6:  Changes In Plasma Glutamine Levels In All Patients 
 
Figure 7.6: Surgery reduces plasma glutamine levels in all patients combined up till 72 hr post-op. 
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Figure 7.7: Plasma Glutamine Levels In Treatment Versus Non Treatment Groups 
 
Figure 7.7: Plasma glutamine levels appear to increase in the treatment group compared with controls 
where a downward trend is observed. Group 1 = controls and group 2 = treatment group. The treatment 
group had an increase of 10 µM while the controls had a 26 µM drop from pre-op levels.  
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Figure 7.8: Changes In Plasma Glutamine At 24 Hr Post- Surgery 
 
 
 
 
Figure 7.8:  The change in plasma glutamine with treatment at 24 hr was not significant (p= 0.602).  Group 
1 = controls and group 2 = treatment group. The symbols ∗ and ○ identify the outliers. 
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Figure 7.9: Effect of Treatment and Non Treatment at 72 hr Post-Surgery  
 
Figure 7.9: is a scatter of the effect treatment on plasma glutamine levels at 72 hr post-op while Figure 
7.10b shows plasma glutamine levels in controls at the same time. An increase is observed in the treatment 
group while a decline is observed in the controls. The change in plasma glutamine with treatment at 72 hr 
was not significant (p= 0.196) but it shows a tendency towards significance. Group 1 = controls and group 
2 = treatment group.  
 
Table 7.6: Changes In Plasma Glutamine At 24 Hr And 72 Hr Post-Surgery 
ANOVA
82691053 1 82691053.39 .275 .602
1.83E+10 61 300609816.2
1.84E+10 62
24427128 1 24427128.43 1.818 .196
2.15E+08 16 13434103.08
2.39E+08 17
Between Groups
Within Groups
Total
Between Groups
Within Groups
Total
G24
G72
Sum of
Squares df Mean Square F Sig.
 
Table 7.6: SPSS derived ANOVA table showing a summary of the degree change in plasma glutamine at 
24 hr (G24) and 72 hr (G72).  
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Figure 7.10: Age versus Changes in Plasma Glutamine Levels 
 
 
Figure 7.10: There was no significant difference in plasma glutamine levels in relation to age. The symbols 
∗ and ○ identify the outliers. 
 
 
7.3.2. The Effect of Glutamine Treatment on Plasma Antioxidants 
The pre-operative plasma antioxidant capacity in the controls was higher than that 
of the treatment group. However treatment resulted in an increase while surgery reduced 
plasma antioxidant capacity (Table 7.7). Post-operative glutamine treatment increased the 
total plasma antioxidant levels after 24 hr (p=0.005) [Table 7.8a]. The increase was also 
evident but not significant at 72 hr (p= 0.142) [Table 7.8b]. 
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Table 7.7: Plasma Antioxidant Capacity in Treatment and Non-Treatment Group 
At 0 hr And 24 hr (FRAP Method). 
 
Table 7.7: SPSS derived. GLNRX 1.00 = controls; GLNRX 2.00 = treatment group; FRAP0 = Plasma 
antioxidant capacity on admission; FRAP24 = Plasma antioxidant capacity at 24 hr. Glutamine treatment 
increased plasma antioxidant capacity in the treatment group the controls had reduced antioxidant capacity 
(p=0.005). 
 
Table 7.8a: Glutamine Rx Versus Plasma Antioxidant Levels At 24hr (FRAP 
Method).  
ANOVA
DFRAP
942349.9 1 942349.863 8.295 .005
6929968 61 113606.026
7872317 62
Between Groups
Within Groups
Total
Sum of
Squares df Mean Square F Sig.
 
Table 7.8a:  SPSS derived. Treatment resulted in significant difference in plasma antioxidant capacity 
(p=0.005). 
 
 
Report
692.9355 527.5806
31 31
392.21218 259.76794
548.6250 627.9063
32 32
289.04891 275.16029
619.6349 578.5397
63 63
348.56523 270.30382
Mean
N
Std. Deviation
Mean
N
Std. Deviation
Mean
N
Std. Deviation
GLNRX
1.00
2.00
Total
FRAP0 FRAP24
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Table 7.8b: Glutamine Rx Versus Plasma Antioxidant Levels At 72 hr  (FRAP  
Method) 
Table 7.8b: SPSS derived. The difference in plasma antioxidant between treatment and control groups was 
not significant (p=0.142) but had the tendency. 
 
7.3.3. The Effect of Glutamine Treatment on Red Cell Glutathione: 
The pre-operative mean red cell GSH level in all patients was 910.27 µM and the 
two groups were homogenous (p= 0.619) [Table 7.9]. Glutamine therapy resulted in 
increased glutathione levels in the red cell at 24 hr (Figure 7.11) but not sustained at 72 hr 
and no further increase observed (Figure 7.12). In the non-treatment group a decline was 
noticed at 24 hr followed by a rebound at 72 hr. Non-cancer patients had significant 
depletion in red cell glutathione levels at 24 and 72 hr compared to cancer patients who 
had an increase irrespective of treatment category (Figure 7.13; Table 7.10). 
 
Table 7.9: Preoperative Red Cell Glutathione Levels 
Treatment 
Category 
Numbers Mean T-test for 
equality of 
means (Sig. 2-
tailed) 
No treatment 30 954.52 
Glutamine Rx 30 866.02 
0.619 
All Patients 60 910.27  
Table 7.9: mean red cell GSH level was homogenous in both groups (p=0.619) 
ANOVA
158487.4 1 158487.384 2.212 .142
4371490 61 71663.775
4529978 62
Between Groups
Within Groups
Total
Sum of
Squares df Mean Square F Sig.
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Figure 7.11: Glutamine Treatment Vs Red Cell Glutathione At 24 Hr 
 
Figure 7.11: Treatment increased red cell GSH at 24 hr (p= 0.614). The symbols ∗ and ○ identify the 
outliers. 
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Figure 7.12: Glutamine Treatment Vs Red Cell Glutathione at 72 Hr 
Figure 7.12: Depletion in red cell GSH with treatment at 72 hr (p=0.27). The symbols ∗ and ○ identify the 
outliers. 
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Figure 7.13: Glutamine Treatment Vs Red Cell Glutathione (Cancer Versus Non 
Cancer At 24 Hr) 
Figure 7.13: Non-cancer patients had greater depletion in red cell glutathione levels at 24 (P=0.134) and 72 
hr (P=0.055 compared to cancer patients who had an increase irrespective of treatment category. The 
symbols ∗ and ○ identify the outliers. 
 
Table 7.10: Glutamine Treatment Vs Red Cell Glutathione (Cancer versus Non 
Cancer at 24 And 72 Hr) 
Time Statistics Cancer Non Cancer 
Mean Change 72.5467 -90.0000 @ 24 hr 
SEM 181.19834 162.9104 
Mean Change 62.7200 -293.0833 @ 72 hr 
SEM 189.12185 155.21268 
 
Table 7.10: Non-cancer patients had greater depletion in red cell glutathione levels at 24 (P=0.134) and 72 
hr (P=0.055) compared to cancer patients who had an increase irrespective of treatment category 
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7.3.4. The Effect of Glutamine on Strong Oxidants: 
The strong oxidants levels in plasma reflected a similar trend in both treatment 
and control groups. The levels were highest pre-op, there was depletion at 24 hr (Figure 
7.14) and a slight increase but not up to pre-op levels at 72 hr (Table 7.11). Patients in the 
age-group 40-60 yr had the highest level of plasma oxidants pre-op and the greatest 
depletion post-op. Non-cancer patients had greater reduction in post-op oxidant levels 
than cancer patients.  
  Free radical production was less in the treatment group than the non-treatment 
groups (p= 0.036 @ 24 hours) but the absolute difference between these groups was not 
significant (p= 0.143) (Figure 7.15). While the treatment group had a tendency towards 
reduced strong oxidant levels, the controls tended towards increased levels (Figure 7.16). 
 
Table 7.11: Plasma Oxidant Levels at 0 hr, 24 hr and 72 hr 
 
Table 7.11: SPSS derived. GLNRX 1.00 = controls; GLNRX 2.00 = treatment group. Highest levels were 
on admission; At 24 hr there was depletion in both groups; At 72 hr slight increase in both groups but not 
up to pre-op levels.  
Report
1205.74 644.79 710.35
34 34 34
961.947 638.035 568.562
987.56 647.82 696.61
34 34 33
1009.049 539.038 602.904
1096.65 646.31 703.58
68 68 67
984.548 586.192 581.308
Mean
N
Std. Deviation
Mean
N
Std. Deviation
Mean
N
Std. Deviation
GLNRX
1.00
2.00
Total
PLASMA0 PLASMA24 PLASMA72
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Figure 7.14: Effect Of Glutamine On Changes In Plasma Strong Oxidants At 24 Hr. 
 
 
Figure 7.14: Depletion at 24 hr in plasma oxidant levels was similar in both treatment and control groups. 
Patient group 1.00 = control group; group 2.00 = treatment group. The symbols ∗ and ○ identify the 
outliers. 
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Figure 7.15: Effect Of Glutamine On Changes In Urine Strong Oxidants At 24 Hr. 
 
 
Figure 7.15: No significant difference in the changes in strong oxidants in urine between the treatment 
(glnrx 1.00) and the controls (glnrx 2.00).  dstress3 = change in strong oxidants pre-op and post-op. The 
symbols ∗ and ○ identify the outliers. 
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Figure 7.16: Scatter-gram Of Glutamine Treatment Vs Urine Strong Oxidants at 24 
Hr. 
 
Figure 7.16: While the treatment had a tendency towards reduced strong oxidant levels, the controls tended 
towards increased levels. 
 
7.4. Result: Clinical Outcomes of Glutamine Therapy 
The evaluation of clinical outcome in this study is based on the RIW scoring 
system previously described in Chapters 2 and 4. The major components of this scoring 
system include patients complexity and length of hospital stay. Complexity is based on 
the following criteria: no complexity; complexity related to chronic conditions; 
complexity related to serious/ important conditions; life threatening. The effect of 
glutamine treatment on the length of hospital stay was evaluated based on the type of 
surgery and the affected organ. 
The pre-operative glutamine levels were dependent on disease complexity 
whereby patients with greater complexity had higher plasma glutamine levels (p= 0.001) 
(Table 7.12). Disease complexity also appeared to be evenly distributed between the 
Change in urine  oxidant levels at 24 hr
10000-1000
Pr
e-
op
 u
rin
e 
ox
id
an
ts
 (µ
M
 H
2O
2
eq
ui
va
le
nt
)
5000
4000
3000
2000
1000
0
-1000
Patient group
2.00
1.00Pr
e-
op
 u
rin
e 
ox
id
an
ts
 (µ
M
 H
2O
2
eq
ui
va
le
nt
)
130 
treatment group and controls (p= 1.000) therefore the results rule out any selection bias 
(Table 7.12; Figure 7.17). Disease complexity was also a determinant of plasma 
glutamine levels in patients post-operatively at 24 hr and 72hr however treatment 
improved glutamine levels in the presence of disease complexity at 24 hr (p = 0.044) and 
at 72 hr (p= 0.002) (Table 7.12). 
 Disease complexity also provides useful estimate of length of hospital stay  (p= 
0.000) (Table 7.13) wherein patients with greater complexity stayed longer in the hospital 
than those with less complexity. Glutamine treatment however reduced hospital stay in 
patients with greater complexity when compared with similar patients in the non-
treatment group (Figure 7.17- 7.18). 
Glutamine treatment reduced length of hospital stay in all patients by about 1 day (Table 
7.14). In cancer patients there is half-day reduction in hospital stay while in non-cancer 
patients there is 7-day reduction following glutamine treatment (Table 7.15). The 
treatment also significantly reduced hospital stay after craniotomy, however length of 
stay was not changed in Chest surgery patients (all in group 2) nor did laparotomy 
patients appear to achieve any benefit (Figures 7.19).  
Glutamine treatment reduced the RIW score in the study patients (p=0.125) but 
this reduction was significant in patients with greater complexity (p= 0.0005) (Figure 
7.20; Table 7.16).  
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Table 7.12: Complexity of Condition versus Plasma Glutamine Levels 
 
 
Table 7.12: SPSS derived paired sample test. GLN-COPLX = relationship between glutamine levels and 
disease complexity; RX  COPLX between treatment status and disease complexity; G24  COPLX = 
Glutamine level at 24 hr versus disease complexity; G72  COPLX = Glutamine level at 72 hr versus 
disease complexity. Pre-op glutamine levels were dependent on disease complexity (p= 0.001). There was 
no difference in disease complexity between the treatment group and controls (p= 1.000). Treatment 
improved glutamine levels in the presence of disease complexity at 24 hr (p = 0.044) and at 72 hr (p= 
0.002). 
 
 
Table 7.13: Complexity versus Length Of Hospital Stay 
 
 
Table 7.13: Patients with greater complexity stayed longer in the hospital than those with less complexity 
(p= 0.000). 
 
 
 
Paired Samples Test
98.70 320.055 27.963 43.38 154.02 3.530 130 .001
.00 1.384 .100 -.20 .20 .000 191 1.000
4855.4483 17952.68066 2357.302 135.0315 9575.8650 2.060 57 .044
4056.0769 3761.08330 1043.137 1783.2770 6328.8768 3.888 12 .002
GLN - COPLXPair 1
RX - COPLXPair 2
G24 - COPLXPair 3
G72 - COPLXPair 4
Mean Std. Deviation
Std. Error
Mean Lower Upper
95% Confidence
Interval of the
Difference
Paired Differences
t df Sig. (2-tailed)
ANOVA
LOS
5024.537 4 1256.134 10.130 .000
7191.780 58 123.996
12216.317 62
Between Groups
Within Groups
Total
Sum of
Squares df Mean Square F Sig.
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Figure 7.17: Complexity of Condition in Treatment vs. Non-Treatment Groups 
 
Figure 7.17: No significant difference in disease complexity between treatment group (patient group 2) and 
controls (patient group 1) (p= 1.000) 
 
Figure 7.18: Complexity of Condition vs. Length of Hospital Stay 
Figure 7.18: Hospital stay was reduced in treated patients with greater complexity when compared with 
similar controls. The symbols ∗ and ○ identify the outliers. N= Number of patients in each complexity 
group and complexity levels range from 1 to 9. 
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Table 7.14: Effect Of Treatment on Length of Hospital Stay in All Patients 
 
Table 7.14: SPSS derived. Treatment reduced length of hospital stay in all patients combined. 
 
Table 7.15: Summary Table- Effect of Glutamine Treatment in Cancer versus Non-
Cancer Patients 
  
 
Table 7.15: SPSS derived. DXTYPE = disease type; DFRAP = change in plasma antioxidant levels; 
DSTRESS2 = difference in urine strong oxidants at 72 hr; DLOS = difference between the estimated and 
actual length of stay. Treatment increases the plasma antioxidants in non-cancer patients. There was 7-day 
difference between LOS in treated non-cancer patients and controls. Treated cancer patients had 0.2 days 
reduction in hospital stay when compared with controls. 
 
 
LOS  * GLNRX
LOS
14.32 34 14.480
13.65 34 12.766
13.99 68 13.552
GLNRX
1.00
2.00
Total
Mean N Std. Deviation
DFRAP DSTRESS2 DLOS  * DXTYPE
-126.4722 -433.3590 .2711
36 39 38
352.03315 983.50328 6.82285
72.7407 -328.2667 7.4667
27 30 30
335.27057 607.14924 14.45469
-41.0952 -387.6667 3.4456
63 69 68
356.33252 836.96002 11.36217
Mean
N
Std. Deviation
Mean
N
Std. Deviation
Mean
N
Std. Deviation
DXTYPE
cancer
nocancer
Total
DFRAP DSTRESS2 DLOS
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Figure 7.19: Length of Hospital Stay Versus Type of Surgery 
 
Figure 7.19: Craniotomy patients in treatment group had significant reduction in length of stay when 
compared with controls. Chest surgery patients (all in group 2) maintained the expected length of stay 
while treatment did not appear to benefit laparotomy patients. 
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 Figure 7.20: Glutamine Treatment versus RIW Score 
 
Figure 7.20: Glutamine treatment (glnrx 2.00) reduced RIW scores implying cost reduction and improved 
clinical outcome in elective surgery patients in comparison with controls.  
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Table 7.16: Glutamine Treatment or Complexity Versus RIW Score 
 
 
Table 7.16: SPSS derived table. Both complexity and glutamine treatment are determinants of RIW scores 
but complexity is an independent determinant of the score (0.000).  
 
Table 7.17: Glutamine Treatment and Complexity Versus RIW Score 
 
Table 7.17: SPSS derived table. Glutamine treatment reduces RIW scores in patients with greater disease 
complexity (p=0.000).  
 
                                                                                                                                                                                                                
 
 
 
 
Coefficientsa
1.810 1.038 1.745 .086
1.951 .229 .731 8.507 .000
-.945 .608 -.134 -1.555 .125
(Constant)
complex
glnrx
Model
1
B Std. Error
Unstandardized
Coefficients
Beta
Standardized
Coefficients
t Sig.
Dependent Variable: riwa. 
ANOVAb
438.416 2 219.208 37.269 .000a
358.786 61 5.882
797.202 63
Regression
Residual
Total
Model
1
Sum of
Squares df Mean Square F Sig.
Predictors: (Constant), glnrx, complexa. 
Dependent Variable: riwb. 
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7.5. Discussion: 
Evidence based medicine is the method of assessing optimal treatment based on 
the best current knowledge. This allows the transfer of the results of different clinical 
studies into numbers that can be used in practice. Evidence-based therapy is essential for 
the preservation and especially for further development and evolution of high-quality 
surgery with, at the same time, quality assurance in the new millennium [393-395].  
Randomized controlled trials are the best methods to compare the effectiveness of 
different therapeutic interventions which may directly impact patient care [396-398]. Our 
study which will be classified as level 1b represents the top of the hierarchy for finding 
evidence for medical routine which may be used as a reference standard for other clinical 
studies [398, 399]. Most double blind randomized studies are narrow and focused on 
single issues such as trauma, critical care [400], cancer or abdominal surgery [401] which 
makes generalization difficult. Although our study had rigid entry criteria, it focused on 
all major elective surgeries making it a useful tool for developing clinical practice 
guidelines. It also has an outcome component in which the surgical decisions and 
discharge criteria were surgeon dependent for individual patients [344, 402].  
 
7.5.1. Demographics or Patient Selection or Study Population: 
Our study population had 283 intention to treat and 69 candidates who completed 
the protocol making this larger than most similar double blind enteral studies with 40 or 
less patients enrolled [403] [404] [401] [405] [406]. There was no need for power 
analysis since this is the first study looking at the use of oral alanyl-glutamine as a 
precursor of glutamate and its effects on plasma and red cell antioxidant in surgical 
patients [407].  
   
7.5.2. Treatment Selection (Oral Alanyl-Glutamine): 
Oral alanyl-glutamine has been shown to be safe in patients with dengue fever 
and has been used a component of elemental diet [408]. Ala-Gln-supplemented PN is 
clinically safe well tolerated with no side effects as documented by previous researchers 
[409-411]. Kircher et al [411] also showed that alanyl-glutamine had  similar effects as 
glutamine on the immune system. Oral glutamine supplement with TPN was shown to be 
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effective in preventing macrophage mesenteric blood mononuclear cells (M-MNC) 
activation thus avoiding excessive production of cytokines [412] and alanyl-glutamine 
has the advantage of better stability [413]. Our study used the lowest effective dose of 0.3 
g/kg although glutamine doses of up to 0.75 g/kg have been shown to be safe [405, 414].  
The lowest dose was used since this is the first study administering enteral alanyl-
glutamine in the immediate postoperative period (within 8 hr). The dose was well 
tolerated, and it appears the observed changes were somewhat limited due to the low 
dosage. We therefore recommend higher doses within the reference range to obtain 
optimal effect in patient outcome. 
 
7.5.3. Biochemical Outcomes: 
Laboratory outcome test could be used to assess the efficacy of the mode of 
measurement or treatment. The challenge of biochemical evaluation of glutamine rests on 
its multiple direct and indirect functions, not just as a conditional essential amino acid, 
but as a precursor for nucleotide synthesis in fibroblast, lymphocytes and macrophages as 
well as the role it plays in glutathione synthesis [415, 416].  After surgery the availability 
of glutamine becomes critical for the activation of immune cell (neutrophils, monocytes 
and lymphocytes) [235]. Many studies used interleukin 6 and 10 (IL-6 and IL-10) while 
others used TNF α because it is a major product of macrophage activity which is 
dependent on glutamine for energy production [417, 418]. Some studies have shown that 
glutamine therapy helps post-operative patients maintain nitrogen balance in the 
treatment group. The use of the DEXA scan during the study which would have allowed 
us to assess the impact of glutamine on lean body mass was not feasible. The attempt to 
use plasma 3-methyl-histidine to assess the degree of muscle break thereby quantify the 
nitrogen balance [403] was also not possible due to equipment failure.  
This study focused on the role of glutamine as a precusor of glutamate which 
enhances the uptake of cystine and alleviates the glutathioneinduced inhibition of L-γ-
glutamyl-L-cysteine synthase (GCS) thereby enhancing glutathione production [223, 
419]. We therefore evaluated changes in plasma glutamine levels after oral alanyl-
glutamine intake and the impact of this treatment on oxidative parameters. The Oxistress 
assay as a measure of total oxidative stress was also used in evaluation. There was a 
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blinding during the evaluation of the biochemical changes resulting from two post-
operative doses of alanyl-glutamine given at 8 and 24 hour respectively.   
The non-treatment group had a significantly higher mean pre-op plasma 
glutamine levels than the treatment group even though the basis of randomization was the 
extent of surgery (major surgery). Surgery resulted in decreased plasma glutamine levels 
in all patients similar to the study by Exner [405] where glycine-glutamine infusions were 
given to prevent immunosuppression post-surgery. This may be explained by the 
increased demand for glutamine as most studies have shown that during stress or 
catabolic states, glutamine is absorbed in the gut, and liver absorption is increased ten-
fold. This glutamine is also used by the immune system and for the production of gut 
antioxidant. 
Therapy resulted in increased plasma glutamine at 24 hr and this continued until 
72 hr post-op in comparison with pre-op levels while a decrease was observed in the 
controls.  Although these were not statistically significant findings they appear to be 
relevant because the oral supplement at the lowest effective dose has resulted in these 
changes. It is also noteworthy that this is the first report of the sole use of oral alanyl-
glutamine in post-operative patients. Valencia et al [420] reported similar increases in 
glutamate and glutamine levels in plasma of healthy subjects after oral glutamine. In 
addition some animal studies also showed increased blood glutamine after oral glutamine 
therapy [421]. Human studies using parenteral glutamine have made similar observations 
[403] [406]  [401]  [409] while others reported no difference [248]. Overall it appears that 
measuring changes in plasma glutamine is an important mode of evaluating glutamine 
therapy.  
The increase in glutamine levels observed after treatment was translated to 
changes in plasma antioxidants measured using the FRAP assay. A significant difference 
(p=0.01) between total antioxidants in the treated group at 24 hr compared to the control 
was observed with the trend present at 72 hr however not significant (p=0.09). The 
transient increase (non-significant) in red cell GSH in the first 24 hr disappeared at 72 hr. 
This was likely due to the increased use of glutamine by the liver and gut to produce 
antioxidants thus maintaining normal total plasma antioxidants. Kaufmann [421] had 
made similar observation in animal studies reporting an increase in gut GSH after oral 
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glutamine supplementation. On the contrary Valencia et al [420] observed significantly 
lower concentrations of red cell GSH (37%; P = 0.00091) with oral glutamine use in 
healthy volunteers thus concluding GSH biosynthesis and preservation of GSH stores in 
red blood cells may involve rate-limiting substrates other than glutamine. This may be 
explained by the fact that glutamine increases plasma antioxidant levels resulting in a 
negative feedback on red-cell GSH production. 
In both patients groups strong oxidants in plasma were highest pre-operatively 
because both groups had similar disease complexity. The two groups also had depletion 
at 24 hr followed by a slight increase but not up to pre-op levels at 72 hr. The reduction in 
oxidant levels is likely due to patient optimization during surgery and in the immediate 
post-operative period. Age did not appear to be an independent predictor of plasma 
oxidant levels in this study even though there is literature evidence that aging predisposes 
to increased strong oxidant production [381, 422]. Post-op oxidant levels were higher in 
cancer than in non-cancer patients likely because non-cancer patients are chronically ill 
patients that have been shown to produce higher levels of strong oxidants [423, 424]. 
Therefore non-cancer patients are more likely to derive greater benefit from both the 
surgical care and external antioxidant source. Strong oxidant production in urine was 
however less in the treatment than the non-treatment group (p= 0.036 at 24 hr post-op) 
similar to findings in plasma following parenteral dipeptide administration. The absolute 
difference between these groups was however not significant (p= 0.143). While the 
treatment group had a tendency towards reduced strong oxidant levels, the controls 
tended towards increased levels. However some of the controls also had reduced oxidant 
levels at 24 hr probably due to the high baseline glutamine and plasma antioxidant levels 
in these patients. The lack of absolute difference between the treatment and the control 
might be because elective surgery is a controlled trauma that may be physiologically 
equivalent to mild or moderate trauma. The low dose of glutamine used in the study and 
the fact that many patients have access to over the counter antioxidant medication may 
also explain these findings. Treatment did not affect urine oxidant production at 72 hr 
post-op likely because the last dose of alanyl-glutamine was given at 24 hr post-op and it 
has a short half-life. Overall this study suggests that oral glutamine supplementation 
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prevents oxidant production and may be a valuable agent for prevention of oxidative 
stress in surgery patients. 
 
7.5.4. Clinical Outcomes 
 Measuring outcome is not only relevant for research purposes but also in daily 
surgical practice [344, 425]. The study patients were classified based on their complexity, 
type of surgery and their disease. The determinants of clinical outcome in the study were 
the length of hospital stay (used in many surgical studies [272, 426]) and the RIW score. 
Forty-two percent of the study population were in the 60 yr and above age group making 
this comparable with a previous study by Desrosiers et al [426] and many others. The 
reduced length of hospital stay in our treatment group was similar to that in other studies 
with parenteral glutamine supplementation, however our controls had a shorter length of 
stay than these studies reported. Oral alanyl-glutamine supplementation is therefore as 
effective as the parenteral in improving clinical outcome. 
 The complexity of patients condition appears to be an independent predictor of 
both the length of stay and plasma glutamine at 24 and 72 hr. Alanyl-glutamine 
supplementation seemed to reduce length of stay by 7 days in non-cancer patients but by 
only a half day in cancer patients. This could be due to the replenishment of the pre-op 
depletion of glutamine observed in non-cancer patients as compared with the cancer 
patients. Thus supplementation becomes necessary to improve the bodys immune and 
reconstructive ability. There was one mortality (3%) in the treatment group due to 
complications from surgery remote from antioxidant intervention, this is less than other 
studies in major surgery patients [426]. It is quite presumptuous to attribute this to the 
intervention, thus further studies and meta-analysis are needed to answer this question. In 
the earlier study on the natural history of oxidative stress, head injured patients were most 
prone hence the significant reduction in hospital stay in treated craniotomy patients is 
evident of the benefit of oral glutamine supplementation in this group.   
 We had considered using the E-PASS as a supplementary mode of assessment 
however it was technically not feasible to compute all the appropriate parameters. 
Many studies have tried to evaluate the economic benefit of glutamine. Using the 
RIW score which is based on resource utilization, the study showed significant benefit 
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patients with greater complexity, similar to the findings of Mertes [401] who reported 
that parenteral glutamine supplementation reduced the cost of care in major abdominal 
surgery patients. The RIW score also reduced with alanyl-glutamine treatment (p=0.125) 
but this did not appear to be an independent predictor. A similar study by Pytlik, et al on 
transplant patients however did not show any economic benefit with parenteral alanyl-
glutamine [427].  This is probably because the major cost of transplantation is the surgery 
and organ retrieval and changes in supportive care may not affect the cost.   
This study has demonstrated improved clinical outcome with post-operative oral 
alanyl-gluatmine supplementation at a relatively low dose therefore greater benefits are 
likely to be derived from the higher dose of 0.75 g/kg body weight. 
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8. CONCLUSION 
The study of the natural history and modulation of oxidative stress in surgery and 
trauma patients was undertaken based on an identified knowledge gap in the subject both 
in the literature and clinical practice. The three research components include studying the 
natural history of oxidative stress using trauma as a model, developing the novel 
Oxistress assay, and modulating oxidative stress in surgery patients. The research was 
based on the hypothesis that an understanding of the natural history of oxidative stress 
will guide appropriate modulation that will invariably improve patient outcome.  
The concept of oxidative homeostasis involves the intrinsic maintenance of a 
balance between strong oxidant (ROI) and antioxidant production by the body [19]. 
Antioxidants are responsible for preventing the harmful effects of strong oxidants. The 
major oxidants in the body include superoxide anions, hydroxyl ions, lipid radicals and 
hydrogen peroxide [30, 38, 101], while the intrinsic antioxidants include vitamins C & E 
and GSH [39, 40, 42, 43]. Oxidative stress results from an imbalance in which strong 
oxidants are produced at a higher rate than antioxidants [1, 19]. Predisposing conditions 
to oxidative stress include acute and chronic illnesses such as trauma, major surgery, 
infection, diabetes mellitus, inflammatory bowel disease (IBD), renal diseases, cardiac 
diseases and neurological diseases [47-49].  
Previous research on the natural history of oxidative stress had been on animal 
models while most human studies have been on selective aspects and groups of patients 
thus limiting clinical application of oxidative stress. Various laboratory methods were 
evaluated (Chapter 2) and the most relevant ones were applied in studying the natural 
history in patient populations. The selected methods needed to be easy, simple, sensitive, 
and accurate and have potential benefit to the clinical setting. Most methods do not 
individually measure overall oxidative status hence a combination of methods has been 
adopted in previous research to obtain an estimate. A notable aspect of this research is the 
invention of the novel Oxistress assay, a non-invasive single test for overall evaluation of 
oxidative status. The FRAP method [126] was used to estimate total antioxidant capacity 
in plasma, the Asensi modification of Brigelius method [150] was chosen for red cell 
glutathione measurement, protein carbonyl levels (measure of protein oxidant damage) 
were evaluated with the colorimetric method [167], and plasma and urine oxidant levels 
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were measured with the novel Oxistress assay. The role of neutrophils in oxidative stress 
was also evaluated. Neutrophil activity was evaluated with the myeloperoxidase assay 
[428] which though not fast provides accurate and reliable results, while the neutrophil 
count was done by the hospital laboratory. 
The invention of the novel Oxistress assay aimed at an easier and rapid clinically 
applicable method of measuring strong oxidants (H2O2 equivalent) in biological fluids 
such as plasma and urine, occurred at the preliminary phase of the research while 
evaluating existing laboratory methods. The assay can be used with or without the EDTA 
component, the latter being a very good laboratory tool for measuring high levels of 
hydrogen peroxide making it useful in both human and non-human samples. It measures 
antioxidant status, which is a summation of the reaction between antioxidants and strong 
oxidants produced in urine. It also allows an evaluation of circulating strong oxidants 
thereby providing a total picture of the oxidative status of the patient. It is therefore an 
assay that can be singularly used to diagnose oxidative stress in a clinical setting. In 
addition it is fast (5 min), inexpensive and produces a visible color change at 370C. The 
assay has proven to be a reliable clinical diagnostic tool with high sensitivity and 
specificity for oxidative stress based on trials in adults and neonates. Reference values 
were determined in both neonates and adult populations and comparisons with patient 
populations in both groups yielded highly significant differences (p=0.0001). The 
estimated reference value range for the normal population range is 136 µM 260 µM, 
while that of the neonatal population is (140-208 µM). 
The study of the natural history of oxidative stress was conducted on trauma 
patients at the Royal University Hospital, Saskatoon between April and September 2000. 
There were four patient sub-groups - three based on the injury severity score (ISS) and 
the last had pre-morbid medical factors. The change in antioxidant homeostasis in our 
study population was monitored in red cell, plasma and urine over 7 days.  
The results showed trauma depletes red cell GSH level and this effect is maximal 
between 24 and 30 hr.  The most important determinants of the depletion in red cell GSH 
were trauma severity, presence of pre-existing medical problems and the body system 
affected by the trauma. Similar depletion in plasma GSH have been reported following 
severe multiple trauma thus validating our findings [18, 429].  
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A direct relationship between the systemic increase in neutrophil count maximal 
within 6 hr of trauma, trauma severity and depletion of red cell GSH maximal within 24 
hr in the same group of patients was observed. Trauma severity was directly associated 
with increases in both neutrophil count and plasma myeloperoxidase levels (neutrophil 
activity), the latter likely a consequence of the former. Patients with pre-morbid medical 
condition had greater neutrophil activity even with mild trauma. The changes in 
neutrophils are likely responsible for the observed increase in strong oxidant production 
and antioxidant depletion. These results are therefore in keeping with those of other 
authors which suggest neutrophils play a key role in tissue injury and the etiology of 
oxidative stress [330, 331, 370].   
There was significant depletion in plasma antioxidants (p = 0.017) within the first 
30 hr and slight recovery from 72 hr but never reaching admission levels by day 7 in all 
patients. These results are in keeping with those of other authors that trauma results in 
depletion of plasma antioxidants [130, 376]. Trauma severity and pre-morbid medical 
conditions had similar trend as observed in all patients combined.  Plasma oxidant levels 
had two peaks, 1st on admission, second higher peak between 12-18 hr and a significant 
decline at 72 hr. A ten-fold increase in plasma protein carbonyl levels over the study 
period  (mean = 1.49 nmol/mg protein; normal is <0.1 nmol/mg protein) was observed 
following trauma. The peaks were noticed on admission and day 7 with declines within 
6-12 hr and 24 hr therefore plasma protein carbonyl appears to be an early index of 
oxidative damage in trauma. A positive correlation was also observed between raised 
plasma protein carbonyl levels and trauma severity.  There was a similarity in the pattern 
of changes in the plasma oxidant and plasma protein carbonyl levels. A linear 
relationship between oxidant and carbonyl levels in the plasma was observed thus 
implying that the degree of oxidative damage to proteins is dependent on the level of 
strong oxidants in circulation. The overall effect of trauma on plasma oxidative 
homeostasis therefore includes increased free radical production leading to protein 
degradation, antioxidant depletion and subsequent oxidative stress.  
Urine analysis proved to be an informative tool in evaluating oxidative stress and 
promises to be beneficial in clinical diagnosis. Similar to plasma, urine oxidant levels 
(measured with the oxistress assay) correlated with trauma severity, however the peak for 
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urine was 24 hr compared with 18 hr for plasma. The difference in time is due to the time 
required for excretion. Urine oxidant level is the summation of the reaction between 
plasma antioxidants and antioxidants thus making it an index of antioxidant homeostasis. 
The presence of protein carbonyl precipitates in urine was directly related to plasma 
levels and trauma severity as well as the presence of pre-existing medical factors. It is 
therefore a useful screening method for protein degradation after trauma.  
Oxidative stress is associated with increased trauma severity resulting in 
antioxidant depletion, strong oxidant production and protein degradation. The presence of 
pre-morbid medical factors also increases oxidative stress in trauma patients. Therefore 
early introduction of prophylactic antioxidant therapy may be beneficial following trauma 
and is highly recommended.  
Modulation involves the various ways of modifying the bodys response to 
oxidative stress through the use of direct or indirect antioxidant sources. The direct 
sources include vitamins C & E, N-acetyl cysteine, L-2-oxothiazolelidine-y-carboxylase 
(OTC), glycine and glutamine, while indirect sources include phase 2 enzyme inducers 
such in foods such as broccoli, soya milk etc. While there is evidence that parenteral 
glutamine improves clinical and biochemical outcome in patients following major 
surgery [251, 255, 405, 430], no study has reported any clinical benefit with enteral 
glutamine supplementation. Most studies using enteral glutamine have only reported 
improvement in biochemical and immunological parameters [412]. The enteral route of 
nutrition has been shown to be superior to the parenteral route with significantly fewer 
complications. The most significant side effect of enteral nutrition is diarrhea and 
vomiting. The use of elemental diet allows absorption when the gut is in a transition 
phase [270, 284, 285, 431]. There is ample evidence that early enteral feed is cost 
effective and reduces hospital stay [258, 275]. The recommended post operative dose of 
parenteral glutamine is 0.1  0.3 g/kg body weight, however this dose is quite low and 
patients tolerance has been documented at doses as high as 0.75 g/kg body weight 
without any side effects. Outcome evaluation involves laboratory and clinical 
components, with the latter being both patient and provider focused. The clinical trial of 
enteral alanyl-glutamine (an indirect precursor of glutathione via glutamate) 
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supplementation in modulating oxidative stress after major elective surgery was to 
evaluate these two components of patient outcome.  
The prospective double blind trial conducted on surgery patients between 
November 2002 and April 2003 was designed to treat oxidative stress in previously 
identified susceptible patient groups. Glutamine was chosen with the aim of increasing 
GSH levels thereby correcting oxidative stress, and it was clinically acceptable because 
previous use. Oral alanyl-glutamine was found to be a safe supplement in the immediate 
post-operative period. The study revealed depletion in plasma glutamine levels following 
surgery in all patients. Oral alanyl-glutamine was effective even at very low doses (0.3 
g/kg body weight) in increasing plasma glutamine (p= 0.002) and antioxidant levels as 
well as in reducing strong oxidant production (p= 0.005). The difference in plasma 
glutamine levels between the treatment and control groups was however limited probably 
due to the following possible reasons. There is increasing awareness and over the counter 
use of antioxidant supplements hence the higher preoperative plasma glutamine levels 
observed in the control group. Elective surgery is classified as mild to moderate trauma, 
radical production and the need to increase erythrocyte glutathione is therefore limited. 
The other reason for the transient increase observed could be due to the low dose used in 
this study. We therefore recommend increasing the dose up to 0.75g/kg in clinical 
practice in order to maximize the benefit derived from the supplement. Glutamine 
supplement reduced hospital stay in noncancer and higher complexity groups but not in 
the cancer group. This may be because surgery is first line of cancer therapy while it is a 
consequence of inadequate medical treatment in non-cancer patients who usually have 
pre-existing medical factors and previous glutamine depletion. Despite its limitation as a 
measure of economic benefit as shown by Girroti et al [301], the RIW score improved 
with glutamine supplementation. The intervention resulted in significant economic 
benefit in patients with greater disease complexity that will invariably benefit the health 
care system significantly. Higher doses of oral alanyl-glutamine supplementation are 
therefore recommended in major surgery patients both in the pre and post-operative 
periods to enhance improved patient outcome.  
The research on oxidative stress in trauma and surgery patients has provided 
better understanding of the mechanism of oxidative stress, a bedside method of 
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measurement and the evaluation of the effect of treatment on patient outcome. The 
limiting factors for the trial included the number of available patients (n=69) within the 
time frame for the PhD thesis as well as the fact that only one centre was used. It is 
however important to note that this is the first study of its kind using enteral alanyl-
glutamine with a population higher than that in most similar clinical trials making it an 
ideal reference study. 
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Appendix to Chapter 5:  Further Evaluation of the Oxistress Assay 
 
Procedure:  
The process involved the use of different concentrations of the components of the 
assay including two different types of EDTA (acid and sodium) as follows: 
1) Deoxyglucose reagent (100 mM), Thiobarturic acid (TBA) (50 mM), EDTA (1.4 
mM) & Ferrous sulfate (1 mM). 
2) Deoxyglucose reagent (100 mM), Thiobarturic acid (TBA) (50 mM), EDTA with 
sodium (1.4 mM) & Ferrous sulfate (1 mM). 
3) Deoxyglucose reagent (100 mM), Thiobarturic acid (TBA) (50 mM) & Ferrous 
sulfate (1 mM). 
4) Deoxyglucose reagent (50 mM), Thiobarturic acid (TBA) (50 mM) Glucose (100 
mM) & Ferrous sulfate (1 mM). 
5) Glucose reagent (100 mM), Thiobarturic acid (TBA) (50 mM) & Ferrous sulfate 
(1 mM) 
6) Hydrogen peroxide standard was used in all cases in the following concentrations 
50, 100, 250, 500, 1000, 2500, 5000, 10,000 & 20,000 µM 
 The reagents were incubated at either 370C or room temperature overnight or 
used freshly prepared. The hydrogen peroxide and the reagents were mixed at a ratio of 
one in ten (1:10) in both microtitre plates and one ml curvettes. The results were read 
using both the microtitre plate reader and a normal spectrometer. The color changes were 
also scanned over a period of 5 hr. The end results were standard curves and color 
changes. 
 
Evaluating EDTA: 
The peak reading from the spectrometer occurred between 500- 800 µM of 
hydrogen peroxide concentrations with both acid and basic EDTA (Figure 5.6). A decline 
in the spectrometry reading at higher concentrations of hydrogen peroxide produced a U-
curve (Figure 5.7). The removal of EDTA however resulted in a linear graph at all 
hydrogen peroxide concentrations ranging from 0 -2,000 µM working solution (Figure 
5.8). At lower hydrogen peroxide concentrations (less than 800 µM), a rapid consistent 
colour change from pink to red was observed, while at higher concentrations (Figures 5.9 
174 
A-D) the color change was not sustained (10 min). The removal of EDTA from the 
solution resulted in stability of the color and the standard curve at all concentrations over 
90 min and up to 5 hr (Figures 5.10-5.11).  
 
Figure 5.6: Oxistress Assay (with EDTA) With Hydrogen Peroxide Standards 
 
Figure 5.6: This graph indicates that the assay is linear up to 800 µM hydrogen peroxide concentration after 
which the absorbance reduces. Sodium EDTA appears to produce slightly better graph than acid EDTA. 
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Figure 5.7: U-Curve of Oxistress Assay (with EDTA) With Various Dilutions of  
Hydrogen Peroxide Standards 
 
 
Figure 5.7: This curve indicates that the assay is linear up to 800 µM hydrogen peroxide concentration after 
which the absorbance reduces. 
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Figure 5.8: Oxistress Assay (With And Without EDTA) With Hydrogen Peroxide 
Standards 
 
Figure 5.8: Removal of EDTA resulted in a linear graph at higher peroxide 
concentrations (up to 2500 µM). 
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Figures 5.9 A-D:  Color Changes - Oxistress Assay (with EDTA) and 0.88 M  
Hydrogen Peroxide Standard 
 
 
 
 
Figure 5.10: Colour Change In The Oxistress Assay (Without EDTA) Versus  
Hydrogen Peroxide Standards (Up To 2500 µM) 
 
Figure 5.9A: At 5 min After The Reaction: Figure 5.9B: Between 10 15  min  After The Reaction
Figure 5.9C: At 25  min  After The Reaction Figure 5.9D: At 30 min  After The Reaction
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Figure 5.11:  Oxistress Assay (without EDTA) Reaction Over Time 
 
 
 
Figure 5.11: Oxistress assay is an end-point assay that is not affected by the time of reading. 
 
 
Evaluating the Role of Deoxyglucose (Or Glucose)  
This evaluation was done without the EDTA component of the Oxistress Assay in 
order to clearly identify the role of deoxyglucose (or glucose). There was visible colour 
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Figure 5.10A: Colour reaction @ 10 min without EDTA Figure 5.10B: Colour reaction @ 90 min  without EDTA
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change within 10 min of the reaction using the Eppendorf tubes and microtitre plates at 
different peroxide concentrations (Figure 5.12). The change was seen at 250 µM of 
hydrogen peroxide for 50 mM deoxyglucose concentration compared with 100 µM of 
hydrogen peroxide standard for 100 mM deoxyglucose concentration. The colour 
persisted for 4 days at room temperature in both cases but it was more pronounced in the 
100 mM deoxyglucose concentration than 50 mM deoxyglucose concentration.  
 With 100 mM glucose as the assay sugar a visible color change was not observed 
until 500 µM of hydrogen peroxide was used. This peroxide level is five times the 
amount required for similar colour change using equivalent deoxyglucose concentration. 
Deoxyglucose in the assay produced a better linear curve with a correlation coefficient of 
95% compared to 82% for glucose (Figure 5.13).  
 
Figure 5.12: The Effect Of Variable Deoxyglucose Concentrations In The Oxistress 
Assay 
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Figure 5.13: Glucose Versus Deoxyglucose In Oxistress Assay 
 
Figure 5.13: Stored Deoxyglucose produced better correlation coefficient with hydrogen peroxide standards 
at day 4 than freshly made glucose. 
 
EDTA-free Oxistress Assay: 
As a result of the observed limitations with EDTA and glucose, the assay was 
subsequently used without EDTA and deoxyglucose was the preferred sugar. The EDTA-
free Oxistress Assay was thus evaluated using three different methods of preparation to 
determine stability and colour changes with storage and hydrogen peroxide reactions.  
 
Stability and Colour of EDTA-free Oxistress Assay with Storage 
The colour changes in the assay reagent with these storage methods are shown in 
Figure 5.14. 
Method 1: The assay reagent was stored in the fridge (40 C) for 5 days where it 
maintained a clear colour. Some precipitates were noticed but they dissolved once the 
solution was re-warmed to 370 C leaving a slight yellowish colour tinge.  
Method 2: The assay reagent was deoxygenated with nitrogen and stored at room 
temperature for 4 days. Nitrogen was chosen because of its ability to reduce oxygen 
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concentration in solutions thus preventing oxidation and possible colour change. The 
result was a light yellow colour change contrary to expectation. 
Method 3: The assay reagent was divided into two components:  
♦ Reagent 1 (R1) is a mixture of thiobarturic acid (TBA) (50 mM) & Ferrous sulfate 
(1 mM). 
♦ Reagent 2 (R2) is the deoxyglucose reagent (100 mM). 
Reagents 1 and 2 were each sub-divided into two parts stored separately at room 
temperature or in the fridge. Equal volumes of R1 and R2 were mixed prior to use and a 
clear solution was obtained. This result was reproducible after 4 wk of storage of these 
components at room temperature or in the fridge. 
  
Figure 5.14: Colour Changes With The Different Assay Storage Methods 
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( l l )
Oxistress Assay (colourless) 
stored in the fridge (40 C) 
for 5 days. 
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Storage Method Vs. EDTA-Free Oxistress Assay Reaction With Hydrogen Peroxide 
Standards: 
Using the same hydrogen peroxide standards with all the assay methods, a 
correlation coefficient ranging from 82% to 91% was observed (Figure 5.15). The best 
long-term correlation was noticed with the reconstituted R1 and R2 (Method 3). Based on 
these observations the EDTA-free Oxistress assay was either prepared fresh or stored in 
its R1 and R2 components for the rest of the study. The assay was also able to maintain 
its clear colour with reconstitution after storage as well produce colour change with 
hydrogen peroxide standards (Figure 5.16).   
 
Figure 5.15: Scattergram Of Various Storage Methods For EDTA-Free Oxistress 
Assay 
 
 
 
Figure 5.15: Reagents are stable up to 2 wk with the best correlation at 4 days at 40C but storage at room 
temp appears to reduce assay performance. 
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 Figure 5.16: Sustaining Color Change Of After The Reaction: 
 
Figure 5.16: Storage of the assay components for up to 2 wk did not appear to affect colour change. 
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